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Abstract 
Pseudomonas aeruginosa is the predominant opportunistic bacterium that causes chronic 
respiratory infections in cystic fibrosis (CF) patients. This bacterium can develop a high level 
of resistance to multiple classes of antibiotics, and this is partially attributed to the ability of P. 
aeruginosa to grow as a biofilm. Such biofilm offers protection for bacterial cells from the host 
immune defences and antibiotics. In CF patients, tobramycin is one of the most commonly used 
antibiotics. However, because of the increasing level of P. aeruginosa resistance to tobramycin 
and other antibiotics, there is a significant challenge in the treatment and eradication of such 
infections. Therefore, this thesis investigates potential strategies to improve tobramycin 
efficacy in the eradication of P. aeruginosa biofilm. The main aim of this thesis is to evaluate 
the activity of tobramycin under a clinically relevant condition. Other specific aims are to 
investigate the influence of dry powder particle size on antibiofilm activity and to evaluate 
tobramycin combination therapy with non-antibiotic drugs.   
The activity of tobramycin against planktonic and biofilms of P. aeruginosa was determined 
using artificial sputum medium (ASM), which is clinically more relevant than standard growth 
media. It was observed that the susceptibility of strains to tobramycin was reduced by four-fold 
when ASM was used as compared to the minimal MOPS medium. This highlights the 
importance of testing antibiotic susceptibility with a physiologically more relevant medium. 
Beside testing against planktonic cells, the results from biofilms using two different biofilm 
models indicated that eradication of P. aeruginosa biofilms was challenging to achieve with 
only 40-60% reduction in biofilm biomass or number of viable counts were observed in most 
strains, which suggest further research and improvement in tobramycin activity against P. 
aeruginosa is required.  
Tobramycin dry powder inhaler (TOBI Podhaler®) is widely used in the treatment of P. 
aeruginosa lung infections in CF patients. Currently, the models that are used to test the activity 
of tobramycin are not representative of lung infections, and better models would provide a 
significant advantage as these could be used to improve the formulation of dry powder inhalers. 
For instance, one question that has not been addressed is whether antibiotic particle size 
influences the antibiofilm activity against P. aeruginosa. Therefore, in this thesis, the activity 
of tobramycin dry powder was investigated in terms of particle size. This was achieved using 
a Next Generation Impactor (NGI), which was used to fractionate tobramycin powder into 
different particle sizes. The results described here indicate that the antibiofilm activity of 
                                                                                                                                           
21 
tobramycin dry powder inhaler can indeed be affected by the size of the powder particles. 
Against P. aeruginosa biofilms of LMG 27643 and LMG 27649 clinical isolates, smaller 
tobramycin particles (< 2.82 µm) showed better efficacy by ~ 20% as compared to larger 
tobramycin particles (< 11.7 µm) after 3 hours incubation time. No difference was seen after 
long incubation times, but these may not be clinically relevant as tobramycin is cleared from 
the lung in 2-3 hours. This work highlights that particle size of dry powder inhaler can affect 
antibacterial and antibiofilm activity. 
Tobramycin activity in combination with non-antibiotic drugs was also determined, as a limited 
number of previous studies have investigated this issue against biofilms of P. aeruginosa. 
Moreover, most tobramycin combination studies employed standard growth media, whereas 
we analyzed this using a more clinically relevant ASM medium. This work was performed 
firstly by conducting a comprehensive literature review, where several non-antibiotic drugs 
from different classes that showed antibacterial activity against P. aeruginosa were found. 
These drugs include colistin, amitriptyline, chlorpromazine, niclosamide, furanone, quercetin, 
and diethylenetriaminepentaacetic acid. Checkerboard assays were used to evaluate 
tobramycin interactions, and Fractional Inhibitory Concentration (FIC) was used as an index 
to assess the type of interaction. The results from this work were mixed, with outcomes 
dependent on bacterial lifestyles (planktonic vs biofilm), type of strains (laboratory vs clinical 
isolates), and growth medium (ASM vs Mueller-Hinton Broth). For instance, using ASM 
medium resulted mostly in antagonistic interactions between tobramycin and non-antibiotic 
drugs against planktonic cells. Although a more clinically relevant ASM medium was used, 
the in vivo significance of our findings remains to be investigated and if it is confirmed, then 
this suggests careful attention should be considered when other drugs are prescribed 
simultaneously with tobramycin, particularly as most CF patients regularly use of many non-
antibiotic drugs. Apart from antagonistic interactions, some of the non-antibiotic and antibiotic 
combinations did show synergistic interactions with tobramycin against biofilms of PAO1 but 
not against all clinical isolates. Such combinations were observed with amitriptyline, 
niclosamide, and colistin, which resulted in 80% reduction in biofilm biomass as compared to 
tobramycin alone. These combinations could be used as adjuvants with tobramycin for the 
treatment of P. aeruginosa infections, but further in vitro and in vivo experiments are warranted 
to ensure that they are effective.  
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1. Pseudomonas aeruginosa 
 
1.1 Clinical significance                           
 
P. aeruginosa is an opportunistic bacterium, which is the leading cause for several human 
infections particularly in immunocompromised patients (Kipnis et al., 2006). These involve for 
example ventilator-associated pneumonia, catheter-related infections, wound infections, and 
cystic fibrosis (CF) lung infections (Ciofu and Tolker-Nielsen, 2019). For instance, according 
to the Centres for Disease Control and Prevention (CDC) surveillance, P. aeruginosa is the 
second main causative pathogen of nosocomial pneumonia (14 -16%), the third leading cause 
of urinary tract infections (7-11%), the fourth most commonly isolated pathogen from surgical 
site infections (8%), and the major pathogen that caused bloodstream infections (2-6%) (Lister 
et al., 2009). Moreover, P. aeruginosa causes 80% of CF-related lung infections (See Section 
1.3) (Hoiby, 2011; Gaspar et al., 2013), which are considered a significant health problem 
globally and result in high morbidity and mortality rates (Stover et al., 2000; Lenoir et al., 
2007; Ashish et al., 2012; Lutz et al., 2013).  
 
Recently, the CDC reported that in the USA, P. aeruginosa was responsible for 32,600 
infections in hospitalized patients and it was also the causative of an estimated 2,700 deaths 
(CDC, 2017). Besides this, P. aeruginosa is classified as a bacterium that belongs to the 
ESKAPE pathogens, which also includes Enterococcus faecium, Staphylococcus aureus, 
Klebsiella pneumoniae, Acinetobacter baumannii, and Enterobacter spp. (Askoura et al., 2011; 
Housseini B Issa et al., 2018; Reza et al., 2019). These bacteria are of significant concern as 
they cause the majority of nosocomial infections and are increasingly able to escape or resist 
the action of more than one antibiotic in three or more different antibacterial classes 
(Magiorakos et al., 2012). Regarding multi drug resistance (MDR) P. aeruginosa, a report from 
the USA found that 13% of severe infections are caused by MDR P. aeruginosa isolates (Dreier 
and Ruggerone, 2015). Similarly, a study from Europe found that between 2005-2013, 14% of 
P. aeruginosa isolates were MDR (Dreier and Ruggerone, 2015). Such MDR P. aeruginosa 
isolates have a significant high level of resistance to multiple classes of antibiotics such as 
carbapenems, cephalosporins, fluoroquinolones, and aminoglycosides (Dreier and Ruggerone, 
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2015). This situation has led the World Health Organization (WHO) to consider P. aeruginosa 
a priority for the development of new antibiotics (WHO, 2017). Collectively, MDR bacteria 
including P. aeruginosa are considered a global health hazard, particularly as they are expected 
to cause 10 million deaths by 2050 (Reza et al., 2019).  
 
1.1.2 General characteristics and natural habitats 
 
P. aeruginosa (Figure 1.1) is a rod-shaped (1-5 µm long), motile, aerobic, Gram-negative 
bacterium, which has several characteristics that make this organism a versatile pathogen 
(Diggle and Whiteley, 2019). These include the ability of P. aeruginosa to grow in anaerobic 
environments utilizing nitrite (NO2
-) and nitrate (NO3
-) ions as respiratory electron acceptors 
and utilising of different carbon sources for energy production, the ability to survive under 
variety of temperatures up to 42°C, and the ability to produce several virulence factors (See 
Section 1.1.3) that allow for different types of infections (Kung et al., 2010; Ozer et al., 2014; 
Diggle and Whiteley, 2019).  
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P. aeruginosa inhabits various types of environment such as soil, water, plants, animals, and 
humans (Doring et al., 2000; Diggle and Whiteley, 2019). The ability of this bacterium to adapt 
and grow in such diverse niches is attributed to its genome size, which is relatively large. 
(Diggle and Whiteley, 2019). P. aeruginosa PAO1, which was originally isolated from a 
wound infection, is now one of the most commonly used strains in research and has a genome 
size of 6.3 million base pairs (Mbp) that contains 5770 open reading frames (Stover et al., 2000; 
Kung et al., 2010; Diggle and Whiteley, 2019). This large genome can be classified into core 
and accessory genomes. The core represents 90% of the genome and is found in all strains of 
the same species, while the accessory genome represents about 10% and is found only in some 
strains. This genome codes for many transport proteins, enzymes for metabolism, outer 
membrane proteins, and virulence factors, which have an important role in causing infections 
and developing resistance to antibiotics (Rybtke et al., 2011; Ozer et al., 2014). 
 
1.1.3 Virulence factors and pathogenicity 
 
P. aeruginosa uses different types of virulence factors that facilitate its ability to cause 
infections in humans. Such virulence factors include the proteinaceous surface appendages, 
which for each cell involves a single flagellum and multiple type IV pili (Gellatly and Hancock, 
2013). These are known to have a role in surface adhesion, swimming and twitching motilities. 
Additionally, they also have a role in starting the inflammatory response in lung infections 
through binding to epithelial cell receptors called asialo-gangliosides (Gellatly and Hancock, 
2013).  
 
Virulence factors that are secreted by P. aeruginosa involve five different secretion protein 
systems, which are named type I to type V (T1SS to T5SS). Among those, the type III secretion 
system (T3SS) is a major class. This system secretes effector proteins, which are toxic proteins 
that are released directly into the cytosol of host cells and cause damage to host tissue (Lyczak 
et al., 2000). These effector proteins include ExoY, ExoS, ExoT, and ExoU. Among those four 
types, it is known that ExoS and ExoU are major cytotoxins, while ExoT and Exo Y play a 
minor role in host pathogenesis (Gellatly and Hancock, 2013). Another secretion system is the 
type II secretion system (T2SS), which secretes several proteins such as elastases, proteases, 
phospholipase C, and exotoxin A. These are secreted in the extracellular milieu and each one 
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has a specific function. For example, in lung injury, elastases such as Las A and Las B cause 
damage to respiratory epithelial tight junctions. Phospholipase C is another secreted protein, 
which degrades the phospholipids in host cell membranes. Finally, exotoxin A is one of the 
most toxic virulence factors that can cause apoptosis of host immune cells (Driscoll et al., 2007; 
Gellatly and Hancock, 2013). In addition to the above-mentioned secretion systems, another 
type has been characterized and referred to as T6SS (H1-T6SS, H2-T6SS, H3-T6SS) (Filloux 
et al., 2008; de Bentzmann and Plesiat, 2011; Diggle and Whiteley, 2019). It has been found 
that H1-T6SS has a role in chronic infections, whereas the function of the other two has not yet 
been determined (de Bentzmann and Plesiat, 2011). However, T6SS is generally known to 
support the growth of P. aeruginosa by killing the other competing bacterial species and has 
also been found to have a role in biofilm formation (Chen et al., 2015). Other virulence factors 
that are also produced by P. aeruginosa are siderophores, which include pyoverdine and 
pyochelin. These have an important role in scavenging iron, which is an essential nutrient 
necessary for several physiological functions such as energy production and biofilm formation 
(Banin et al., 2005). 
 
1.2 P. aeruginosa and biofilm formation 
 
Biofilms are structured communities of sessile bacterial cells, which are encased within a self-
generated extracellular polymeric substances (EPS) matrix that represents 50-90% of the 
biofilm (Whiteley et al., 2001; Germoni et al., 2016; Whiteley et al., 2017; Roy et al., 2018). 
The composition of this matrix depends on the type of strain and growth conditions (Ciofu and 
Tolker-Nielsen, 2019). Generally, the matrix consists of polysaccharides, lipids, DNA, and/or 
proteins (Hoiby et al., 2010b; Roy et al., 2018). Examples of the polysaccharides that are 
produced by P. aeruginosa and found in the biofilm matrix are Pel, Psl, and alginate. Other 
lipid components that also play a role in the matrix are rhamnolipids, which are glycolipid 
virulence factors that have a role in inhibition of phagocytosis, suppression of cilia function, 
and deactivation of polymorphonucleocytes (Soberón-Chávez et al., 2005). Finally, different 
types of proteins are also included in the biofilm matrix, examples of which are type IV pili, 
Cup fimbriae, and adhesins. Collectively, all of these components have an important role in the 
maintenance and stability of  biofilms (Ciofu and Tolker-Nielsen, 2019).  
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The formation of biofilms by P. aeruginosa is controlled by quorum sensing (QS), which is a 
complex cell- to -cell communication system (Hoiby et al., 2010a; Roy et al., 2018). This is a 
signalling system that enables bacteria to communicate with each other through signalling 
molecules called auto-inducers (Schroeder et al., 2017). Three different auto-inducers are 
produced by P. aeruginosa. These include acyl-homo-serine lactones (AHLs), which are in 
two types. The first AHL is 3-oxo-dodecanoyl homoserine lactone (C12-HSL), which is 
produced by LasI synthase and binds to a transcriptional activator called LasR, which activates 
the production of different genes. The second AHL is butyryl homoserine lactone (C4-HSL), 
which is produced as a part of Rhll synthase and binds to a transcriptional activator termed as 
RhIR (Masák et al., 2014). Beside AHLs, Pseudomonas quinolones signal (PQS) is another 
type of autoinducer, which is also produced by different pathways described elsewhere (Kipnis 
et al., 2006; Gellatly and Hancock, 2013; Diggle and Whiteley, 2019). Following production 
of these autoinducers, they diffuse from the cytoplasm to the extracellular milieu through 
transporter proteins, and when they reach to critical or threshold concentrations, expression of 
several genes including those coding for biofilm formation are induced (Hoiby et al., 2010a; 
Roy et al., 2018).  
 
Biofilm formation in P. aeruginosa occurs in different stages (Figure 1.2). These include the 
initial adhesion of planktonic (freely swimming) bacterial cells to a surface. This attachment is 
mediated through several components, which involve surface appendages such as flagella, type 
IV pili, and also other elements such as Psl (mannose-rich polysaccharide) and adhesion 
proteins termed as Cup-fimbriae (Rybtke et al., 2011). This step is followed by microcolony 
formation, where cells are downregulating flagella production and also undergoing cycles of 
cell division. During this stage, bacterial cells start producing constituents of the extracellular 
matrix that is shown as green areas in Figure 1.2, which offer not the only robust attachment 
of cells to the surface but also strong links to other cells. Moreover, these matrix components 
provide cells inside a biofilm with protection from environmental stressors. After microcolony 
formation, the cells continue to grow leading to the build-up of mature biofilm architecture. 
Finally, this cycle ends with the biofilm dispersion, which is induced for instance by the 
restriction of nutrients, and in particular oxygen, iron, and carbon. The biofilm dispersion 
results in releasing of individual planktonic cells, which start to disseminate to other surfaces 
and cause further infections (Hoiby et al., 2010a; Taylor et al., 2014; Kang and Kirienko, 2018).  
 
 




Figure 1.2. Representative stages of biofilm formation. Reproduced from Taylor et al., 2014, with permission. 
See text for details. 
 
1.3 P. aeruginosa and cystic fibrosis 
 
One of the common biofilm-related infections that are caused by P. aeruginosa are lung 
infections in CF patients (Williamson et al., 2012; Ciofu et al., 2015).  CF is a genetic disease 
that affects around 70,000 people worldwide (Moreau-Marquis et al., 2015). This inherited 
disease results from mutations in a gene that encodes for the cystic fibrosis transmembrane 
conductance regulator (CFTR) protein (Heijerman et al., 2009).  Mutations in the CFTR gene 
lead to a malfunction in chloride channels that are controlled by CFTR. This, in turn, results in 
an imbalance of electrolytes and water movement across cell membranes. Such impairment 
leads to alteration in the physical properties of mucus, which becomes highly dehydrated, thick, 
and viscous (Doring et al., 2000). The abnormal mucus causes a reduction in the effectiveness 
of mucociliary clearance, which results in the accumulation and formation of mucus plugs in 
the endobronchial region of the lung. Since mucus accumulates, this offers a fertile 
environment for the proliferation of several types of bacteria (Heijerman et al., 2009; Moore 
and Mastoridis, 2017).  Bacterial lung colonization in CF patients varies according to age group 
(Gaspar et al., 2013).  For instance, the Cystic Fibrosis Trust national report 2018 (UK CF 
Registry, 2018) shows that the most commonly isolated bacteria during childhood are 
Haemophilus influenzae and Staphylococcus aureus (Figure 1.3), whereas during adulthood P. 
aeruginosa becomes the most dominant bacterium (Figure 1.3).  
 




Figure 1.3. Prevalence of respiratory pathogens by age. Reproduced from UK Cystic Fibrosis, 2018 National 
Data Report (UK CF Registry, 2018) with permission. 
 
CF patients acquire the initial infection with P. aeruginosa directly through inhalation from the 
surrounding environment (Germoni et al., 2016), but it can also be acquired by transmission 
between patients (Doring et al., 2000; Gaspar et al., 2013). Once P. aeruginosa enters the lungs, 
it binds strongly through flagella and type IV pili to epithelial cell receptors called asialo-
gangliosides that are highly expressed in damaged lung tissue (Goldberg and Pier, 2000). 
During colonization in the lung, P. aeruginosa develops different phenotypes. For instance, in 
early CF lung infections, the colonization is mostly caused by non-mucoid phenotypes 
(Bjarnsholt et al., 2005), which may be susceptible to antibiotic treatment (Chuchalin et al., 
2009; Damron and Goldberg, 2012). However, during long-term infection, P. aeruginosa 
undergoes prominent genetically and phenotypically diversifications, which result in the 
appearance of different phenotypes with enhanced antibiotic tolerance.    
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One such phenotype is the small-colony variants (SCVs), which grow as a small colony of 1-3 
mm in diameter and emerge after prolonged antibiotic therapy due to high selection pressure. 
This phenotype is characterised by an enhanced adhesive ability to tissue (Haussler et al., 2003; 
Malone, 2015). This is attributed to their ability to produce Pel and Psl exopolysaccharides that 
are important in biofilm formation (Malone, 2015). Additionally, SCV phenotypes are known 
to be auxotrophic with a slow growth rate and enhanced antimicrobial tolerance (Haussler et 
al., 2003; Hocquet et al., 2003; Malone, 2015).  
 
Another phenotype that is frequently isolated from CF patients and has considerable attention 
in medical research is the mucoid variant (Goldberg and Pier, 2000). This mucoid phenotype 
is triggered by the inflammatory response and oxidative stress environment in the CF lung, 
which is characterized for instance by the presence of reactive oxygen species such as hydrogen 
peroxide (H2O2) that is released by neutrophils undergoing respiratory burst (Bjarnsholt et al., 
2005; Ciofu et al., 2012). Such reactive oxygen species cause mutations in the mucA gene 
(Rybtke et al., 2011), which encodes a transmembrane protein that works as the principal 
negative controller of the AlgU (also known as the AlgT) protein.  AlgU is a sigma factor that 
is required for the initiation  transcription of genes for alginate production through binding to 
the promoter of a gene called algD (Campόdonico et al., 2008). This in turns leads to the 
overproduction of alginate, which is an exopolysaccharide that consists of repeating polymers 
of mannuronic and glucuronic acid (Kipnis et al., 2006; Hogardt and Heesemann, 2010). 
Alginate is considered one of the major components of the EPS matrix in biofilms formed by 
mucoid P. aeruginosa strains. In respect of in vitro mucoid isolates, it is evident that such 
phenotypes quickly transform to non-mucoid variant and this is due to mutation suppression 
(Bergan and Hoiby, 1975; Pritt et al., 2007). Generally, the emergence of mucoid variants in 
CF lung leads to a poor prognosis because such variants are known to have a significant role 
in protecting P. aeruginosa from phagocytosis and antibiotics (Kipnis et al., 2006; Driscoll et 
al., 2007). This consequently leads to a high degree of tolerance towards several classes of 
antibiotics including aminoglycosides such as tobramycin (Hentzer et al., 2001; Ernst et al., 
2007; Ciofu et al., 2012; Lamppa and Griswold, 2013; Roy et al., 2018).   
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1.4 P. aeruginosa and antibiotic resistance 
 
P. aeruginosa has an enhanced ability to quickly adapt to changing conditions such as antibiotic 
exposure, which leads to the development of resistance (Dozzo and Moser, 2010). P. 
aeruginosa antibiotic resistance is growing, and this is also accompanied by the emergence of 
multi-drug resistant strains, for which treatment options are limited (Dozzo and Moser, 2010; 
Tunney et al., 2018). For instance, a recent report from the WHO has listed P. aeruginosa as a 
critical pathogen that requires urgent research and development of antibiotics (WHO, 2017). 
The development of antibiotic therapy requires a better understanding of the mechanisms of 
such resistance. Several resistance mechanisms have been documented, which involve both 
acquired and intrinsic resistance, as well as phenotypic tolerance (Khalil et al., 2008; Taylor et 
al., 2014; Wright, 2016). Acquired resistance has been reviewed elsewhere (Breidenstein et al., 
2011; Schroeder et al., 2017), but intrinsic and phenotypic resistance mechanisms are discussed 
in more detail below. 
 
1.4.1 The outer membrane permeability 
 
Gram-negative bacteria including P. aeruginosa are characterized by the presence of an outer 
membrane in their cellular structure. This outer membrane acts as a barrier and restricts the 
permeability of both hydrophilic and hydrophobic drugs (Nehme et al., 2018). Generally, the 
outer membrane comprises of two asymmetric layers, which are the inner core phospholipid 
and the outer leaflet that contains lipopolysaccharides (LPS) (Nehme et al., 2018). The latter 
consist of hydrophilic moieties of a core oligosaccharide that is linked to O antigen. These 
moieties provide a hydration environment. The core oligosaccharide is also covalently bound 
to lipid A, a hydrophobic moiety that is known to be in a gel-like state with very low fluidity 
(Delcour, 2009; Muheim et al., 2017). This composition of the outer membrane strongly limits 
the penetration of hydrophobic drugs (Muheim et al., 2017). For example, the penetration of 
hydrophobic drugs is limited by 50 to 100-fold in the outer membrane lipopolysaccharides as 
compared to the inner cytoplasmic phospholipid membrane (Nikaido, 2003). Hydrophilic drugs 
can cross the outer membrane via protein channels that are embedded within the outer 
membrane and are termed as β-barrel porins (Delcour, 2009; Muheim et al., 2017). However, 
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these porin channels are not always functional and also have a low permeation, which is 
restricted by the charge and the molecular mass of compounds (Nikaido and Vaara, 1985; 
Nikaido, 2003; Khalil et al., 2008). For instance, only drugs with a molecular mass < 600 g/mol 
can passively diffuse through these channels. Other charged hydrophilic drugs with a molecular 
mass > 600 g/mol can penetrate the outer membrane by a different pathway, which is referred 
to as self-promoting uptake (Nikaido, 2003). This uptake is characterized by the electrostatic 
interactions between cationic drugs and anionic lipopolysaccharide of the outer membrane. 
This mechanism was observed to occur mostly with drugs with high molecular mass and 
positively charged such as polymyxin or aminoglycoside antibiotics (Nehme et al., 2018). 
Accordingly, it is obvious that P. aeruginosa permeability either through porins or self-
promoted uptake is restricted by drug properties and the functionality of these barriers, and all 
of these represent a significant challenge for drug uptake. Importantly, drug penetration in P. 
aeruginosa is reported to be 12 to 100-fold lower than the outer membrane permeability in 
other Gram-negative bacteria such as E. coli (Gellatly and Hancock, 2013; Domalaon et al., 
2018). This is related to different characteristics of the outer membrane in E. coli, in which 
there are trimeric porins (e.g. OmpC, OmpF) that allow quick penetration of substances. 
However, in P. aeruginosa there are rather specific and fewer porins (e.g. OprF, OprD), which 
are also monomeric with a relatively small opening that only permits slow diffusion of 
substances (Nikaido, 2011; Dreier and Ruggerone, 2015). 
 
1.4.2 Multi-drug efflux pumps  
 
Another mechanism of intrinsic resistance is through multi-drug efflux pumps, which have a 
major role in P. aeruginosa resistance to several antibiotics (Beceiro et al., 2013). These efflux 
pumps remove drug molecules from the periplasm and cytoplasm, thus significantly lowering 
intracellular drug concentrations (Kiser et al., 2010; Nikaido and Pagès, 2012). In P. 
aeruginosa, it has been determined that there are twelve efflux pumps belonging to the family 
of  Resistance Nodulation-Cell-division (RND) proteins, four of which have been characterised 
for their important role in antibiotic resistance (Nikaido, 1996; Nikaido, 2011; Nikaido and 
Pagès, 2012).  
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These efflux pumps are MexAB-OprM, MexXY-OprM, MexCD-OprJ, and MexEF-OprN 
(Table 1.1). Such pumps differ in their substrate affinity and each pump extrudes a wide range 
or specific classes of antibiotics (Table 1.1). For instance, MexAB is the most commonly 
expressed efflux pump among the other pumps, and export a wide variety of antibiotic drugs 
from different families such as fluoroquinolones, cephalosporins, β-lactamase inhibitors, 
penicillins, and carbapenems (Lister et al., 2009; Housseini B Issa et al., 2018). Other efflux 
pumps are only expressed under particular conditions and are more specific in the drugs they 
export (Housseini B Issa et al., 2018). For example, the MexXY pump is known to have a 
major role in exporting aminoglycosides such as tobramycin (Aeschlimann, 2003; Hocquet et 
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Table 1.1 Multi-drug efflux pumps with known antibiotic substrate in P. aeruginosa.  






























































a the name of the antibiotic class, b the name of agents in that class.  
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In order for these pumps to export antibiotics, each pump has tripartite structure (Figure 1.4), 
with their components acting synergistically in a collaborative manner. Each pump consists of 
a linker or a membrane fusion protein (MFPs; MexA, MexC, MexE, MexX), a transporter 
protein belonging to the RND family (MexB, MexD, MexF, MexY), and an outer membrane 
channel protein (OprM, OprJ, OprN) (Nikaido and Pagès, 2012). Antibiotic or drug can be 
removed from the cytoplasm, periplasm, and from the cytoplasmic membrane by the RND 
transporter protein using the proton motive force as a source of energy. MFPs act as a 
connection between the transporter proteins and the outer membrane proteins, which act in the 
last step in the process of removing antibiotics (Aeschlimann, 2003; Askoura et al., 2011; Li et 
al., 2015). Collectively, the abundance of effective efflux pump systems combined with the 
reduced permeability of the outer membrane all contribute to the intrinsic resistance to 
antibiotics in P. aeruginosa (Delcour, 2009). 
 
 
Figure 1.4. Schematic structure of the most commonly expressed efflux pumps (MexAB-OprM) in P. 
aeruginosa. MexB is the transporter protein RND that transports drug using proton motive force as a source of 
energy. MexA is the linker or membrane fusion protein, and OprM is the outer membrane protein. Reproduced 
from (Askoura et al., 2011). See details in the text.  
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1.4.3 Phenotypic or adaptive tolerance  
 
Besides the intrinsic resistance in P. aeruginosa, phenotypic or adaptive tolerance also plays 
an important role. This tolerance is largely associated with environmental conditions, which 
include for example specific modes of growth such as biofilm formation. It is estimated that 
more than 80% of human infections are biofilm-related, among them infections caused by P. 
aeruginosa (Song et al., 2016; Meylan et al., 2017). As discussed earlier (Section 1.2), P. 
aeruginosa forms biofilms in several infections including lung infections in CF patients. Such 
biofilms are difficult to eradicate as these have a tolerance that may be 100-1000 fold increased 
as compared to their planktonic counterparts (Roberts et al., 2015; Roy et al., 2018).  
 
The tolerance of biofilms is attributed to several structural properties and environment created 
in the biofilm.  For instance, each biofilm is surrounded by an EPS matrix (Roberts et al., 2015). 
The components of this matrix could bind or adsorb antibiotics, which might result in a 
reduction of its penetration into a biofilm. As an example, the biofilm matrix of P. aeruginosa 
contains anionic polymers such as extracellular DNA and alginate, which could bind cationic 
antibiotics such as tobramycin and limit its diffusion (Hoiby et al., 2010a; Rybtke et al., 2011; 
Ciofu et al., 2015). However, neutral antibiotics such as the fluoroquinolones (e.g. 
ciprofloxacin) can readily penetrate the biofilm matrix (Ciofu and Tolker-Nielsen, 2019). 
 
Other factors that enhance antimicrobial tolerance are biofilm specific conditions, which affect 
the characteristics of bacterial cells (Roy et al., 2018). For example, some bacterial cells inside 
a biofilm are in a (semi-)dormant state, which is due to the reduced availability of nutrients and 
oxygen. Such cells are known to have a low metabolic rate with a decreased level of gene 
expression and protein synthesis (Rybtke et al., 2011; Williamson et al., 2012), which results 
in slow rates of growth and reduced susceptibility to antibiotic treatment. Several antibiotic 
classes such as tetracycline, fluoroquinolones, and aminoglycosides have a higher killing 
activity on rapidly dividing cells as compared to slowly growing counterparts, because in the 
latter the rate of  synthesis of proteins and DNA, which are targets for the previously mentioned 
antibiotics, is at a very low level (Williamson et al., 2012; Ciofu et al., 2015; Ciofu and Tolker-
Nielsen, 2019). Polymyxin antibiotics are an exception with colistin being also active against 
slowly growing cells (Rybtke et al., 2011; Ciofu et al., 2015). This is mainly attributed to the 
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mechanism of action of colistin, which primarily depends on the disruption of the outer and 
cytoplasm membranes causing cell lysis (Ciofu and Tolker-Nielsen, 2019).  
 
Besides the role of EPS and dormancy of cells in biofilm tolerance to antibiotics, other factors 
can also have a role in this. For instance, the microaerobic conditions particularly deep inside 
a biofilm have been shown to enhance tolerance to some antibiotics such as tobramycin. This 
is because the uptake of tobramycin (See Section 1.5.1) into bacterial cells is an energy-
dependent process and, also, part of the bactericidal activity of tobramycin depends on the 
production of reactive oxygen species. All of these processes require the presence of oxygen, 
and an anaerobic environment could therefore significantly impair tobramycin activity (Hoiby 
et al., 2010a; Roy et al., 2018; Ciofu and Tolker-Nielsen, 2019). Furthermore, due to the dense 
population of bacterial cells inside a biofilm, fractions of these bacterial cells are exposed to 
sub-minimal inhibitory concentrations of antibiotics (Hoffman et al., 2005). Such 
concentrations could also promote antibiotic tolerance, as it has been shown that sub-lethal 
concentrations of antibiotic agents could induce biofilm formation (Wassermann et al., 2016; 
Roy et al., 2018). Finally, cells inside a biofilm experience a high level of mutations that could 
lead to a mucoid conversion , as explained earlier, and resulting in increased the levels of 
antibiotic resistance (Roy et al., 2018). Indeed, there are significant chances for horizontal gene 
transfer inside a biofilm, which could also promote antimicrobial resistance (Hoiby et al., 
2010b; Beceiro et al., 2013). 
 
1.4.4 Aminoglycoside resistance in P. aeruginosa 
 
The resistance of P. aeruginosa toward aminoglycoside antibiotics has been well documented 
(Bassetti et al., 2018). For instance, the European Antimicrobial Resistance Surveillance 
system (EARSS) has determined resistance in this pathogen around Europe. In several 
European countries, it has been found that aminoglycoside resistance is high. For example, as 
determined by the EARSS surveillance in 2018 (Figure 1.5), the percentage of resistance in P. 
aeruginosa clinical isolates was 50.7% in Romania, 37.4% in Slovakia, 26.5% in Greece, and 
26% in Poland. In the UK, the resistance is low 4.5% (EARS-NET, 2018), however, it should 
be noted that this was increased from only 1.9% in 2010 (EARS-NET, 2010).  
 




Figure 1.5. Distribution of aminoglycoside resistance in P. aeruginosa in EARS-Net countries in 2018 (EARS-
NET, 2018). 
 
P. aeruginosa resistance to aminoglycosides including tobramycin is related to the outer 
membrane permeability and efflux pumps as discussed above (Gaspar et al., 2013). For 
instance, the permeability of these porin channels to aminoglycosides such as tobramycin is 
relatively low because of the small porin size of < 600 Da, and other studies suggested that 
such porin limits the penetration of any molecules larger than 200 Da. As the molecular weight 
of tobramycin (467.5 Da) is relatively large, this can strongly restrict tobramycin penetration 
(Zgurskaya et al., 2015). Besides this, aminoglycosides are considered a substrate for MexXY 
efflux pumps, which can extrude antibiotics from cells before reaching their cellular target 
(Nikaido and Pagès, 2012). Additionally, other mechanisms of resistance also have an 
important role (Avent et al., 2011). Firstly, there may be acquired resistance that occurs through 
the expression of aminoglycoside modifying enzymes (Avent et al., 2011; Halfon et al., 2019). 
These enzymes include aminoglycoside acetyltransferases that target the antibiotic at NH2- 
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groups, and aminoglycoside phosphotransferases that target antibiotic at OH- groups. Such 
alterations to the aminoglycoside molecule can impair the binding affinity to their target, 
resulting in loss of antibacterial activity. Another resistance mechanism is through target site 
modifications, which include for instance methylation of the ribosomal 16S rRNA subunit, 
which decreases the binding affinity of drug molecules to the target site (Ramirez and 
Tolmasky, 2010).  
 
1.5 Antibiotic treatment for P. aeruginosa lung biofilm infections 
 
Antibiotics are the standard drugs for the treatment of P. aeruginosa lung infections (Greally 
et al., 2012). Several antibiotic classes have been used, these include β-lactams such as 
extended-spectrum penicillin (e.g. piperacillin-tazobactam), monobactam (e.g. aztreonam), 
carbapenems (e.g. meropenem), and cephalosporins (e.g. ceftazidime, cefepime). Other 
antibiotic classes are fluoroquinolones (e.g. ciprofloxacin), polymyxins (e.g. colistin or 
polymyxin E), macrolides (e.g. azithromycin), and aminoglycosides (e.g. tobramycin) (Rybtke 
et al., 2011; Ashish et al., 2012; Ciofu et al., 2012; Bassetti et al., 2018). Aminoglycosides and 
particularly tobramycin are the most widely used therapy in the treatment of P. aeruginosa 
infections in CF patients (Konstan et al., 2011; Gaspar et al., 2013). Therefore, this thesis 
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1.5.1 Tobramycin mechanism of action 
 
As discussed earlier, tobramycin belongs to the class of aminoglycoside antibiotics, which 
exert their activity by inhibiting protein synthesis. Tobramycin suppresses protein production 
by irreversible binding to the 30S subunit of the bacterial ribosome, thereby enhancing 
mistranslations and errors in protein synthesis (Doring et al., 2000; Heijerman et al., 2009; 
Avent et al., 2011; Krause et al., 2016). To achieve this, tobramycin needs to be taken up by 
bacterial cells. The uptake of tobramycin into bacterial cells takes place through two steps, 
which are all concentration-dependent but differ in their energy requirements.  
 
The first step is the energy-independent uptake, which includes an electrostatic interaction 
between the cationic tobramycin and anionic lipopolysaccharides in the outer membrane 
(Avent et al., 2011). Such interaction can result in the displacement of cations (Mg+2, Ca+2), 
which have an important role in maintaining the stability and the integrity of the outer 
membrane. Therefore, elimination of these cations from their binding sites disrupts the outer 
membrane and enhances the permeation of tobramycin directly into the periplasm of bacteria 
(Avent et al., 2011; Domalaon et al., 2018).  
 
The second step is an energy-dependent transport process that requires ATP, which is produced 
by ATP-synthetase (Ramirez and Tolmasky, 2010). This step includes two phases, which are 
the slow phase (I) and the rapid phase (II) (Nikaido, 2003; Avent et al., 2011). During phase I, 
tobramycin adsorbs to the cytoplasmic membrane and enters in low concentrations. These 
small amounts of tobramycin lead to the interruption of protein synthesis, which results in the 
production of impaired membrane proteins. The latter create non-specific channels or pores 
when inserted into the cytoplasmic membrane, which induces further uptake of tobramycin via 
the rapid phase II (Ramirez and Tolmasky, 2010; Krause et al., 2016). During phase II, the 
uptake of tobramycin is accelerated leading to more inhibition of protein production and finally 
cell death. Through this mechanism tobramycin has a bactericidal action against several aerobic 
Gram-positive and -negative pathogens (Ramirez and Tolmasky, 2010). Among the Gram-
negative bacteria, tobramycin for instance inhibits the growth of Klebsiella pneumonia, 
Escherichia coli, and P. aeruginosa (Heijerman et al., 2009; Krause et al., 2016).  
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1.5.2 Tobramycin administration 
 
Several routes of administration for tobramycin have been used in the treatment of P. 
aeruginosa CF lung infections. Unfortunately, oral delivery of tobramycin is not feasible 
because of the low bioavailability following oral administration (Ramirez and Tolmasky, 2010; 
Krause et al., 2016). This is attributed to the hydrophilic properties of tobramycin, which result 
in the efflux of tobramycin by P-glycoprotein pumps in the brush border of the small intestine 
and prevent its absorption from the gut (Banerjee et al., 2000). Tobramycin is bioavailable via 
the intravenous route, but this requires high doses to get an effective concentration in the 
respiratory epithelial tissue and bronchial secretions (Lenoir et al., 2007; Gaspar et al., 2013). 
Such high plasma levels are associated with severe side effects such as nephrotoxicity and 
ototoxicity (Lenoir et al., 2007; Ramirez and Tolmasky, 2010; Avent et al., 2011; Becker, 
2013). Therefore, to avoid the concerns that are associated with poor oral bioavailability and 
the side effects of parenteral administration, the pulmonary administration of tobramycin by 
inhalation is the most widely used route in the treatment of CF lung infections (Lenoir et al., 
2007).  
 
1.5.3 Inhaled tobramycin  
 
Inhaled tobramycin is considered as the frontline treatment for chronic CF lung infections with 
P. aeruginosa (Chuchalin et al., 2009; Konstan et al., 2011; Krause et al., 2016; Moore and 
Mastoridis, 2017; Jung et al., 2018; Moller et al., 2019). This is due to the local action of 
inhaled tobramycin directly at the site of infection and also has the advantage that higher 
concentrations can be achieved as compared to parenteral administration (Tiddens, 2004; 
Geller et al., 2011). Importantly, the occurrence of systemic organ toxicity is lower in 
comparison with an intravenous administration (Tiddens, 2004; Lenoir et al., 2007; Chuchalin 
et al., 2009; Heijerman et al., 2009; Bos et al., 2015; Krause et al., 2016). Moreover, delivering 
tobramycin by inhalation can reduce the emergence of antibiotic resistance due to the 
diminished exposure of the normal bacterial flora (Labiris and Dolovich, 2003; Chuchalin et 
al., 2009; Jung et al., 2018). With regards to patient outcomes, inhaled tobramycin results in 
better lung function, reduces hospitalisation duration time, and decreases the usage of 
intravenous antibiotics (Chuchalin et al., 2009). Therefore, inhaled tobramycin has been 
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recommended as the maintenance therapy in chronic CF patients by the European Consensus 
guidelines (Chuchalin et al., 2009). Two types of tobramycin inhalation formulation are 
available, which are tobramycin nebulizer solutions and inhalation powder (Tiddens, 2004; 
Tiddens et al., 2014). 
 
1.5.3.1 Tobramycin nebulization 
 
Nebulization of tobramycin in solution is frequently used in CF patients and has been shown 
to promote lung function, but this formulation has some drawbacks (Konstan et al., 2011). 
These include long treatment time for at least 20 min (Gaspar et al., 2013). Moreover, the drug 
is delivered using nebulizers, which are bulky devices that also require regular cleaning and 
disinfection (Geller et al., 2011; Konstan et al., 2011). Besides this, drug delivery from these 
devices results in a poor lung (5-11%) deposition (Pilcer et al., 2013; Hamed et al., 2017). 
Additionally, the drug in solution form is unstable at room temperature and requires specific 
storage conditions (VanDevanter and Geller, 2011). Collectively, these factors negatively 
affect the adherence of patients, especially considering that CF patients regularly use several 
other medications including inhaled drugs such as bronchodilators and mucolytics (Hamed et 
al., 2017). Therefore, a more appropriate delivery system has been developed using a dry 
tobramycin inhalation powder.  
 
1.5.3.2 Tobramycin inhalation powder  
 
The inhaled dry powder formulation of tobramycin overcomes the shortcomings of the 
nebulized solutions. For instance, tobramycin dry powder formulation is administered via a 
simple portable device (Figure 1.7) that only requires ~5 min administration time. Moreover, 
tobramycin dry powder formulation has better lung deposition of about 50% as compared to 
the inhaled solution.  Also, no specific storage conditions or regular disinfections are required 
(Gaspar et al., 2013). Therefore, this leads to a decrease in the burden of treatment and better 
patient adherence, thereby improving treatment success (Geller et al., 2011; Woods and 
Rahman, 2018). The in vitro and in vivo efficacy as well as safety of tobramycin dry powder 
formulation have been documented, which have shown improvement in lung functions and 
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reduction in bacterial density (Konstan et al., 2011). The FDA approved tobramycin dry 
powder inhaler for CF patients is TOBI Podhaler® (Figure 1.7), which is made up of 
tobramycin as an active drug and other excipients. Tobramycin powder from 28 mg capsule is 
aerosolized using Podhaler device (Figure 1.7) by the energy of the patient’s own inspiration 
(Konstan et al., 2011). This means the particles in the powder are separated from each other 
and carried in the airstream down to the lungs where they deposited (See details below). Similar 
to TOBI Podhaler®, another FDA-approved dry powder inhaler antibiotic for CF patients is 
Colobreath®, which contains colistin as an active ingredient (Woods and Rahman, 2018). 
Beside the abovementioned approved dry powder inhalers, there are number of antibiotics that 
are currently in the process of development as a dry powder formulation, these include 
levofloxacin, ciprofloxacin, and clarithromycin (Tiddens et al., 2014). 
 
Figure 1.7. TOBI Podhaler® 28 mg (unpublished image).  
 
Antibiotic from dry powder formulation is delivered via inhalation, in which after dry powder 
antibiotic is inhaled, the particles deposit into different compartments of the lung. Briefly, the 
lung consists of two regions (Figure 1.8), which are the conducting and the respiratory zones. 
The conducting zone includes trachea, bronchi, bronchioles, and terminal bronchioles, whereas 
the respiratory zone comprises of the respiratory bronchioles, alveolar ducts, and alveolar sacs 
(Hoiby, 2011). With regards to P. aeruginosa colonization, it has been found by a study from 
the Cystic Fibrosis Centre in the Copenhagen that non-mucoid strains are mostly present in the 
conducting zone, while mucoid variants distribute in both the conducting and respiratory zones. 
The reason for this could be because the mucoid variants are protected from immune defence 
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mechanisms such as polymorphonucleocytes in the conducting zone or alveolar macrophages 
in the respiratory zone (Bjarnsholt et al., 2009; Gaspar et al., 2013).  
 
 Figure 1.8. The conductive and respiratory zones (Z) of the lung. Conducting region that distributes 
through the 1st to the 16th airway generations or divisions, while respiratory zone represents the generations from 
17th through 23rd. Reproduced from (Hoiby, 2011).  
 
Following inhalation, these different zones in the lung receive inhaled drug particles, and the 
deposition of drug particles in such zones depends on several factors such as patient-associated 
factors and inhaled powder formulation properties (Tiddens et al., 2014). These characteristics 
involve particle shape, density, and size (Figure 1.9). Our particular interest was in powder 
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particle size and its impact on the pharmacological activity of the inhaled drugs. For instance, 
inhaled drug powder is known to be polydisperse in nature (Figure 1.9), with particles in the 
range of 3 - 10 µm mostly depositing in the conducting zone, whereas smaller drug particles in 
a range of 1-3 µm mainly deposit in the respiratory zone (Verbanck et al., 2006; Geller et al., 
2011; Nafee et al., 2014). From a clinical efficacy point of view, for such differently sized 
particles to exert their pharmacological activity, they must dissolve in the first instance and this 
depends on the size of these particles, which in turn can influence drug efficacy (Nafee et al., 
2014). For instance, it is unknown how these different particle sizes could influence the activity 











Figure 1.9. Scanning electron micrograph of tobramycin inhalation powder with different particle sizes 
(unpublished image). 
 
The effect of particle size has, however, been studied for other drugs. For instance, nebulised 
solution of dornase alfa (a mucolytic agent that is used by CF patients), showed a trend of a 
better lung function when this drug was administered as small particles of 3.42 µm as compared 
to large particles of 6.87 µm (Shah et al., 1997; Heijerman et al., 2009). The authors explained 
this by the ability of small particles to penetrate into peripheral airways, while the penetration 
of larger particles is disrupted due to the pathologic conditions in the lung, which include 
structural changes and narrowing of the airways due to the mucus plugging, inflammation, and 
infection (Shah et al., 1997; Heijerman et al., 2009). Similarly, a study with inhaled 
beclomethasone nebulised solution that is used in asthmatic patients, also showed improvement 
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in lung functions when it was administered as extra fine particles of 1.1 µm compared to fine 
particles of 4 µm (Vanden Burgt et al., 2000; Van Schayck and Donnell, 2004; Leach et al., 
2009). In the same way, other studies have reported that reduction in drug particle size is an 
efficient method to improve dissolution rate and absorption of orally administered drugs (Jinno 
et al., 2006; Liu et al., 2015). For example, a study with cilostazol, an oral anti-platelet and 
vasodilator drug, has shown better dissolution rate and solubility when it was delivered in small 
particle size of 2.4 µm as compared to the large particle size of 13 µm (Jinno et al., 2006). 
Therefore, a deep understanding of the impact of antibiotic particle size on its activity against 
P. aeruginosa biofilms could offer important data for the improvement and development of dry 
powder inhaler antibiotics.  
 
1.6 Tobramycin combination therapy  
 
To date, despite the improvement in antibiotic therapy for the management of P. aeruginosa 
infections, these are still difficult and challenging to eradicate (Silver, 2016; Wright, 2016; 
Momin et al., 2018; Miró-Canturri et al., 2019). The Infectious Disease Society of America has 
considered P. aeruginosa as one of top-threatening multi-drug resistant pathogens, for which 
considerable efforts should focus on the discovery and development of antibiotic therapies 
(Kung et al., 2010). Therefore, finding new strategies for treating such infections is warranted 
and recommend (Doern, 2014; Wright, 2016; Umerska et al., 2018).  
 
Such strategies may involve combination antibiotic therapy. For example, several studies have 
reported that the use of aminoglycosides as monotherapy is one of the possible reasons for the 
inefficient treatment of P. aeruginosa infections (Driscoll et al., 2007; Bjarnsholt et al., 2018). 
Therefore, using two or more antibiotics in combination could potentially improve the activity 
of the currently available antibiotics (Balke et al., 2006; Imperi et al., 2013; Otto et al., 2019). 
Such an approach restores antibacterial activity and reduces antibiotic resistance because 
targeting bacterial pathogens through different inhibition mechanisms simultaneously renders 
bacteria unable to tolerate antibiotic treatment, making it harder to evolve resistance (Sader et 
al., 2003; Wright, 2016).  
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Currently, investigating tobramycin combinations with non-antibiotic drugs has attracted 
considerable interest as compared to traditional combinations with antibiotic agents (Wright, 
2016; Laudy et al., 2017; Liu et al., 2017; Otto et al., 2019). This is mainly because of the 
current situation of antibiotic resistance and decreasing pipeline production of new antibiotics, 
in which using non-antibiotic drugs can be advantageous in different ways. For instance, these 
drugs do not affect bacterial growth, which can result in decreasing antibiotic selection pressure 
for resistance. Moreover, the development and improvement of these drugs are easier and 
quicker than producing new antibiotics, particularly because these non-antibiotics drugs are 
already FDA-approved. Additionally, the information on the pharmacokinetics and 
pharmacodynamics of these drugs is known and established. Therefore, the number of pre-
clinical and clinical studies needed to evaluate its efficacy for another indication are much less 
(Rampioni et al., 2017b; Maiden et al., 2018; Miró-Canturri et al., 2019).  
 
Recently, several non-antibiotic drugs have been found to possess anti-bacterial activity against 
biochemical processes without affecting bacterial growth (Imperi et al., 2013; Nehme et al., 
2018; Miró-Canturri et al., 2019). Examples of these are anti-depressants such as amitriptyline 
and sertraline, which showed activity against Gram-negative pathogens including P. 
aeruginosa. Such activity was found to be due to the inhibitory effect on efflux pumps (Kaatz 
et al., 2003; Mandal et al., 2010; Ayaz et al., 2015).  Niclosamide and albendazole are anti-
helminthic drugs that have shown activity against P. aeruginosa through inhibition of QS  
(Imperi et al., 2013; Chen et al., 2018; Singh and Bhatia, 2018; Domalaon et al., 2019).  Anti-
hypertensives are also another classe that has been shown activity against bacterial pathogens. 
This activity is associated with their ability to decrease concentrations of cations such as 
sodium and potassium, which can counteract the action of some antibiotics such as tobramycin. 
Examples of drugs in this class are amlodipine and amiloride (Middleton et al., 2005). The 
other group that has shown activity are flavonoids such as quercetin, whose antibacterial action 
is related to the suppression of QS (Pawlikowska-Pawlęga et al., 2007; Siriwong et al., 2016; 
Roy et al., 2018). Another class of non-antibiotic drugs with antibacterial activity are anti-
psychotics such as chlorpromazine and thioridazine. The activity of these is related to the 
disruption of the bacterial cytoplasmic membrane (Amaral et al., 2001; Dastidar et al., 2013; 
Nehme et al., 2018). Chelating agents such as diethylenetriaminepentaacetic acid also have 
antibacterial action by sequestering cations in the outer membrane (Banin et al., 2006; Finnegan 
and Percival, 2015). Finally, furanone is a natural compound that has antibacterial action 
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through QS suppression (Hentzer et al., 2002; Maeda et al., 2012; Rampioni et al., 2017b; 
Miró-Canturri et al., 2019). In summary, investigating the role of non-antibiotic drugs as an 
adjuvant with tobramycin could be a promising strategy to improve the antibacterial activity of 
tobramycin particularly in the current situation of global hazard concern about antibiotic 
resistance and the decreasing development of new antibiotics.  
 
1.7 Hypothesis and aims  
 
The introduction above has described P. aeruginosa lung infections and the effect of inhaled 
tobramycin in the treatment of biofilms formed by this bacterium. Currently, most studies that 
evaluate the in vitro activity of tobramycin rely on testing its efficacy against P. aeruginosa 
biofilms as an aqueous solution. However, as discussed earlier, in lung infections, tobramycin 
is usually delivered as a dry powder formulation. This tobramycin powder formulation has 
characteristics that could have an effect on the antibiofilm activity. Importantly, such 
characteristics are missing in the currently used in vitro models. Our hypothesis is that the 
particle size of tobramycin dry powder inhaler influences the activity against P. aeruginosa 
biofilms. The manipulation of particle size would therefore offer a new mechanism to improve 
the activity of inhaled tobramycin. However, the effects of particle size on antibacterial activity 
have not been previously documented. To test our hypothesis, tobramycin powder was 
fractionated into different sizes using pharmaceutical techniques, and these fractions were then 
used to challenge P. aeruginosa biofilms. In addition, we aimed to investigate the synergy of 
non-antibiotic drugs in combination with tobramycin, as this could be a second route through 
which tobramycin formulations could be improved. 
 
The specific aims of the thesis were: 
 
▪ To evaluate the activity of tobramycin against a number of P. aeruginosa isolates using 
a clinically relevant medium and two different in vitro biofilm models.  
 
▪ To develop and optimize in vitro models that allow the study and characterisation of 
tobramycin dry powder inhalations. These require the use of a pharmaceutical size 
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analyser to separate tobramycin powder into different particle size categories, and 
chemical analysis to quantify the mass of tobramycin powder.  
 
▪ To investigate the influence of these differently sized particles against P. aeruginosa 
isolates in a model that possibly simulates lung infections. 
 
▪ To investigate the influence of tobramycin combinations therapy with non-antibiotic 
drugs against P. aeruginosa biofilms using a clinically relevant medium, and to 



















               




Part A- Microbiological techniques  
2.1 Chemicals and bacterial culture media 
All chemicals and culture media were purchased from Sigma-Aldrich or Fisher Scientific, 
unless stated otherwise. TOBI Podhaler ® was purchased from Novartis.  
2.2 Bacterial strains  
All bacterial strains used in this research are listed in Table 2.1. Strains were preserved as 
glycerol stocks at – 80 °C in sterile cryogenic vials. P. aeruginosa glycerol stocks were 
prepared by mixing the bacterial cells with 70% (w/v) glycerol to a final concentration of 20 
% (v/v) glycerol. Overnight cultures were prepared in either Mueller-Hinton broth (MHB) or 
MOPS minimal medium and incubated 16-18 h at 37°C.  
Table 2.1 Bacterial strains used in this study. 
Strain Details Source Reference 
P. aeruginosa lab strains  
              PAO1   (Stover et al., 
2000) 
             NCTC 6750    
  P. aeruginosa clinical CF isolates 
⹂





Large genome, converted to 
mucoid; produces LPS which 
lacks O-side chains; lacks 
motility 
Boston, MA, chronic CF 
patient 
 




Paediatric CF patient (mucoid) 
form hospital de Santa Maria, 
Lisbon 
Libson Portugal, CF 
patient 
 
(Leitão et al., 
1996) 
 
          LMG 27649 
Stable CF sputum mucoid 
isolate; alginate hyperproducer; 
has functional QS system. 
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2.3 Alginate detection assays 
 
2.3.1 Congo red agar  
 
This experiment was performed to differentiate between two different P. aeruginosa 
phenotypes, mucoid and non-mucoid. This was carried out using Congo red agar described 
elsewhere (Mishra et al., 2015). Briefly, the medium was composed of brain heart infusion 
(BHI; 37 g/L), sucrose (50 g/L), agar (10 g/L) and Congo red stain (0.8 g/L). Sucrose solution 
was prepared separately, and filter sterilized to avoid its degradation by heat, and Congo red 
was prepared as a concentrated aqueous solution and autoclaved at 121°C for 15 min. After 
this, Congo red and sucrose were added to the BHI agar medium after it was cooled down to 
55°C. Finally, mucoid and non-mucoid isolates were cultivated on prepared BHI agar plates 
and were incubated at 37°C for 24 h. Alginate producing strains are indicated by black colonies, 
whereas non-producing strains are indicated by red colonies. 
 
2.3.2 MacConkey agar 
 
The MacConkey agar assay was used also to detect slime-producing strains as described 
elsewhere (Evans and Linker, 1973). Briefly, MacConkey agar was prepared according to the 
manufacturer’s instructions. MacConkey agar was supplemented with 5% glycerol as a good 
source for alginate or biofilm production. Bacterial suspensions were streaked out onto the 
surface of MacConkey agar. Afterward, plates were incubated for 48 h either at 37°C or at 
room temperature 25°C, as it was reported that slime production is better at room temperature 
(Evans and Linker, 1973). The appearance of slimy colonies was considered a positive 
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2.4 Bacterial growth media 
 
2.4.1 Mueller-Hinton Broth (MHB) 
 
MHB is a nutrient-rich medium and it consists of beef infusion solid 2 g/L, casein hydrolysate 
17.5 g/L, and starch 1.5 g/L.  MHB was prepared according to the manufacturer’s instructions 
and sterilized by autoclaving at 121°C for 20 min.   
 
2.4.2 Minimal MOPS Medium (MOPS) 
 
MOPS (3-(N-Morpholino) Propane-Sulfonic Acid) is a chemically defined minimal medium. 
MOPS medium was prepared as described elsewhere (LaBauve and Wargo, 2012) and was 
filter sterilized using a Nalgene vacuum filtration system® (Thermo Scientific; 0.22 µm; 75 
mm filter). 
 
2.4.3 Artificial Sputum Medium (ASM) 
 
ASM was prepared following the protocol previously described by Kirchner et al (2012) with 
components that are, as closely as possible, similar to CF sputum. It contains a highly 
glycosylated protein, mucin, essential and non-essential amino acids, salts, and DNA. Briefly, 
5 g mucin from porcine stomach type II, which has a long chain of O-linkages, was slowly 
dissolved overnight in 250 ml sterile Milli-Q water at 4°C. Similarly, 4 g deoxyribonucleic 
acid DNA from salmon sperm was slowly dissolved overnight in 250 ml sterile Milli-Q water 
at room temperature. Then 5.9 mg of a chelating agent, diethylenetriaminepentaacetic acid 
(DTPA), 5 g NaCl, and 2.2 g of KCl; were dissolved in 100 ml Milli-Q sterile water. After 
which, mucin, DNA, and DTPA, NaCl, KCl were all combined with the addition of 5 g 
casamino acids (Bacto). The volume was brought to 1 L with sterile Milli-Q water.  The pH 
was adjusted to 6.9 by adding 1.81 g Tris-base to mimic CF sputum pH, which varies from 6.5 
to 7.1 (Kirchner et al., 2012). Then the solution was autoclaved at 121°C for 15 min (Ghani 
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and Soothill, 1997; Aristoteli and Willcox, 2003). Afterward, a 5 ml of egg yolk emulsion was 
added. The prepared ASM was stored at 4°C.  
 
2.5 Antibiotic sensitivity 
 
2.5.1 Minimum inhibitory concentration (MIC)  
 
The MIC tests were performed as described elsewhere (Andrews, 2001) using the macro-
dilution protocol. The MIC is defined as the lowest concentration of an antibiotic agent that 
results in an inhibition visible growth of a microorganism after overnight incubation. 
 
2.6 Biofilm assays 
 
2.6.1 96-well plate assay 
 
Biofilm formation was performed using a 96-well plate assay as described elsewhere (Merritt 
et al., 2005; Coffey and Anderson, 2014), which was used to investigate the activity of 
tobramycin against P. aeruginosa biofilms. Briefly, overnight cultures were adjusted to an 
optical density (OD600) of 0.05 with MHB, MOPS medium, or ASM and then 100 µl aliquots 
were added to 96-well microtiter plates (Costar). Next, the microtiter plates were incubated at 
37°C for 24 h on a 3D plate rotator at 20 rpm. Afterward, planktonic bacteria were removed, 
and biofilms were gently washed three times with phosphate-buffered saline (PBS). Then the 
biofilms were treated by adding 100 µl fresh medium per well containing various 
concentrations of tobramycin and incubated for a further 24 h. This was followed by removing 
planktonic cells, washing biofilms three times with PBS, and drying plates for 1 h at 60°C. 
Following this, the biofilms were stained with 125 µl of 0.1% (v/v) crystal violet solution (CV; 
Prolab Diagnostics) for 15 min. Excess crystal violet stain was removed by washing plates in 
trays filled with lukewarm tap water three times. After this, the bound crystal violet was 
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solubilized by adding 150 µl of 30% (v/v) acetic acid. The absorbance was measured at a 
wavelength of 595 nm. 
 
2.6.2 Colony biofilm assay 
 
This assay was performed as described elsewhere (Merritt et al., 2005) and used to analyse 
tobramycin or colistin activity against P. aeruginosa biofilms. Briefly, two sterile 
semipermeable polycarbonate membranes (Whatman; 0.2 µm pore size, 25 mm) were placed 
on the surface of MH (Oxoid) agar plates (Figure 2.1). Then an aliquot of 50 µl of overnight 
culture, adjusted to an OD at 600 nm of 0.05, was spotted on each membrane. After that, the 
inoculated membranes were incubated for 48 h at 37°C to permit biofilm formation. The 
polycarbonate membranes were moved to fresh agar plates with sterile forceps on a daily basis. 
On the third day, 30 µg tobramycin or 50 µg colistin discs (Oxoid) were placed on the biofilms 
using sterile forceps and then incubated for a further 24 h as above. After this, biofilms were 
harvested by resuspension in 900 µl of sterile PBS, vortexed vigorously, and serially diluted. 
Serial dilutions from 10-1 to 10-7 were performed in sterile PBS for the suspended cells and 10 
µl of the 10-5, 10-6, and 10-7 dilutions were spotted as three drops for each dilution on MH agar 
plates and incubated for 24 h at 37°C. On the following day, the number of colonies was 
counted, and the Colony Forming Unit (CFU)/ml was determined using the Miles and Misra 
equation. 
 Colony Forming Unit (CFU/ml) = ((number of colonies * dilution factor) / volume of culture 
plated) 
 
 Figure 2.1 Colony biofilm assay. Schematic depiction of a colony biofilm assay.      
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2.7 The in vitro tobramycin drugs combination assay 
 
Tobramycin and drugs/compounds combination interactions against P. aeruginosa were 
investigated using a checkerboard technique. Drugs used in the combination study are listed in 
Table 2.2.  
 
Table 2.2 The drugs/compounds used in combination study with tobramycin. 
Drugs/Compounds name Property Reference 
Colistin  Polymyxin antibiotic (Herrmann et al., 2010) 
Amitriptyline hydrochloride Anti-depressant (Miró-Canturri et al., 2019) 
Niclosamide Anti-helminthic (Imperi et al., 2013; Domalaon 
et al., 2019) 
Amiloride Diuretic (Giunta et al., 1984; Treerat et 
al., 2008) 
Quercetin Plant flavonoid (Gopu et al., 2015) 
Chlorpromazine 
hydrochloride 
Anti-psychotic (Miró-Canturri et al., 2019) 
Diethylenetriamine 
pentaacetic acid 
Chelating agent (Miró-Canturri et al., 2019) 
4-hydroxy-2,5-dimethyl-
3(2H) furanone 
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2.7.1 Checkerboard assay  
 
A checkerboard microdilution assay was conducted to examine interactions of tobramycin 
according to a previously published technique (Domalaon et al., 2019). This was performed 
using 96-well microtiter plates (Figure 2.2). Firstly, stock and diluted solutions of these drugs 
were prepared on the same day of experiment either in sterile Milli-Q water or dimethyl 
sulfoxide (DMSO), which was used at a final concentration of 0.2%. Bacterial cultures grown 
overnight were diluted 1:100 in MHB and allowed to grow to exponential phase for 3-4 h. After 
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8 2/8 4/8 8/8 16/8 32/8 64/8 128/8 256/8 512/8 
4 2/4 4/4 8/4 16/4 32/4 64/4 128/4 256/4 512/4 
2 2/2 4/2 8/2 16/2 32/2 64/2 128/2 256/2 512/2 
1 2/1 4/1 8/1 16/1 32/1 64/1 128/1 256/1 512/1 
0.5 2/.5 4/0.5 8/0.5 16/0.5 32/0.5 64/0.5 128/0.5 256/0.5 512/0.5 
0 2 4 8 16 32 64 128 256 512 
 
Second drug/compound concentrations (µg/ml) 
  
Figure 2.2. The illustration above shows how tobramycin and second drug/compound were 
distributed in checkerboard assay using 96-well plate. The controls are indicated by the green color, the 
wells where each combination are intersecting are indicated by pink colors. Vertical gray wells represent 
tobramycin concentrations alone, whereas the horizontal gray wells represent second drug/compound 
concentrations alone. The numbers displayed in the figure represent tobramycin/second drug final concentrations 
in µg/ml. 
 
In brief, in each well of 96-well plate, the final volume was brought up to 150 µl as the 
following, firstly the 96-well plate was inoculated with 50 µl of diluted bacterial culture, then 
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100 µl of different concentrations of tobramycin (Figure 2.2) dissolved in ASM was 
individually dispensed in the columns of each respective concentration. Similarly, for the 
second compound, 100 µl of different concentrations dissolved in ASM was dispensed in the 
rows of each respective concentration (Figure 2.2). Then for the drug combinations, 50 µl from 
tobramycin and 50 µl from the second compound of each individual concentrations were 
distributed in a cross-fashion into 96-well plate as shown in Figure 2.2.  Next, two controls 
were included in each plate, the positive control (medium with Pseudomonas strain) and the 
negative or sterility control (medium only).  After this, the plates were incubated overnight at 
37°C for 16-18 h on a 3D- rotator at 20 rpm.  
 
Following incubation, the absorbance of each well was measured using a microplate reader at 
a wavelength of 595 nm. The MIC of separate or combined drugs wells was considered to be 
the wells without growth, where MICs were calculated and defined as described elsewhere 
(Meletiadis et al., 2010). Briefly, we firstly subtracted the blank from each well. Secondly, we 
considered that those wells that are close to zero as no growth, in which close to zero was 
defined as any well with < 10% of the highest absorbance value that we had. Finally, the 
checkerboard data were analysed by calculating fractional inhibitory concentrations (FICs) and 
the average of the FICs index from three checkerboard repeats was used to classify results 
(synergy, antagonist, indifference) using the following formula previously described (Ghorbani 
et al., 2017). 
FIC = FIC drug A + FIC drug B 
        = MICAB/MICA + MICBA/MICB 
FIC of drug A = MIC of drug A in combination with drug B/ MIC of antibiotic A alone 
FIC of drug B = MIC of drug B in combination with antibiotic A/ MIC of drug B alone. 
The FIC index data were interpreted according to the following criteria described before 
(Sopirala et al., 2010). Synergy was defined as an FIC index of ≤ 0.5, additive was defined as 
an FIC index >0.5 and ≤ 1, indifferent was defined as an FIC index > 1 and ≤ 4, and antagonistic 
was defined as an FIC index > 4. 
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2.7.2 Evaluation of tobramycin and drugs/compounds combinations against 
biofilm 
 
To investigate the activity of tobramycin drug combinations against P. aeruginosa biofilm, the 
96-well plate assay was used as described earlier (Section 2.6.1). Briefly, overnight cultures 
were adjusted to an OD600= 0.05 with MHB and then further diluted 1:100 in ASM. An aliquot 
of 100 µl was added to 96-well microtiter plates. Next, microtiter plates were incubated at 37°C 
for 24 h on a 3D plate rotator at 20 rpm. Afterward, planktonic bacteria were removed, and 
biofilms were treated by adding 100 µl fresh ASM per well containing different concentrations 
of either tobramycin alone/compound alone or a combination of both tobramycin and 
drug/compound. The plates were incubated for a further 24 h. Then the biofilms were 
quantified as described in section 2.6.1.  
 
Part B - Pharmaceutical techniques  
 
2.8 TOBI Podhaler® and Next Generation Impactor (NGI) measurement 
methodologies 
 
2.8.1 TOBI Podhaler ® 
 
TOBI Podhaler® 28 mg (Novartis, UK) is a dry powder inhalation formulation of tobramycin 
(Figure 2.3), and it is approved as maintenance therapy for chronic P. aeruginosa infections in 
cystic fibrosis patients aged 6 years and older (McKeage, 2013). Tobramycin from TOBI 
Podhaler ® was analyzed in terms of particle size distribution using an instrument called a Next 
Generation Pharmaceutical Impactor (NGI; Copley Scientific, Nottingham-UK). The NGI 
consists of several parts, and more details about the NGI components will be in chapter 4 
(Section 4.1). 
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Figure 2.3. TOBI Podhaler® 28 mg (unpublished image). 
 
2.8.2 Tobramycin particle size analysis  
 
2.8.2.1 Scanning Electron Microscopy (SEM) 
  
Tobramycin particles from all the NGI stages were collected separately on glass fibre filters 
using the method that will be described below (Section 2.8.5). These particles were analyzed 
using SEM by applying conditions stated elsewhere (Li et al., 2014). Tobramycin samples were 
fixed into aluminum stubs (Agar Scientific) using double-sided adhesive carbon tabs (Agar 
Scientific). Then, the samples were coated with a thin film of gold using a sputter coater 
(Edwards Sputter Coater S 150B). The coating process was operated at 1 kV of voltage for 3 
min. The images were captured using Jeol SEM (Jeol Jsm-6480LV Scanning Electron 
Microscope), and several magnifications levels were used. The captured images were further 
analyzed for size determination using the software package ImageJ (University of Wisconsin-
Madison, Broad Institute of MIT and Harvard, and Max Planck Institute of Molecular Cell 
Biology and Genetics).  For every ImageJ analysis, manual particle size measurements were 
performed, and for every measurement fix criteria were used as following, all particles in the 
given image were measured even the small particles that were on top of large particles, specific 
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number of particles were selected randomly, the same magnification was used for all images, 
and the diameters of all particles were measured in the vertical direction.  
 
2.8.3 Quantification of tobramycin mass deposited in the NGI 
 
2.8.3.1 High Performance Liquid Chromatography-Mass Spectrometry (HPLC-MS) 
quantification 
 
An HPLC-MS method for the determination of tobramycin deposited on the NGI stages was 
developed and validated. The chromatographic system that was used consists of a pentafluoro 
phenyl F5 column (Phenomenex; 2.6 µM, 2.1 x 100 mm) as the stationary phase, which was 
used with a flow rate of 0.3 mL/min at 25°C and an injection volume of 10 µL of each sample 
was injected in triplicate. The mobile phase involved utilizing two solvents, which were 100% 
water with 0.1% (v/v) formic acid as solvent A and 100% methanol with 0.1% (v/v) formic 
acid as solvent B. The proportion of these solvents in the mobile phase was controlled during 
the analysis by the UHPLC instrument. Elution was carried out with 0% mobile phase B for 3 
min followed by a linear gradient to 100% B for 7 min.  Mass spectrometer (Bruker Daltonik 
GmbH, Bremen, Germany) was operated in electrospray time of flight (ESI) positive-ion MS 
mode, and the following conditions were used during the MS analysis. The capillary voltage 
was set to 4500 V, nebulizing gas at 4 bar, and drying gas at 12 L/min at 220°C. The tobramycin 
concentration in injected samples (and thus the mass of deposited tobramycin on NGI 
compartments) was determined by constructing a calibration curve using kanamycin as an 
internal standard. A tobramycin sulphate stock solution for the calibration curve was prepared 
in Milli-Q water at a concentration of 500 µg/ml, which then was diluted in Milli-Q water to 
provide desired working concentrations (5-20) µg/ml. Kanamycin stock solution was prepared 
in Milli-Q water at a concentration of 400 µg/ml, then kanamycin was added to achieve a final 
concentration of 4 µg/ml in every calibration and unknown sample. Following the addition of 
kanamycin, samples were vigorously vortexed prior to HPLC-MS analysis. All stock solutions 
were prepared on the same day of the experiment, and HPLC-MS analysis was performed with 
24 h.  
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2.8.4 Tobramycin capsule filling and humidity control 
 
Hydroxypropyl methylcellulose capsules (HPMC; transparent; size #3; Capsugel®; UK) were 
used in this study for tobramycin filling. Before each experiment, capsules were filled manually 
with the tobramycin powder from the TOBI Podhaler® and weighed using a four-place 
analytical balance (Sartorius, Balance Technology, UK). They were then stored for 24 h in a 
sealed desiccator under a controlled temperature of 25°C and relative humidity (RH) of 43%. 
This RH was produced using a saturated salt solution of potassium carbonate (K2CO3) (Miller 
et al., 2017). Temperature and relative humidity were monitored using a thermohygrometer 
that was placed inside the desiccator. In the following day, these capsules were fired through 
the NGI as described below (Section 2.8.5). 
 
2.8.5 Determination tobramycin particle size distribution following 
aerosolization from the TOBI Podhaler® 
 
The NGI was used to analyse the tobramycin particle size distribution following aerosolization 
from TOBI Podhaler®. The test was performed as described in the British Pharmacopeia for 
dry powder inhalers (DPIs). Before testing, the NGI stages were coated with a solution of 1% 
v/v glycerol in methanol (VWR chemicals) to minimize particle bounce. The solution was left 
to dry for around five minutes during which the methanol evaporated leaving behind a thin 
layer of glycerol. 
 
A tobramycin capsule was placed within the TOBI Podhaler® device, then the capsule was 
pierced by pressing the blue button on the inhaler device (Figure 2.4; 1). After this, the closed 
Podhaler® device was tightly connected to ensure a good seal with a mouthpiece adaptor 
(Figure 2.4; 2) joined to the induction port (Figure 2.4; 3). The pre-separator (Figure 2.4;4) was 
filled with 15 ml Milli-Q water. After that, the NGI parts were joined together and closed. A 
critical flow controller (Figure 2.4; 6, Copley Scientific, Nottingham-UK) was used to adjust 
the flow rate of the air. This flow controller was connected to a vacuum air pump (Figure 2.4;7, 
Copley Scientific, Nottingham-UK), which was used to produce airflow through the NGI. The 
flow rate was determined using a digital flow meter (See Figure 2.8 below, DFM 2000, Copley 
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Scientific, Nottingham-UK). Flow rates of either 30 L/min and 60 L/min were consistently 
maintained throughout all the investigations. These two flow rates were selected because they 
are representative of the flow rates in CF patients (Tiddens et al., 2014), and the  diameters for 
particles collected on each stage of the NGI are known for these flow rates (Marple et al., 
2003). The vacuum pump was switched on and allowed to stabilise, before the value of the 
critical flow controller was opened for 10 seconds to draw air through the NGI and aerosolise 
the tobramycin powder into the NGI compartments.  
 
Figure 2.4 Complete closed NGI setup system. Inhaler device (1), mouthpiece adaptor (2), induction port 
(3), pre-separator (4), NGI (5), critical flow controller (6), vacuum air pump (7). (unpublished image) 
 
After the dispersion of tobramycin powder (Figure 2.5), the NGI was disassembled and each 
individual component including the capsule, mouthpiece adaptor with induction port was 
washed with known volumes of Milli-Q water into separated volumetric flasks to recover 
tobramycin (Figure 2.5). Similarly, the pre-separator, each collection stage S1-S7, and MOC 
were also washed with known volumes of Milli-Q water. Then each collection stage was placed 
on a magnetic stirrer for 10 min to ensure complete dissolution and recovery of tobramycin. 
Then, the extracted samples were collected in glass autosampler vials for analysis after 
appropriate sample dilutions were made. The mass of tobramycin deposited on each collection 
stage, mouthpiece, induction port, and pre-separator was determined by HPLC-MS as 
discussed in section 2.8.3. 
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Figure 2.5. NGI in an open position. A nozzle plate with several nozzles diameters (1), a stage plate (2) 
with seven collection stages (S1-S7) and MOC: micro-orifice collector to collect the incoming powder from the 
above nozzles. (unpublished image) 
 
2.8.6 Determination of the mass of tobramycin deposited on the aerosol 
collection apparatus attached to different NGI stages 
 
The aerosol collection apparatus with a glass fibre filter is an instrument that was introduced 
to the main NGI compartments to collect tobramycin particles (more details in chapter 4, 
section 4.1). The glass fibre filter (Figure 2.6) was replaced for each repeat of the experiment 
and the flow rate was adjusted for each experiment after placing the filter in the aerosol 
collection system.  
 
Two types of aerosol collection apparatuses were used, either a single (Figure 2.7) or double 
aerosol collection apparatus (Figure 2.8). The aerosol collection apparatus parts were 
assembled together and mounted either on either stage 2 or stage 4. The experimental set up 
with aerosols collection apparatus was performed as mentioned before (Section 2.8.5) with 
some modifications as follows. First, a rubber stopper (Figure 2.7; 1) was placed in the air 
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outlet from stage 2 or stage 4 to disrupt airflow and ensure the collection of all tobramycin 
particles. Second, the aerosol collection apparatus with a glass fibre filter (Copley®, 25 mm 
diameter, 1 µm pore size) was mounted either at stage 2 or stage 4 to collect tobramycin 
particles. Finally, every part of the NGI was washed as described above (Section 2.8.5), with 
the addition to the filter washing. Accordingly, the filter was rinsed with known volumes of 
Milli-Q water and sonicated for 10 min in an ultrasonic water bath to ensure complete 
dissolution of tobramycin powder.  
 
Figure 2.6. Aerosol collection apparatus with glass fibre filter inserted (1) to collect tobramycin particles. 
(unpublished image) 
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Figure 2.7. NGI with a rubber stopper (1) and a single aerosol collection apparatus (2) down the NGI. 
(unpublished image) 
 
Figure 2.8 NGI incorporated with a digital flow meter at the top of the NGI, and a double aerosol collection 
apparatus with two collection sites down the NGI. (unpublished image) 
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2.9 Applying different tobramycin particle sizes to P. aeruginosa 
biofilms 
 
After quantifying and equalizing the mass of tobramycin particles collected on the glass fibre 
filters at different NGI stages and flow rates using the methods outlined in the above (Section 
2.8.5 and 2.8.6), this experiment here was performed to examine the effect of different sized 
tobramycin particles on the eradication of P. aeruginosa biofilms. Briefly, colony biofilms 
were grown as outlined above (Section 2.6.2). Then the biofilms were treated with equal doses 
and different sized tobramycin particles (more detailed in chapter 4). This was performed by 
applying the glass fibre filters that hold tobramycin particles with direct physical contact on 
the top of the biofilms, controls were covered with a filter without tobramycin. Then, the 
biofilms with and without the treatment were incubated for 1.5, 3, 5, 6, 8 and 24 h at 37°C. 
Afterward, the CFU was determined as presented before (Section 2.6.2). 
 
2.10 Statistical analysis  
 
Data were presented as the mean ± standard error of the mean (SEM) of n ≥ 3 independent 
biological repeats. Results were analysed using GraphPad Prism 7 by applying either one-way 
or two-way ANOVA, followed by multiple comparisons using Tukey or Dunnett tests. 
Additionally, the Student t-test was also used. Values of p< 0.05 were considered statistically 
significant. In figures where the data are normalised and shown as a percentage of the control, 
statistical analysis was carried out on raw, non-normalised data values.  
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3.1 Introduction  
 
Pseudomonas aeruginosa is an opportunistic Gram-negative bacterium that causes serious and 
life-threatening infections in immunocompromised individuals such as in cystic fibrosis (CF) 
patients. In CF lung infections, P. aeruginosa is the predominant pathogen that has a major 
role in increased morbidity and mortality rates among those patients. This is attributed to the 
ability of this bacterium to resist the action of several antibiotic classes. Such resistance 
involves the limited permeability of the outer membrane, the abundance of efflux pumps, and 
phenotypic features including biofilm formation (Nikaido and Pagès, 2012; Ciofu et al., 2015; 
Muheim et al., 2017).  
 
Biofilms are highly organized communities of cells that are attached to each other and/or to 
surfaces and are embedded within a self-synthesized extracellular polymeric substance (EPS) 
matrix, mainly containing extracellular DNA, polysaccharides, and/or proteins (Furiga et al., 
2015). These biofilms are characterized by a high tolerance rate for both immune defensive 
mechanisms and for most of the available antibiotic therapies. For instance, it is assumed that 
cells inside biofilms are 10-1000 times less susceptible to anti-microbial therapies than 
planktonic free-floating cells (Patton et al., 2010; Marshall et al., 2016; She et al., 2018). This 
is attributed to, for example, a low metabolic rate for cells inside the biofilms as this can impair 
the activity of some antibiotics. Another factor is related to the effect of the EPS matrix, which 
may act as a barrier and impede the penetration of antibiotics into biofilms (Schneider-Futschik 
et al., 2018). 
 
Generally, P. aeruginosa biofilms in CF patients are treated with different classes of 
antibiotics, which are one of the cornerstone therapies for chronic lung infections (Greally et 
al., 2012). Aminoglycosides are one of the most commonly used antibiotic classes for the 
treatment of such infections in CF patients (Tre-Hardy et al., 2010). Aminoglycosides consist 
of several agents; however, tobramycin is the most prevailing used aminoglycoside in those 
patients (Olivares et al., 2017). Tobramycin has a well-known and established efficacy against 
P. aeruginosa in patients with CF. The bactericidal activity of  tobramycin is related to its 
ability to inhibit protein synthesis through binding to the 30 S ribosomal subunit that leads to 
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disruption of protein production and finally cell death (Babić et al., 2010; Tre-Hardy et al., 
2010; Olivares et al., 2017). Currently, P. aeruginosa resistance to tobramycin is growing and 
many factors have been reported to enhance tobramycin resistance in P. aeruginosa. Firstly, 
there is a general belief that using antibiotics at sub-inhibitory doses can modulate several 
processes in bacteria such as gene expression, virulence activities, quorum sensing (QS), and 
biofilm formation (Cummins et al., 2009; Andersson and Hughes, 2014; Sato et al., 2018). 
Studies demonstrated that tobramycin at sub-lethal concentrations can act as a signalling 
molecule and can alter the expression of several genes (Hoffman et al., 2005; Tahrioui et al., 
2019). These changes can result in inducing the formation of robust biofilms and accelerating 
antimicrobial tolerance towards tobramycin (Babić et al., 2010). Therefore, more studies are 
needed to clearly understand the effects of tobramycin at sub-MICs level, particularly that there 
is a relatively small number of studies available on the effects of tobramycin at sub-MICs in 
clinical CF isolates.            
                                        
Iron also plays a role in promoting tobramycin tolerance through enhanced formation of 
biofilms by P. aeruginosa (Cai et al., 2009). Iron is an essential element required by P. 
aeruginosa for several physiological processes including energy production, oxygen transport, 
gene expression, and biofilm formation (Moreau-Marquis et al., 2009). During chronic CF lung 
infections, iron homeostasis is imbalanced and elevated from normal very low level of 10-18 M 
to a high concentration of 63 µM. Indeed, others have reported that the elevated iron level can 
reach up to 130 µM or sometimes above 200 µM, which results in the exacerbation of lung 
damage (Schaible and Kaufmann, 2004; Berlutti et al., 2005; Kreamer et al., 2015; Ezraty and 
Barras, 2016; Tunney et al., 2018). This elevated level of iron is attributed to the lung injury, 
inflammation, and decreasing activity of lactoferrin, an iron-binding protein, as a result of 
degradation by bacterial proteases (Berlutti et al., 2005; Tunney et al., 2018). Such a high iron 
concentration can therefore serve as a stimulus factor to enhance biofilm formation in CF lung 
infections (Marshall et al., 2016). Accordingly, this would enhance the tolerance of P. 
aeruginosa to antimicrobial treatment such as tobramycin (Oglesby-Sherrouse et al., 2014).  
 
The host environment in CF lung infections can also affect the activity of tobramycin (Sherrard 
et al., 2014). For instance, in a CF lung, P. aeruginosa grows in a viscous dehydrated mucus 
(Moore and Mastoridis, 2017). This mucus consists of several components including DNA, 
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mucin glycoproteins, and others (Lai et al., 2009). Currently, there is growing evidence that 
these mucus constituents could interact with tobramycin and dramatically inhibit its activity 
(Schneider-Futschik et al., 2018). Accordingly, a clinically relevant medium called artificial 
sputum medium (ASM) has been developed, which is a culture medium consisting of CF 
sputum-like components including, mucins, DNA, salts, and amino acids (Kirchner et al., 
2012). Recently, few studies have used such medium to evaluate the impact of mucus 
components on the in vitro activity of tobramycin against P. aeruginosa. Therefore, it is 
essential to consider testing tobramycin susceptibility by using growth media that reflect 
pathologic conditions at the site of infection. 
 
Besides the role of tobramycin in the management of P. aeruginosa lung infections, colistin is 
also used in the treatment of CF patients. Colistin (polymyxin E) is a cyclic polypeptide 
antibiotic, which has a documented efficacy against Gram-negative bacteria (Pamp et al., 
2008). Colistin exerts antibacterial action through an extracellular mechanism, which depends 
on self-promoting uptake (porin channels independent) via direct interaction with the outer 
membrane components (Chiang et al., 2012). Such binding takes place by binding colistin to 
negatively charged phosphate groups within the surface molecule lipid A in the 
lipopolysaccharide of the bacterial outer membrane. This interaction results in the displacement 
of divalent cations, disruption of the outer membrane, and finally leakage of cell contents 
(Pamp et al., 2008). Resistance to colistin has evolved in many P. aeruginosa isolates (Fong et 
al., 2018). This resistance includes the ability of P. aeruginosa to create some the modifications 
in the colistin target site. Such modifications are mediated by expressing genes that are 
responsible for modification of the lipopolysaccharide layer, in which these called 
lipopolysaccharide modification genes pmr (Rybtke et al., 2011). Expression of such genes 
results in decreasing the net negative charge of the lipopolysaccharides in the outer membrane, 
and this is by the addition of a functional amino arabinose group instead of phosphate negative 
group in lipid A (Hamad et al., 2012). This functional group leads to reduced colistin binding 
affinity and consequently strengthens the outer membrane (Delcour, 2009). Additionally, it has 
been found that outer membrane vesicles (OMVs), which are released from the outer 
membrane by Gram-negative bacteria including P. aeruginosa, play a role in colistin resistance 
(Beceiro et al., 2013). These small spherical vessels are enriched with several constituents such 
as outer membrane proteins, lipopolysaccharides, phospholipid, virulence factors, quorum 
sensing signalling molecules, and nucleic acid such as DNA and RNA (Jan, 2017). These 
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components enable suppression of host immune defence and enhanced biofilm formation, 
which consequently leads to enhancing antibiotic tolerance (Jan, 2017). Finally, other studies 
have determined that colistin tolerance is also associated with the biofilm mode of growth. For 
instance, some bacterial cells inside a biofilm are with high metabolic activity and these are 
known to be less susceptible to colistin treatment than other slowly multiplying cells because 
the former cells can alter the outer membrane lipopolysaccharide layer through up-regulation 
pmr and mexAB-oprM genes (Haagensen et al., 2007; Pamp et al., 2008; Herrmann et al., 2010). 
 
This chapter aimed to evaluate the activity of tobramycin against biofilms of P. aeruginosa 
PAO1 and clinical CF isolates into several aspect. Firstly, to study the anti-biofilm activity of 
tobramycin using two different biofilm models. Secondly, to evaluate factors that can affect 
antibiofilm activity of tobramycin. These include studying the following, the impact of 
tobramycin at sub-MICs on the formation of biofilms, the influence of iron concentrations on 
anti-bacterial and anti-biofilm activity of tobramycin. Moreover, to evaluate the use of a 
clinically relevant ASM medium on the activity of tobramycin. Finally, to assess the activity 














3.2.1 Alginate producing strains 
 
To verify the mucoid state of P. aeruginosa CF clinical isolates, MacConkey agar and Congo 
Red agar were used to achieve this. However, the difference between mucoid and non-mucoid 
clinical CF isolates was not so obvious, with minimal differences in colours on these agar 
plates. Nevertheless, two clinical isolates had a different appearance when they were grown as 
a colony biofilm with a slimier appearance. These strains are LMG 27648 and LMG 27649, 
which were isolated from CF patients, and both are described as alginate producer (See 
Materials and Methods Chapter, Section 2.2). Therefore, the mucoid appearance that was 
observed indicates that they are phenotypically different. This was likely associated with the 
presence of alginate. 
 
3.2.2 The in vitro activity of tobramycin against planktonic P. 
aeruginosa  
 
Tobramycin is the mainstay therapy for the treatment of P. aeruginosa lung infections in CF 
patients (Babić et al., 2010). Therefore, our aim was to investigate its activity against a group 
of clinical CF isolates of P. aeruginosa. The minimum inhibitory concentrations (MICs) for 
planktonic lab strains and clinical CF isolates of P. aeruginosa were determined in MOPS 
medium using a macro-dilution protocol. MOPS medium was used in our studies in a way to 
mimic nutrient conditions in the lung, where bacteria grow under restricted nutrient conditions 
(Maeda et al., 2012; Charrier et al., 2014). As shown in Table 3.1, PAO1 and all of the clinical 
isolates were found to be susceptible to tobramycin with MICs ≤ 1µg/ml with the exception for 
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Table 3.1. The MICs of tobramycin against lab strains and clinical CF isolates P. aeruginosa 
determined in triplicate by macro-dilution method in MOPS medium. 
 
 
3.2.3 The in vitro activity of tobramycin against biofilms of P. 
aeruginosa using different biofilm models  
 
3.2.3.1 The in vitro activity of tobramycin determined using 96-well 
microtiter plate biofilm assay  
 
In the earlier section, the activity of tobramycin was determined against the planktonic form of 
P. aeruginosa, but it was also essential to explore its activity against the biofilm counterparts 
using a 96-well plate assay.  Accordingly, the strains were grown in MOPS medium for 24 h 
and then challenged with range of tobramycin concentrations. Since the objective of studying 
tobramycin activity is to predict what might occur in vivo, we selected clinically achievable 
tobramycin concentrations (16-204 µg/ml), which were measured in the CF lung after 
tobramycin inhalation (Bahamondez-Canas et al., 2018). Our results showed that the response 
of the tested strains for tobramycin was different. For instance, tobramycin resulted in a strong 
reduction in biofilm biomass by around 80-90% in LMG 27649 and NCTC 6750 (Figure 3.1 
C and E). However, for the other tested strains LMG 27643 and PAO1 (Figure 3.1 A and D) 
Lab strains/clinical CF isolates of P. 
aeruginosa 
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the amount of biofilm biomass was reduced to only 50-60%. The least reduction in biofilm 
biomass was observed in LMG 27648 (Figure 3.1 B) by just 40% at the concentrations from 
30-200 µg/ml. The different response that was observed in this strain could be attributed to its 
mucoid nature, as mucoid strains presumably are known to be more tolerant to tobramycin than 
non-mucoid counterparts, which could be due to alginate polysaccharide (Ciofu et al., 2012; 
Moller et al., 2019).  
 
Figure 3.1. The in vitro activity of tobramycin against P. aeruginosa biofilms determined using 
the 96-well plate assay. (A – C) show clinical CF isolates and (D-E) indicate lab strains. Wells in a 
96-well plate contained different concentrations of tobramycin (dissolved in MOPS medium) with an inoculum 
were incubated for 24 h at 37°C. The control represents biofilms without tobramycin. Error bars represent the 
standard error of the mean from five independent experiments with at least six technical replicate wells. Statistical 
significance was analysed using one-way analysis of variance (ANOVA) followed by Dunnett’s multiple 
comparison test. Statistically significance differences between treated biofilms (***, p<0.001; ****, p<0.0001) 
and the control are indicated. Full details of the statistical analysis are shown in appendix 1 and 2. 
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3.2.3.2 The in vitro activity of tobramycin determined using colony biofilm 
assay 
 
In the previous section, the anti-biofilm activity of tobramycin was measured using the 96-well 
plate model. Here, it was of interest to test this activity using a different model, the colony 
biofilm assay, which is possibly a better representative of biofilms in the lung, as unlike the 
96-well plates, it has an air interface. To that purpose, all P. aeruginosa clinical isolates 
(LMG27643, LMG27648, and LMG27649) and lab strains (PAO1 and NCTC 6750) were 
inoculated on polycarbonate membranes that were placed on MH agar plates and allowed to 
develop biofilms for 48 h and then challenged with 30 µg tobramycin discs for 24 h at 37°C. 
The results showed (Figure 3.2 A; B; C; D; and E), in all tested strains, tobramycin moderately 
reduced the amount of viable count by approximately 60%. 
Figure 3.2. The in vitro activity of tobramycin against P. aeruginosa using the colony biofilm assay. 
(A – C) show clinical CF isolates and (D-E) indicate lab strains. All P. aeruginosa biofilms were grown 
for 48 h in MOPS medium, treated with 30 µg/disc tobramycin, and incubated for 24 h at 37°C. The controls 
represent biofilms without tobramycin. The data shown represent the standard error of the mean from three 
biological repeats and each biological repeat consisted of at least two technical repeats. Statistics were analysed 
using unpaired 2-tailed t test. Statistical significance differences between treated biofilms (***, p<0.001; ****, 
p<0.0001) and the control are indicated. Full details of the statistical analysis are shown in appendix 1. 
 




3.2.3 The in vitro influence of sub-MIC tobramycin against 
biofilms of P. aeruginosa 
 
After studying the effect of therapeutic concentrations of tobramycin in the earlier sections, our 
aim here was to examine the influence of sub-MICs of tobramycin against P. aeruginosa 
biofilms. In CF lung infections, bacterial cells grow inside a biofilm and such biofilm might 
act as a barrier that can decrease the penetration of antibiotics. This could result in exposing 
bacterial cells to sub-inhibitory concentrations of antibiotics (Hoffman et al., 2005; Linares et 
al., 2006).  
 
Several studies found that antibiotics at sub-therapeutic concentrations could enhance various 
functions in bacteria such as the expression of virulence genes, motility, and biofilm formation 
(Cummins et al., 2009; Ratjen et al., 2009; Morita et al., 2014; Tahrioui et al., 2019). We were 
particularly interested in the latter and therefore, to address this effect, a range of sub-minimal 
inhibitory concentrations of tobramycin were used to challenge biofilms of P. aeruginosa using 
the previously described 96-well plate assay. All strains were tested with the MIC value as the 
highest concentration. Generally, under the tested conditions the results showed that there was 
a trend toward enhancing biofilm formation at sub-MICs of tobramycin albeit this trend was 
not reached to the statistical significance level, and it was not obvious in all cases. For instance, 
in LMG 27643 (Figure 3.3; A) there was a slight increase, in a dose-dependent manner, with 
biofilm biomass increased by approximately up to 50% as compared with that in the absence 
of tobramycin. Similarly, in the lab strain PAO1 (Figure 3.3; B), there was a moderate increase 
in biofilm formation in a dose-dependent pattern with an exception at 0.03 and 0.1 µg/ml. 
However, in the other strains (LMG 27648 and LMG27649) these trends were not observed 
(Figure 3.3, C and D). Noteworthy to mention is that in all tested strains, even at the MIC 
values (indicated in green bars), biofilm formation was observed. Taken together, these results 
suggest that tobramycin at doses below or at the MIC has a little effect on biofilm formation 
and, depending on the strain, could even promote biofilm formation in P. aeruginosa. 
 




Figure 3.3. The effect of sub-MICs of tobramycin on biofilm formation in P. aeruginosa. (A, C, 
D) show clinical CF isolates and (B) indicates a lab strain. The 96-well plate assay was used as 
described in materials and methods. Wells in a 96-well plate contained MOPS medium supplemented with 
an inoculum were incubated for 24 h at 37°C. This was followed by treatment with a range of sub-MIC tobramycin 
concentrations and incubated in the same conditions described above. The controls represent the P. aeruginosa 
biofilms without tobramycin treatment. The data shown presented the standard error of the mean from three 
biological repeats with at least six technical repeats. Statistical significance was analysed using one-way analysis 
of variance (ANOVA) followed by Dunnett’s multiple comparison test. White bars: controls, Pseudomonas 
without tobramycin; pink bars: Pseudomonas exposed to sub-MICs tobramycin; green bars: Pseudomonas 
exposed to MICs of tobramycin. Full details of the statistical analysis are shown in appendix 1 and 2.  
 
A previous study has shown that the composition of the growth medium can have a significant 
effect on biofilm formation (Haney et al., 2018). Therefore, it was of interest to determine if 
MOPS medium that we used would have an effect on the obtained results. Therefore, the 
experiments were also performed using MHB (rich medium) instead of MOPS medium. The 
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results (Figure A-D) showed that by using MHB there was no effect of tobramycin at sub-MIC 
on enhancing biofilm formation.  
Figure 3.4. The effect of sub-MICs of tobramycin on biofilm formation of P. aeruginosa. (A, C, 
D) show clinical CF isolates and (B) indicates a lab strain. The 96-well plate assay was used as 
described in materials and methods. Wells in a 96-well plate contained MHB medium supplemented with 
an inoculum were incubated for 24 h at 37°C. This was followed by treatment with a range of sub-MIC tobramycin 
concentrations and incubated in the same conditions described above. The controls represent the P. aeruginosa 
biofilms without tobramycin treatment. The data shown presented the standard error of the mean from three 
biological repeats with at least 6 technical repeats. Statistical significance was analysed using one-way analysis 
of variance (ANOVA) followed by Dunnett’s multiple comparison test. White bars: controls, Pseudomonas 
without tobramycin; pink bars:  Pseudomonas exposed to sub-MICs tobramycin; green bars: Pseudomonas 
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3.2.4 The in vitro influence of iron on P. aeruginosa 
 
In the section discussed before, the biofilm formation as the result of using sub-MIC 
tobramycin was evaluated. Here, our aim was to explore more about the role of other factors 
in enhancing biofilm formation. Recently, the influence of iron on enhancing biofilm formation 
and resistance to tobramycin in P. aeruginosa has received considerable attention in research 
(Oglesby-Sherrouse et al., 2014). For instance, it was previously established that the in vivo 
iron levels in CF lung infections play a major role in the recalcitrance of P. aeruginosa to 
tobramycin (Oglesby-Sherrouse et al., 2014). Therefore, the role of iron was investigated 
against P. aeruginosa planktonic growth rate, biofilm formation, and tobramycin susceptibility. 
 
3.2.4.1 The in vitro influence of iron on planktonic growth rate 
 
This experiment was performed to assess the impact of iron on the growth rate of planktonic 
P. aeruginosa. Overnight cultures were prepared and diluted 1:100 into MOPS medium 
supplemented with different ammonium iron citrate (NH4)5[Fe(C6H4O7)2] concentrations, 
followed by incubation at 37°C. The growth rates were monitored hourly over six hours. Data 
revealed (Figure 3.5, A-D) that iron concentration had no effect on the growth rates of 
planktonic P. aeruginosa clinical isolates and PAO1. This means under the tested conditions, 
iron is not a limiting factor for P. aeruginosa growth. It was also noted that a small difference 
in growth rate under high iron level was observed only at 4 h in two clinical isolates LMG 
27643 and LMG 27649 (Figure 3.5 B and C). This time point more or less corresponds to the 
end of the exponential growth phase, indicating that at low iron concentrations the bacteria may 
enter the stationary phase slightly earlier. However, it should be noted that this experiment has 
only performed once, and it needs to be demonstrated that results are reproducible. The same 
experiment was also performed but without adding any iron to MOPS medium. The results 
(data not shown) suggested that MOPS medium without iron did not support the growth of 
LMG 27649 clinical isolate, but other clinical isolates and PAO1 were able to grow, indicating 
that there is a low concentration of iron present as contaminate that can support the growth of 
other strains. The addition of 0.01 µM iron to the medium was however sufficient also for LMG 
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27649 growth, and this concentration was therefore used in all subsequent experiments as the 
low iron condition.  
Figure 3.5. The effect of different iron levels on the growth rate of planktonic P. aeruginosa.  (A-
C) indicate clinical CF isolates and (D) shows a lab strain PAO1. Bacterial cells were grown at 37°C 
in MOPS medium supplemented with either 0.01 µM or 100 µM of iron. Growth measurements were taken every 
hour. The data shown one biological repeat (n = 1).  
 
3.2.4.2 The in vitro influence of iron on planktonic susceptibilities to 
tobramycin (MICs)  
 
As the above section described the effect of iron on the growth rate of P. aeruginosa, this 
section was to understand whether different ammonium iron citrate (NH4)5[Fe(C6H4O7)2] 
availability can affect P. aeruginosa susceptibility towards tobramycin.  A recent study has 
examined the effect of iron on MICs of tobramycin against P. aeruginosa and the results 
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showed that different iron availability has no effect on MIC values (Musk et al., 2005). To 
replicate this, the MICs for tobramycin in MOPS medium supplemented with either low iron 
(0.01 µm) or high iron (100 µm) was measured using macro-dilution assay. The MIC data are 
presented in Table 3.2. Our results suggested that the MICs for tobramycin were similar under 
different iron availabilities for all tested clinical CF isolates and lab strain and the results were 
in accordance with the above-mentioned study.  
 
Table 3.2. The MICs of tobramycin in low iron and rich iron MOPS medium against lab strain PAO1 
and clinical CF isolates P. aeruginosa were determined in triplicate by macro-dilution assay.  
 
 
3.2.4.3 The in vitro influence of iron on biofilm formation in P. aeruginosa 
and boosting resistance of tobramycin   
 
After we illustrated the effect of iron on planktonic P. aeruginosa susceptibilities towards 
tobramycin in the previous section, it was interesting to know how the biofilm susceptibility to 
tobramycin is affected by different iron concentrations. Therefore, to address this issue, clinical 
CF isolates and lab strains P. aeruginosa were inoculated in the 96-well plates containing 
MOPS medium supplemented with different concentrations of ammonium iron citrate 
(NH4)5[Fe(C6H4O7)2]. The concentrations included were 8, 63, and 100 µm iron; these 
represent the standard iron concentration in MOPS medium, and the elevated concentrations 
found in CF lungs respectively (Berlutti et al., 2005; LaBauve and Wargo, 2012; Ezraty and 
Lab strain/clinical CF 
isolates of P. aeruginosa 
MICs (µg/ml) in low iron 
(0.01 µm) 
MICs (µg/ml) in high 
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Barras, 2016). Then the biofilms were incubated for 24 h at 37°C, after this they were 
challenged with 50 µg/ml tobramycin and incubated for a further 24 h. The results (Figure 3.6 
A-D) showed that there was no significant difference between various iron concentrations on 
biofilm biomass and tobramycin resistance. 
 
Figure 3.6. The influence of different iron availability on biofilm formation and tobramycin 
resistance of P. aeruginosa. (A- B) show clinical CF isolates and (C-D) indicate lab strains. The 
96-well plate assay was used as described in materials and methods. Wells in a 96-well plate contained 
different concentrations of iron in MOPS medium supplemented with an inoculum, and then the plate was 
incubated for 24 h at 37°C. This was followed by treatment with 50 µg/ml tobramycin concentrations dissolved 
in various iron concentrations. Blue bars: 8 µM iron, pink bars: 63 µM iron, and green bars: 100 µM iron. The 
data shown are presented as standard error of the mean from three independent experiments with at least six 
technical replicates. Statistical significance was analysed using one-way analysis of variance (ANOVA) followed 
by Tukey multiple comparison test. Full details of the statistical analysis are shown in appendix 1. 
 
In the previous pre-liminary iron experiment on biofilm formation, the effect of different iron 
availability on biofilm formation was tested. Here, we sought to test the effect of low iron levels 
of 0.01 µM as probably represent restricted iron concentration in healthy lung and compare it 
to the high iron level of 100 µM that represents the concentration in CF lung. This was 
evaluated on a range of tobramycin concentration. Results obtained for LMG 27648, LMG 
27643, and PAO1 (Figure 3.7; A, B, and D) showed that at 100 µM iron, there was a trend of 
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enhancing tobramycin tolerance as compared to 0.01 µM iron, albeit this was not statistically 
significant. Conversely, for the other strain, NCTC 6750 (Figure 3.7, C), we found that trend 
for low iron concentration, while this was not the case for the high iron concentration again 
this was statistically not significant. This may be because at low iron concentrations, P. 
aeruginosa enhances expression of mexA-mexB -oprM gene operon. This leads to the synthesis 
of the MexA-MexB-OprM efflux pump, in which it is considered one of the highly 
characterized pumps of resistance nodulation division (RND) family. It is well-known that 
MexAB-OprM provides an intrinsic resistance for P. aeruginosa against several antibiotics 
including tobramycin (Ezraty and Barras, 2016; Rampioni et al., 2017a; Diggle and Whiteley, 
2019). However, it is unclear why this happened only with NCTC 6750 strain.  
Figure 3.7. The influence of different iron availability on biofilm formation and tobramycin 
resistance of P. aeruginosa. (A-B) show clinical CF isolates and (D) indicate a lab strain. The 96-
well plate assay was used as described in materials and methods. Wells in a 96-well plate contained 
different concentrations of iron in MOPS medium supplemented with an inoculum, and then the plates were 
incubated for 24 h at 37°C. This was followed by treatment with tobramycin dissolved in various iron 
concentrations. Green bars: 100 µM iron, blue bars: 0.01 µM iron, the controls represent biofilms without 
tobramycin. The data shown are presented as the standard error of the mean from three independent experiments 
with at least six technical replicates. Statistical significance was analysed using two-way analysis of variance 
(ANOVA) followed by Tukey multiple comparison test. Full details of statistical analysis are shown in appendix1. 
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3.2.5 The in vitro activity of tobramycin using artificial sputum 
medium (ASM)  
 
In all of the above sections, the activity of tobramycin was analysed using MOPS medium. 
Currently, a study has importantly recommended the use of a more clinically relevant medium 
to test the activity of antibiotics against P. aeruginosa (Kirchner et al., 2012). Accordingly, in 
this section, we aimed to get further insights on exploring tobramycin activity under a condition 
that is as close as possible simulate the chemical environment of the CF lung. To achieve this, 
ASM was developed and optimized as outlined in the Materials and Method chapter. This ASM 
contains mucin, DNA, amino acids, and salts. The highly glycosylated proteins (mucin) and 
DNA are the main macromolecular components of the CF sputum (Yang et al., 2010; Huang 
et al., 2015). Amino acids are also found in a high concentrations in CF sputum in a range 
between 3.77 – 6.77 mg/L (Barth and Pitt, 1996), where this is attributed to the infection and 
inflammation. This is because neutrophils and pathogens release proteases that degrade 
proteins, resulting in the release of peptides and amino acids (Thomas et al., 2000; Yang et al., 
2010). This medium was used to examine the activity of tobramycin against planktonic and 
biofilms of P. aeruginosa.  
 
3.2.5.1 The in vitro activity of tobramycin against planktonic P. aeruginosa 
in ASM 
 
The antibacterial activity of tobramycin (MICs) was determined against planktonic lab strain 
and clinical isolates of P. aeruginosa in ASM medium using the macro-dilution assay. As 
shown in Table 3.3, PAO1 and all of the clinical isolates were found to be susceptible to 
tobramycin with MICs 4 µg/ml. However, there was a four-fold increase in the MICs as 
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Table 3.3. The MICs of tobramycin against PAO1 and clinical CF isolates P. aeruginosa determined 
in triplicate by macro-dilution method in ASM medium. 
 
3.2.5.2 The in vitro activity of tobramycin against biofilms of P. aeruginosa 
in ASM 
 
As the previous section showed that ASM had an effect on the activity of tobramycin against 
planktonic P. aeruginosa, this encouraged us to study its effect on the biofilm phenotypes. 
Therefore, all P. aeruginosa clinical isolates and PAO1 were inoculated on polycarbonate 
membranes that were placed on MH agar plates and allowed to develop biofilms using ASM 
for 48 h and then challenged with 30 µg tobramycin discs for 24 h at 37°C. Unexpectedly to 
what is already known about the role of ASM components, where they bind tobramycin and 
reduce its activity and also in comparison to the results outlined earlier in MOPS medium 
(Section 3.2.3.2), tobramycin retained its activity against ASM grown biofilms where it 
displayed a significant reduction in the viable count by 60% against LMG 27649, LMG 27643 
and PAO1 (Figure 3.8 B; C; and D). Likewise, the remaining clinical isolate LMG 27648 
(Figure 3.8 A), behaved similarly as other isolates, where there was a reduction in the viable 
count by 40% as compared to control, but it was statistically not significant.  
 
Lab strain/clinical CF isolates of P. 
aeruginosa 














Figure 3.8. The in vitro activity of tobramycin in ASM against P. aeruginosa determined using the 
colony biofilm assay. (A – C) show clinical CF isolates and (D) indicates a lab strain. All the clinical 
isolates or a lab strain were grown in ASM for 48 h and then treated with 30 µg/disc tobramycin and incubated 
for 24 h at 37°C. The controls represent the biofilms without tobramycin. The data shown represent the standard 
error of the mean from three independent experiments with at least two technical replicates. Statistical significance 
was analysed using unpaired 2-tailed t test. Statistical significance differences between treated biofilms (***, 
p<0.001) and the control are indicted. Full details of the statistical analysis are shown in appendix 1. 
 
3.2.6 The in vitro activity of colistin against planktonic and biofilms 
of P. aeruginosa 
 
Earlier, the activity of tobramycin was determined against P. aeruginosa. Here, we aimed to 
evaluate the activity of colistin, which is another antipseudomonal antibiotic that has been 
introduced for the treatment P. aeruginosa lung infections due to the emergence of multidrug 
resistance pathogens (Gutu et al., 2013). Accordingly, the following sections will investigate 
the activity of colistin against planktonic and biofilms phenotypes of P. aeruginosa using ASM.  
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3.2.6.1 The in vitro activity of colistin against planktonic P. aeruginosa in 
MOPS and ASM media 
 
To investigate the antibacterial activity of colistin against planktonic P. aeruginosa, MICs were 
established against a lab strain PAO1 and clinical isolates of P. aeruginosa in MOPS medium 
and compared to the MICs in ASM using macro-dilution protocol. As shown in Table 3.4, in 
MOPS medium, PAO1 and all of the clinical isolates were found to be susceptible to colistin 
with MICs ≤ 1 µg/ml. Similarly, in ASM all the strains were susceptible but with a slight 
increase in the MICs by a two-fold in PAO1 and in two clinical isolates, (LMG 27648 and 
LMG 27649), whereas the MIC for the other clinical isolate LMG 27643 was not changed with 
ASM.  
 
Table 3.4. The MICs of colistin against PAO1 and clinical CF isolates P. aeruginosa determined in 
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3.2.6.2 The in vitro activity of colistin against biofilms of P. aeruginosa 
determined in ASM medium  
 
In the above section the activity of colistin was investigated against planktonic P. aeruginosa. 
In the current section, it was important to determine the in vitro activity of colistin against 
biofilms of P. aeruginosa clinical CF isolates (LMG27648, LMG27649, and LMG27643 and 
lab strain PAO1). Therefore, the strains were inoculated on polycarbonate membranes that 
were placed on MH agar plates and allowed to develop biofilms using ASM for 48 h, then these 
challenged with 50 µg colistin discs for 24 h at 37°C. The results (Figure 3.9 A and B) for 
LMG 27648 and LMG 27649 clinical isolates showed that colistin caused a 40% reduction in 
the viable count but this was statistically not significant (p> 0.05).  In comparison with other 
strains, LMG 27643 and PAO1 (Figure 3.9 C and D), a significant (p < 0.05) reduction in the 
viable count by 60% was observed.  
 
Figure 3.9. The in vitro activity of colistin against P. aeruginosa biofilms determined using the 
colony biofilm assay. (A – C) show clinical CF isolates and (D) indicates a lab strain. All clinical 
isolates and a lab strain were grown in ASM for 48 h and then treated with 50 µg/disc colistin, and incubated for 
24 h at 37°C. The controls represent biofilms without colistin. The data shown represent the standard error of the 
mean from three independent experiments with at least two technical replicates. Statistical significance was 
analysed using unpaired 2-tailed t-test. Statistically significant differences between treated biofilms (**, p<0.01) 
and the control. Full details of the statistical analysis are shown in appendix 1. 
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3.3 Discussion  
 
In this chapter, we investigated the activity of tobramycin against planktonic cultures and 
biofilms of P. aeruginosa clinical CF isolates and lab strains. Also, we determined the effects 
of several factors on the antibiofilm activity of tobramycin including, the influences of 
tobramycin at sub-MICs and the effect of various iron availability. Indeed, the effect of growth 
media MOPS and ASM on tobramycin activity was determined. Finally, we also examined the 
activity of colistin against planktonic and biofilms of P. aeruginosa. 
 
Tobramycin is one of the most commonly used antibiotics in the treatment of P. aeruginosa 
infections in CF patients (Kaushik et al., 2016). Therefore, in this study, tobramycin 
susceptibility was evaluated using two biofilm models. Firstly, the 96-well plate biofilm assay 
was used because it has several advantages (Coffey and Anderson, 2014). One of those is the 
applicability to perform screening for a large number of bacterial strains in a single assay 
(Merritt et al., 2005). Moreover, its protocol is simple to perform using common laboratory 
instruments. However, besides these benefits this assay does has some drawbacks such as using 
the crystal violet. The latter stains biomass, which is not equivalent to a viable count as it will 
stain both dead and alive cells as well as the extracellular polymeric matrix (Coffey and 
Anderson, 2014). Therefore, to address the limitations that could result in an overestimation 
mass of adherent bacteria, the microtiter plate assay was also combined with another biofilm 
model, the colony biofilm assay (Merritt et al., 2005). In the colony biofilm model, biofilms 
grow at the air surface-interface. This way of growing is probably a better reflection of how 
biofilms grow in the lungs. Additionally, the parameter that was used to assess the activity of 
tobramycin in colony biofilm assay was through counting the number of living bacterial cells 
instead of total biofilm biomass. This assay also has its disadvantages, such as the 
underestimation of the number of living cells that are counted. As this assay only measures the 
number of the living culturable cells, however, the biofilms have also populations that they are 
alive but non-culturable because of their very low metabolic rate (Azeredo et al., 2017). Our 
data from both biofilm assays indicated that using tobramycin at the clinically achievable 
concentrations was only able to reduce biofilm biomass/viable count by 40-60%, however, 
complete eradication was not observed in all of the tested strains. Such tolerance of these 
biofilms to the action of tobramycin could be explained by several mechanisms, however, we 
have not tested any of them. These mechanisms involved the slowed growth rate of cells inside 
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biofilms, the decreased penetration of tobramycin through biofilm matrix (Field et al., 2005; 
Ye et al., 2018), and recently there are reports suggested that P. aeruginosa cells inside the 
biofilm can resist antibiotics including tobramycin by a genetic changes, which resulted in 
producing cyclic glucose polymers termed as periplasmic glucans that can sequester 
tobramycin and decrease its activity (Rogan et al., 2004; Hill et al., 2005). Importantly these 
data could explain the current challenges for the treatment of these biofilms in the clinical 
setting. Our data were in accordance with previous study (Field et al., 2005), which showed 
that using tobramycin at a dose up to 128 mg/L both under aerobic and anaerobic conditions 
was unable to eradicate biofilms of P. aeruginosa clinical CF isolates and PAO1.  
 
The implications of exposing P. aeruginosa biofilms to sub-lethal concentrations of 
tobramycin was investigated in our study. Our findings revealed that there was a trend of slight 
induction of biofilm formation, but it was statistically not significant. In contrast to our 
findings, other studies found a significant and clear induction of biofilm formation of 
tobramycin at sub-MICs (Hoffman et al., 2005; Tahrioui et al., 2019). It is, however, 
noteworthy to mention that different strains and growth media were used in those studies. For 
example, the study by Tahrioui et al (2019) used different strain of P. aeruginosa H103. 
Another study by Hoffman et al (2005) was performed using MHB growth medium. To 
reproduce their work, our experiments were re-performed using MHB. Surprisingly, our results 
did not change by using the MHB. This highlights an issue raised in a number of studies, in 
which there are concerns with the lack of standardisation in biofilm research, while there should 
be a requirement to follow guidelines and standards for describing experimental methods. 
These standards have been established for several biological studies including biofilms 
research to facilitate repeatability and reproducibility of the experiments (Taylor et al., 2008; 
Boudarel et al., 2018). However, due to the lack of standardization, there is a significant 
heterogenicity and variability in the results obtained and published in literature. Such 
variability is related to different biofilm protocols, designs with various growth conditions that 
are used in the experiments, such as growth media composition, pH, and temperature, as all of 
which can lead to variation in the results. Therefore, it is difficult to reproduce and compare 
results between the published studies (Taylor et al., 2008; Boudarel et al., 2018).  
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A previous study demonstrated that iron has a major role in P. aeruginosa infections (Banin et 
al., 2005). In this context, the influence of iron on growth rate and susceptibility of planktonic 
P. aeruginosa towards tobramycin in terms of MICs was measured. Regarding the planktonic 
growth rate, the data suggested that neither nil or low iron (0.01 µM), nor high iron (100 µM) 
concentrations had an effect on the growth rate of P. aeruginosa. Similarly, the MIC data 
indicated that there was no change in tobramycin activity in low and high iron levels, and we 
can therefore conclude that iron is not a limiting factor under the tested conditions.  Our work 
was in agreement with Cai et al. (2009), where they found that MICs for tobramycin did not 
change under iron repletion (100 µM) and iron depletion conditions. Noteworthy to mention 
that in this study they used 2, 2-dipyridyl as a chelator to induce an iron restricted environment 
in the MHB medium.  
 
The effect of iron on biofilm formation in P. aeruginosa was also assessed. Our results 
suggested a trend of increased tolerance to tobramycin in some of the tested P. aeruginosa 
strains under high iron (100 µm) conditions and a trend of decreased tolerance under low iron 
concentration (0.01 µm) with exception of P. aeruginosa NCTC 6750. However, the difference 
between the two iron concentrations was not statistically significant. One explanation for these 
data may be that our MOPS medium has another source of iron rather than the specified 
amounts, which could be as a contaminant in some of the salts, and this means the actual 
concentrations in MOPS medium are higher than the assumed concentrations. This was 
confirmed (data not shown) in our work, where three strains out of four were able to grow in 
MOPS without any addition of iron, which could suggest the presence of iron contamination 
in the medium. Such a problem has been discussed by Ezraty et al (2016), as one of the sources 
for the variable iron results obtained in the literature. Indeed, under low iron tested 
concentration, the bacterial cells enter into slow metabolism mode of growth, which could 
make them also less susceptible to tobramycin treatment (Williamson et al., 2012). Another 
possible reason is that under iron-restricted conditions, iron sequestration genes are upregulated 
in P. aeruginosa. These genes result in activation of an iron uptake system using siderophores 
such as pyoverdine and pyochelin (Gi et al., 2015). In contrast, in iron-load conditions 
siderophore production is downregulated. Our data were in agreement with what was found by 
Oglesby-Sherrouse et al (2014), where they observed that using iron 100 µM resulted in 
enhancing tobramycin resistance in PAO1 biofilm and this effect was removed when they 
added deferasirox as an iron chelator. In the contrary, our work was in conflict with what Musk 
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and colleagues found (Musk et al., 2005), as they determined that iron resulted in enhanced 
susceptibility to tobramycin. The most plausible explanation for this could be because 
differences in experimental design such as the use of a different P. aeruginosa strain (PA14), 
which was grown in a different medium (Tryptic soya agar, TSA). In addition, they used very 
high iron concentrations of up to 500 µM, which might be not clinically relevant. This high 
concentration could result in biofilm disruption and enhanced tobramycin susceptibility. Such 
an increase in the susceptibility is mainly attributed to the formation of reactive oxygen species, 
such as a hydroxyl species through the Fenton reaction. This reactive oxygen species can be 
dangerous and toxic to bacterial cells by attacking their cellular components and causing DNA 
breakage (Schaible and Kaufmann, 2004). 
 
A more clinically relevant medium ASM was also used to evaluate the activity of tobramycin 
and colistin against planktonic P. aeruginosa. Our results showed that the MICs of tobramycin 
and colistin were increased in ASM medium by four and two-fold respectively as compared to 
the MOPS medium. However, even the MICs values were increased, they still considered 
susceptible to either tobramycin or colistin according to BSAC breakpoints (Andrews, 2007). 
It should be noted that those breakpoints are only determined in standard media such as Iso-
Sensitest or Mueller-Hinton broth. One explanation would be because of the components that 
are present in ASM. These for instance include mucin and DNA, which might act as an inhibitor 
for tobramycin because of electrostatic interactions between poly-anionic mucins or DNA and 
cationic tobramycin or colistin. Such binding could result in less free available tobramycin or 
colistin and consequently reducing their bacterial killing potency. Our findings were in good 
agreement with what previously reported (Huang et al., 2015; Schneider-Futschik et al., 2018).   
For instance, Huang et al (2015) found an elevation in MICs for tobramycin and colistin against 
several Gram-negative bacteria including P. aeruginosa when these antibiotics were incubated 
with different concentrations of mucin, which is one of the main components of CF sputum. 
This suggest that the components of CF sputum decrease the bioavailability of antibiotics, 
which consequently results in decreased the efficacy. Similarly, the work that has been done 
by Schneider-Futschik et al (2018) suggested that the components of ASM medium resulted in 
the elevation of MICs for colistin and other polypeptides antibiotics against P. aeruginosa. Our 
data and other cited papers suggest that it is essential to consider using a more clinically 
relevant culture media for testing the susceptibility of antibiotics.  
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Surprisingly, under the biofilm conditions, ASM did not affect tobramycin potency and the 
activity was almost similar to that in the MOPS medium. Similar work has been done 
previously (Braun et al., 2018), but that study used natural human mucus, which revealed a 
significant decrease in tobramycin activity. This could be explained by different characteristics 
between ASM and human mucus. For instance, the elasticity and viscosity of human mucus 
might affect intermolecular forces interactions between mucus and drugs. Finally, the activity 
of colistin was also evaluated against biofilms of P. aeruginosa. The data showed that colistin 
resulted in a 50-60% reduction in the viable count, however, complete eradication was not 
achieved. It is possible that this is a reflection of the findings in another study (Pamp et al., 
2008), which found that colistin was able to kill the P. aeruginosa bacterial subpopulation with 
low metabolic activity, but not the subpopulation of the biofilm with a high metabolic activity. 
However, we did not confirm here that it was only the cells with high metabolic activity that 




In this chapter, the activity of one of the most clinically important antibiotics in the treatment 
of CF patients, tobramycin, was evaluated against P. aeruginosa biofilms using ASM. 
Tobramycin resulted only in a 40-60% reduction in biofilm biomass/viable count in most of 
the tested strains, however, complete eradication of P. aeruginosa biofilms was challenging. 
This could highlight for important clinical consequences of such infection. Similarly, such data 
was also observed with colistin, where only a 50-60% reduction in viable count was achieved. 
The presence of resistant P. aeruginosa biofilms simultaneously with the declining rate of the 
pipeline development of new antibiotics suggests that it is important to search for an alternative 
way to effectively use the currently available antibiotics to overcome biofilms resistance. 
Therefore, our aim in the next following chapters is to explore the possible mechanisms that 
could be used to improve the activity of tobramycin against P. aeruginosa biofilms. This will 
be achieved by examining two main possible strategies. Firstly, the activity of tobramycin as a 
dry powder inhaler will be investigated utilizing one of the most important physical properties 
of the powder, particle size, as a possible way to enhance tobramycin efficacy. Secondly, the 
activity of tobramycin will be evaluated by establishing an effective drug combination with 
tobramycin as another possible ways to promote its activity.  
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4.1 Introduction  
 
The most commonly identified pathogen in chronic CF lung infections is P. aeruginosa, which 
is settled and localized in a thick mucus layer in the trachea-bronchial region of the respiratory 
airways. Treating such infections using the systemic delivery of antibiotic agents is challenging 
because high doses are required to reach the lung tissue. Such doses are associated with severe 
adverse reactions. Therefore, the pulmonary delivery of antibiotics is an attractive approach for 
the treatment of lung infections (Worlitzsch et al., 2002; Geller et al., 2011). This is because 
delivering the drug directly to the site of infection achieves high therapeutic concentrations and 
rapid onset of action. Furthermore, minimum adverse reactions are achieved due to the limited 
systemic absorption (Yang et al., 2009; Mangal et al., 2018).   
 
Pulmonary delivery of antibiotics is widely used in the treatment of P. aeruginosa lung 
infections in CF patients, and this is through using inhaled antibiotics. The inhaled antibacterial 
drugs are in two forms, being either nebulized solutions or dry powder formulations. Currently, 
the approved nebulized antibiotic solutions for the treatment of CF lung infections are colistin, 
aztreonam, and tobramycin (Geller et al., 2011; Ambrus et al., 2018). These nebulised solutions 
have a well-documented efficacy (Chuchalin et al., 2009), but they are also associated with 
some disadvantages. Among them, there is a prolonged administration time of 15-20 minutes. 
Moreover, these nebulized solutions are administered via bulky devices, which also requires 
the presence of a power source. Finally, the stability issues of nebulized solutions need that 
they are stored in a refrigerator (VanDevanter and Geller, 2011). All these together can reduce 
the adherence of patients to the treatment and can consequently result in the treatment failure.  
 
Dry powder inhalers have addressed the limitations that are encountered with using nebulized 
solutions (Geller et al., 2011). For instance, dry powder inhalers are portable, easy to use by 
patients with a much shorter administration time (~ 5 minutes). Furthermore, the solid state is 
chemically more stable than the liquid state (Yang et al., 2014; Lee et al., 2016; Ambrus et al., 
2018). Despite the advantages of dry powder inhalers, they still have some issues for delivering 
high doses, in which patients need to load and inhale multiple capsules to achieve the target 
dose, and as a result of this, patients could experience mild to moderate cough as an adverse 
drug reaction, although this gradually disappears with time (Parumasivam et al., 2017).  




The currently approved inhaled dry powder antibiotics for treating P. aeruginosa CF lung 
infections are colistin and tobramycin. For instance, TOBI Podhaler® 28mg is an approved dry 
powder inhalation formulation of tobramycin, which is widely used in CF patients (McKeage, 
2013). As a drug product, TOBI Podhaler® consists of the active ingredient, tobramycin sulfate 
(~85%) and excipient components. Among them, distearoylphosphatidylcholine (DSPC;14% 
(w/w)), which acts as a shell-forming agent that decreases interparticle attraction forces. Other 
excipients that are important during the process of dry powder production are sulfuric acid to 
adjust the pH, and calcium chloride as an emulsion stabilizer (VanDevanter and Geller, 2011; 
Weers and Miller, 2015).  
 
Following inhalation of tobramycin powder, the inhaled particles deposit on the lung airway 
surface and once the deposition occurs, the physiological fate of these particles depends on a 
complex interaction between different factors. These involve the pathologic conditions in the 
lungs and the nature and physical properties of inhaled particles. In CF lung infections, inhaled 
drug particles are required to overcome several barriers, and these can significantly affect their 
pharmacological efficacy. Initially, deposited particles must dissolve in the mucus. This is then 
followed by diffusion to reach the target that is mostly localized and colonized inside this 
viscous dehydrated mucus. During this penetration process, the inhaled antibiotic might 
interact with the mucus components such as mucins and/or DNA, which in turn can influence 
the efficacy of the inhaled antibiotic by limiting its bioavailability at the target site. Beside this 
barrier, another obstacle to overcome, is the biofilm matrix around the bacteria that mainly 
consists of alginate polysaccharides and other molecules (Bos et al., 2017). Apart from 
pathological conditions in the lung, another factor can also play a role in the fate of inhaled 
particles, which is the physical state of inhaled powder. For instance, the process of dissolution 
is influenced by the physical properties of inhaled particles such as particle size (Timsina et 
al., 1994; Wenzler et al., 2016; Ciciliani et al., 2017). 
 
 
Drug particle size is an important property that can influence both the deposition and fate of 
particles in the respiratory airways. Normally, inhaled drug particles are polydisperse in nature 
with a large particle size range (Deng et al., 2018). These include particles >10 µm, which are 
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mostly deposited in the oropharyngeal region and do not reach the lungs. Other particles are 
between 3-10 µm, which are mostly deposited in the trachea-bronchial region. Furthermore, 
particles at a range of 1-3 µm target the alveolar zone of the lungs. Particles that are smaller 
than <1 µm are known to be exhaled out of the lung due to the low inertia and gravitational 
powers which are insufficient to deposit them (Nafee et al., 2014). Therefore, inhaled powder 
particle size is an important characteristic of the powder, which can impact several processes 
from deposition to absorption and clinically efficacy (Pilcer et al., 2008; Taki et al., 2010).  
   
Currently, in vitro antibiotic activity against biofilms is measured by using biofilm models such 
as 96-well plate assay. In these, the activity is tested on antibiotics that are completely dissolved 
in liquid, ready to be absorbed by biofilms that are also submerged in liquid. However, in CF 
lung infections, antibiotics are widely administered as an inhaled dry powder, where air-
interface biofilms are exposed to the drug as dry particles with different particle sizes. These 
particle sizes could have an impact on antibiotic activity. Accordingly, such a critically 
important property of inhaled dry powder is missing from the currently used biofilm models. 
Therefore, this highlights the need for a model that is a better representative of the in vivo 
conditions. Such model should allow modelling of lung infections and studying the impact of 
particle size on the antibacterial activity of inhaled antibiotics. This can be performed by using 
a particle size pharmaceutical analysis assay combined with a biofilm model that is a more 
representative of the lung. One model that better reflects the in vivo lung environment is the ex 
vivo model that uses pig bronchial tissue (Harrison and Diggle, 2016). However, because of 
the time that might be required to establish and optimize such model to enable deposition of 
dry powder antibiotic, we therefore used a simpler in vitro model called colony biofilm (Merritt 
et al., 2005). This in vitro model for instance is unlike a 96-well plate assay (Coffey and 
Anderson, 2014), as the colony biofilm assay does provide an air interface and enables the 
deposition of dry powder antibiotics. This can help to further understand the role of particle 
size on antibiotic efficacy, which could be useful for improving the pharmacologic activity of 
inhaled antibiotics. 
 
The in vitro particle size characterization of inhaled drug aerosols is mostly carried out using 
cascade impactors. The most commonly used impactor is a Next Generation Pharmaceutical 
Impactor (NGI) (Marple et al., 2003). The NGI is an instrument used to measure in vitro 
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behaviour of inhalable dry powder products (Rowland et al., 2018), in which NGI sequentially 
separates drug aerosols into various size categories from larger to smaller particles on the basis 
of the particles’ aerodynamic diameter (Guo et al., 2008; Roberts and Mitchell, 2013; Wang et 
al., 2017). The aerodynamic diameter of a particle is the parameter that characterizes aerosol 
movements and depositions in the lungs (Pilcer et al., 2008; Wang et al., 2017). The deposition 
of the inhaled drugs on NGI compartments represents as closely as possible aerosol deposition 
in the respiratory system, thus, it is designed to operate in a range of flow rates from 30 to 100 
L/min (Roberts and Mitchell, 2013). These are similar to flow rates that have been measured 
in most CF patients at age 6 years and older, however, some patients generated higher flow 
rates up to 170 L/min (Tiddens et al., 2014).  
 
The NGI system consists of several parts (Figure 4.1), which includes an inhaler device, 
mouthpiece adaptor, induction port, pre-separator, seven impactor stages, and micro-orifice 
collector (MOC). Firstly, the inhaler device which contains the drug aerosol encased within a 
capsule is attached to the mouthpiece adaptor. The next part is the induction port, which is a 
pipe with a right-angle bend that operates possibly similar to the oropharyngeal region of 
patients, and it acts as an entrance of incoming aerosols from the inhaler device. The following 
part is the pre-separator, which is interposed between the induction port ending and the 
beginning of the fractionation stages. This pre-separator is considered as the initial size-
separating stage comprising of a plate with 6 nozzles designed to collect the coarse or over-
sized particles (50-100 µm), whilst the finer particles continue in the air stream for further size 
fractionation in the impactor stages (Mitchell et al., 2007; Roberts and Mitchell, 2019). Other 
NGI setup system in Figure 4.1 such as critical flow controller and air pump has been described 
before (See Materials and Methods Chapter, Section 2.8.5).  
 




Figure 4.1. Complete NGI setup system. Inhaler device (1), mouthpiece adaptor (2), induction port (3), 
pre-separator (4), NGI (5), critical flow controller (6), Air pump (7). (unpublished image) 
 
The other components of the NGI are the seven impactor stages (Figure 4.2), each of which 
parallels with a plate containing one or more circular nozzles with decreasing diameters as 
shown in Figure 4.2. Such a design allows each stage to act as a size separator of the incoming 
aerosols, where each stage captures particles larger than a specific aerodynamic diameter as 
shown in Table 4.1, which are previously determined by Marple et al (2003), in which these 
values were determined following calibration of the NGI with monodispersed aerosols. Finally, 
the last part of the NGI is the MOC, which is designed to collect the very fine particles (Mitchell 
et al., 2007; Roberts and Mitchell, 2013).  
Figure 4.2.  NGI in an open position. A nozzle plate with several nozzle diameters (1), a stage plate (2) 
with seven collection stages (S1-S7) and MOC: micro-orifice collector to collect the incoming powder from the 
above nozzles. (unpublished image) 
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Table 4.1. Cut-off aerodynamic diameter for each NGI stage at flow rates of 30 L/min and 60 L/min 
(Marple et al., 2003).  
 
 
The deposition of particles from the standard NGI occurs directly on a solid impactor stage. 
This leads to high-speed deposition of particles in a small area resulting in the formation of 
strong agglomerates which then behave as larger particles (Price and Shur, 2018). Therefore, 
in addition to the standard NGI described above, for some experiments, an aerosol collection 
apparatus (Figure 4.3) was also introduced into the NGI. This collection system enables a slow 
and uniform deposition of aerosol particles over a single, large surface area of glass fibre filter 
instead of particle deposition directly on impactor stage. Particles therefore deposit slowly and 
subsequently behave as a single particle. Different types of aerosol collection apparatus were 
used in this study (See Material and Method Chapter, Section 2.8.6). 
 
NGI stages  Cut-off diameter (µm) at  
30 L/min 
Cut-off diameter (µm) at 
60 L/min 
Stage 1 11.7 8.06 
Stage 2 6.40 4.46 
Stage 3 3.99 2.82 
Stage 4 2.3 1.66 
Stage 5 1.36 0.94 
Stage 6 0.83 0.55 
Stage 7 0.54 0.34 
 MOC 0.36 0.14 




Figure 4.3 Schematic diagram of aerosol collection apparatus. Reproduced from (Price and Shur, 2018) 
with permission.  
 
Using the NGI model for testing dry powder inhaler requires finding a quantification assay to 
determine the amount of drug that is deposited in every compartment of the NGI. Numerous 
analytical assays have been reported to quantify antibiotics including, microbiological (Kirby-
Bauer disk diffusion) and chemical assays. (Dafale et al., 2016). Among the chemical assays, 
high-performance liquid chromatography (HPLC) is the most widely used and  known to be an 
accurate and sensitive analysis of aminoglycoside antibiotics including tobramycin (El-Zaher 
and Mahrouse, 2013). However, tobramycin like all aminoglycoside antibiotics has a 
significant challenge in its determination and analysis using the traditional HPLC-UV 
(Blanchaert et al., 2017), because of the lack of a UV absorbing chromophore in its molecular 
structure. A chromophore is a chemical substance in a compound that responsible for absorbing 
UV light at a specific wavelength (Guo et al., 2006). Therefore, the detection of tobramycin 
using a UV-detector is unfeasible unless a derivatization process is used. However, this 
derivatization technique has some disadvantages including the stability of the derivatized 
analyte, its laborious nature with several sample preparations, and its low precision (Attema-
de Jonge et al., 2008; Chen et al., 2014). Because of this, nowadays mass spectrometry MS 
used as an alternative, which does not require any complicated derivatization reactions. This 
HPLC-MS is known to have good sensitivity and selectivity for tobramycin determination. 
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This work described in this chapter aimed to provide a comprehensive investigation of the 
activity of tobramycin dry powder inhaler against P. aeruginosa biofilms.  The investigations 
were in terms of studying the effect of differently sized tobramycin particles on its anti-biofilm 
activity. To achieve this, several preliminary experimental designs were needed. Therefore, the 
initial aims were to measure tobramycin powder particle size using the NGI and then to 
establish and validate an assay to quantify tobramycin powder from the NGI. This was followed 
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4.2 Results  
4.2.1 Tobramycin particle size analysis  
4.2.1.1 SEM analysis  
 
SEM analysis was used to image tobramycin particles that had been extracted from the NGI 
stages using the method outlined in the Materials and Methods Chapter (Section 2.8.5). The 
size of particles deposited on the various stages of the NGI do not require routine measurement, 
as these are determined by the geometry of the NGI and as such are known in advance. 
However, deposition in the NGI is determined by aerodynamic diameter. So, our aim in this 
section was to determine particle size distributions in terms of geometric diameters for particles 
collected from various stages of the NGI. Representative SEM micrographs for tobramycin 
particles are shown in Figure 4.4. SEM micrographs show polydisperse, approximately 
spherical, and porous microparticles. These SEM images were further analysed for physical 
























   
  
   
  
Figure 4.4. Representative SEM micrographs of tobramycin particles from NGI stages at 
different flow rates. Stage 2, at 30 L/min (A) and at 60 L/min (B). Stage 4, at 30 L/min (C) and at 60 L/min 
(D). Stage 5, at 30 L/min (E) and at 60 L/min (F). Stage 6, at 30 L/min (G) and at 60 L/min (H).  All pictures were 
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4.2.2.1 Tobramycin particle size distribution in terms of physical diameter 
 
In the section above, SEM images of tobramycin particles were captured, here these images 
were further analysed in order to obtain useful information about tobramycin particle size 
distribution and geometric diameters. To that aim, tobramycin particle size distributions plots 
were constructed as shown in Figure 4.5. Particle size distributions were produced by plotting 
the cumulative proportion of undersized particles (by number) against particle size (on a log -
scale). Our data (Figure 4.5, A), showed that on stage 2 at 30 L/min, the particle size 
distribution included coarse particles with diameters between 1-10 µm, which were not seen 
on stages 4 to stage 6 (Figure 4.5, B to H), where the particle size distributions were in the finer 
size range.  
 
Using the data from Figure 4.5, the geometric diameter characteristics for tobramycin particles 
were calculated and are summarized in Table 4.2. The particle size distribution of tobramycin 
is characterized by the D50 (geometric median diameter), which is the diameter at which 50% of 
the sample mass is smaller than this size and 50% is larger. Also, the D10 and D90 were 
measured, which represent the diameters of the particles at which 10% and 90% of the sample 
mass are less than this size. The D50 values were < 6 µm and decreased progressively from 
stage 2 to stage 6, as expected. In addition, the D50 values decreased from 30 L/min to 60 L/min, 
proving that finer particles are collected at a higher flow rate.  
 




Figure 4.5 Comparison of the cumulative particle size distributions of tobramycin particles from 
TOBI Podhaler® measured from different stages of the NGI at 30 L/min and 60 L/min 
respectively. Stage 2 (A-B), stage 4 (C-D), stage 5 (E-F), stage 6 (G-H). 
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Table 4.2. Comparison of tobramycin particle size distribution from different NGI stages at different 
flow rates. Geometric diameters are defined as D10, D50, and D90. 
 30 L/min 60 L/min 












Stage 2 2.73 5.56 11.30 0.696 1.42 2.88 
Stage 4 0.93 1.76 3.30 0.712 1.35 2.29 
Stage 5 0.65 1.19 2.17 0.55 1.05 1.99 
Stage 6 0.59 0.98 1.62 0.58 1.00 1.73 
 
It should be noted that these geometric diameters are not directly comparable with the 
previously described aerodynamic diameters in Table 4.1, because the measurements are based 
on a different definition of the diameter of a particle and a different method of particle 
quantification (number vs mass).  
 
4.2.2 Tobramycin quantification assay 
 
Following the first group of preliminary work, the second set of preparational work was to 
develop an assay to quantify tobramycin from the NGI. To that purpose, tobramycin 
quantification was carried out using HPLC-MS. Initial results (Figure 4.6) revealed a poor 
linear relationship with the correlation coefficient of r2= 0.8732. Other non-linear regressions 
(data not shown) were also applied, however, these had not improved the correlation coefficient 
and internal standard was required to improve precision of our data.  




Figure 4.6 Tobramycin calibration curve. Area under the curve of tobramycin versus concentration of 
tobramycin. 
 
The internal standard is a substance that should have the same signals as the analyte, but should 
be distinguishable from the analyte, which means the internal standard should have similar 
structural and chemical properties as the analyte (Blanchaert et al., 2017). Accordingly, the 
internal standard that was chosen to tobramycin (Figure 4.7, A) is kanamycin (Figure 4.7, B) 
because it has similar structure to tobramycin. 
 
 (A)                       (B)  
Figure 4.7 Chemical structure of tobramycin (A) and kanamycin, internal standard, (B). 
 
Tobramycin calibration curve following the addition of kanamycin as an internal standard  is 
depicted below (Figure 4.8). A good linear relationship between the area ratio of tobramycin-
kanamycin and corresponding concentrations was determined. As can be seen from the curve, 
the correlation coefficient of r2 = 0.998 improved significantly as compared to the previously 
obtained (Figure 4.6). Therefore, it was decided to keep adding the internal standard in all our 
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HPLC-MS quantification assays. For the next following sections, this assay was used to 
quantify tobramycin from the NGI. 
 
Figure 4.8 Tobramycin calibration curve. Area ratio between tobramycin to kanamycin (internal standard) 
vs concentration of tobramycin. 
 
4.2.3 Tobramycin particle size distribution in terms of 
aerodynamic diameter  
 
After establishing an HPLC-MS assay in the previously described section, our aim here was to 
use this assay to determine the particle size distribution of the aerosol emitted from the TOBI 
Podhaler® at 30 L/min and at 60 L/min flow rates. This was achieved using the NGI, and so 
was expressed in terms of aerodynamic diameter as a function of tobramycin mass (in contrast 
to the SEM analysis described above). In this regard, a tobramycin capsule for each experiment 
was aerosolised through the NGI for 10 seconds, which was chosen as it is sufficient for 
complete dispersion of the powder from the capsule. The results are displayed in Figure 4.9 A 
and B, which show tobramycin aerodynamic particle size distribution profiles from the NGI in 
terms of mass. These aerodynamic diameters are previously calculated by Marple et.al (2003) 
as outlined in Table 4.1. The data revealed that at 30 L/min (Figure 4.9, A), tobramycin particle 
size distribution was mostly between 6.4-0.83 µm with less mass deposited on the other stages. 
At 60 L/min (Figure 4.9, B), tobramycin particle size distribution was between 4.46-0.55 µm 
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with lower masses deposited on the other stages. These data were used to determine the 
tobramycin dose, collection stage at the tested flow rates in subsequent experiments. 
Figure 4.9 Aerosol particle size distribution of tobramycin powder from TOBI Podhaler® device 
following aerosolization into the NGI at different flow rates. At 30 L/min (A) and at 60 L/min (B). The 
NGI was operated for 10 seconds, and one capsule of 28 mg/test was aerosolized for each flow rates. Error bars 
represent the standard error of the mean from five independent experiments for each flow rate. Stages 1-7 indicate 
the impactor stages, followed by their corresponding lower aerodynamic diameter in parentheses. MOC: micro-
orifice collector.  
 
4.2.4 Tobramycin collection and mass measurements from the NGI 
  
In the same way as above, HPLC-MS assay was used also in this section to quantify tobramycin 
mass that was deposited in the NGI. Tobramycin mass measurements were performed to 
identify the masses of different sized tobramycin particles. To that purpose, the NGI was 
operated as previously outlined in the Materials and Methods chapter (Section 2.8.5 and 2.8.6) 
with minor modification, in which commercially available TOBI 28 mg tobramycin capsules 
were replaced with manually filled capsules with tobramycin powder extracted from TOBI 
Podhaler® capsules. This was because the high dose contained in the commercially available 
product resulted in a high mass collected on the filter. This was difficult to collect because it 
resulted in damage of the filters. Tobramycin was collected from the NGI using the aerosol 
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collection apparatus, because of the advantages that are offered by this system as described in 
section 4.1.  
 
4.2.4.1 Tobramycin mass deposited in the single aerosol collection apparatus 
mounted on stage 2  
 
In this section, our initial aim was to determine tobramycin capsule filling dose, which resulted 
in the collection of similar tobramycin masses on filter in single aerosol apparatus (Figure 4.10) 
at stage 2 of the NGI at different flow rates (i.e. with different particle sizes). To that purpose, 
the initial manually filled dose of tobramycin was 2.5 mg to be aerosolized at 60 L/min. This 
filling dose was chosen after testing several filling doses through a trial and error process. The 
second step was to find a new filling dose to be fired at a flow rate of 30 L/min, which resulted 
in the collection of the same mass as that was obtained from aerosolizing 2.5 mg tobramycin 
at 60 L/min at stage 2. The results (Figure 4.11) revealed that loaded tobramycin capsules with 
4.4 mg at 30 L/min and 2.5 mg at 60 L/min, resulted respectively in collection a mean mass of 
0.993 mg for particles < 11.7 µm and a mean mass of 0.96 mg for particles < 8.06 µm, the 
difference between the collected masses was about 3.4% (p > 0.05).  
 
Figure 4.10. The whole NGI with the single aerosol collection apparatus connected down to the NGI. 
(unpublished image). 




Figure 4.11 Comparison of tobramycin masses with different particle sizes deposited on the filter 
in the single aerosol collection apparatus mounted on stage 2 of the NGI. The NGI was operated for 
10 seconds, and tobramycin capsules of 4.4 mg and 2.5 mg were fired at 30 and 60 L/min respectively. Error bars 
represent the standard error of the mean from ten independent experiment. Statistical significance was analysed 
using unpaired 2-tailed t test (p> 0.05). Full details of the statistical analysis are shown in appendix 1. 
 
For the following sections, the double aerosol collection apparatus (Figure 4.12) replaced the 
single aerosol collection device. This is because the latter did not work properly at a high flow 
rate of 60 L/min, when filters from different manufacturers were used. Such filters were 
damaged and made the collection of tobramycin particles impossible. Accordingly, using the 
double aerosol apparatus resulted in the dividing the airflow and decreasing the pressure on the 
filters, because it consists of two filters for particles collection. These two filters within this 
apparatus collect two equal masses simultaneously, which meant that half the amount of 
tobramycin collected on the filter of the single aerosol collection apparatus (Figure 4.10) was 
collected on each of the two filters of the double aerosol collection apparatus.  




Figure 4.12. NGI incorporated with a double aerosol collection apparatus down to the NGI. (unpublished image) 
 
4.2.4.2 Tobramycin masses deposited on double aerosol collection apparatus 
 
In the previous section, the determined filling doses of tobramycin successfully resulted in the 
collection of approximately equal masses of tobramycin with different particle sizes on single 
aerosol collection apparatus mounted on stage 2. Next, our aim was to determine if these 
tobramycin filling doses are also applicable to the other NGI stages, and in particular when the 
double aerosol collection apparatus was used. Because this aerosol collection apparatus has 
two sites with filters (F1, F2) to collect particles, it was important to confirm that both sites 
collect the same mass. Therefore, this device was mounted individually from stage 2 to stage 
6 of the NGI and the manually loaded 4.4 mg and 2.5 mg tobramycin capsules/experiment were 
aerosolised through the NGI at 30 L/min and at 60 L/min respectively. The data revealed 
(Figure 4.13, A-H) that at stages from 2 to 6, similar tobramycin masses were collected on both 
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Figure 4.13. Comparison of tobramycin masses deposited on the filters in the double aerosol 
collection apparatus were housed on multiple stages of the NGI at (30 and 60) L/min respectively. 
Stage 2 (A-B), stage 4 (C-D), stage 5 (E-F), and stage 6 (G-H). NGI was operated for 10 seconds and tobramycin 
capsules of 4.4 mg and 2.5 mg were fired at 30 and 60 L/min respectively. F1, F2 are representing the filters that 
collect different sized tobramycin particles on double aerosol collection apparatus. Error bars represent standard 
error of the mean from four independent experiments for each stage and every filter. Statistical significance was 
analysed using unpaired 2-tailed t test (p> 0.05). Full details of the statistical analysis are shown in appendix1. 
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4.2.4.3 Tobramycin masses deposited on double aerosol collection apparatus 
mounted on stage 2 and stage 4 
 
In the earlier work, tobramycin filling doses and approximately equal masses were measured 
on the double aerosol collection apparatus that was mounted on the same stages at different 
flow rates and particle sizes. In this section, our aim was to determine filling doses of 
tobramycin capsules that enable the collection of similar masses of differently sized particles, 
using double aerosol collection apparatus mounted on different stages and at different flow 
rates. In this context, numerous trials and errors were made to establish the filling doses for 
tobramycin capsule that allowed us to collect the same mass of tobramycin on the aerosol 
collection apparatus mounted firstly on stages 2 at 30 L/min and secondly on stage 4 at 60 
L/min, in order to collect particles < 11.7 µm and < 2.82 µm respectively. The results suggested 
(Figure 4.14) that filling tobramycin capsules with 4.4 mg and 4.3 mg to be aerosolised at 30 
L/min, stage 2 and at 60 L/min, stage 4, respectively, resulted in the collection a mean mass of 
0.513 mg for particles < 11.7 µm and a mean mass of 0.476 mg for particles < 2.82 µm and the 
difference between masses was about 7.8% (p> 0.05). 
 
Figure 4.14. Comparison of tobramycin masses with different particle sizes deposited on the 
filters in the double aerosol collection apparatus. Pink bar: tobramycin particles < 11.7 µm that were 
collected from stage 2 at 30 L/min. Purple bar: tobramycin particles < 2.82 µm that were collected from stage 4 
at 60 L/min. Error bars represent standard error of the mean from ten independent experiments. Statistical 
significance was analysed using unpaired 2-tailed t test (p> 0.05). Full details of the statistical analysis are shown 
in appendix 1. 
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4.2.5 The influence of differently sized tobramycin particles against 
P. aeruginosa biofilms 
 
In the previous sections, equal masses of tobramycin with different particle sizes were collected 
from the NGI. The next step in this section was to investigate the effect of small and large 
micron-sized tobramycin particles against P. aeruginosa biofilms. This is because drug particle 
size influences the physical properties of a drug such as the dissolution rate (Shekunov et al., 
2007; Wang et al., 2017).  It is generally recognized that dissolution rate of small-sized particles 
can be significantly better than the large-sized particles, which is attributed to the larger surface 
area of the small particles (Watts and Williams, 2011; Riley et al., 2012; van der Wiel et al., 
2017; Tay et al., 2018).  Therefore, we aimed to test the influence of such different tobramycin 
particle sizes against bacterial biofilm. Notably, due to technical issues and the trial and error 
process described above, the influence of differently sized particles was initiated by studying 
tobramycin particles with a small difference in size range, which was then followed with the 
comparison of particles with a large difference in size.  
 
4.2.5.1 The influence of tobramycin particles < 11.7 µm and < 8.06 µm against P. 
aeruginosa biofilms  
 
In this section, our aim was to evaluate the activity of small and large micron-sized tobramycin 
particles against P. aeruginosa biofilms. To that end, the colony biofilm assay was used to 
grow biofilms of P. aeruginosa strains as outlined in the Material and Methods chapter (Section 
2.6.2), in which these strains were grown for 48 h in ASM medium by inoculation of 100 µl of 
bacterial culture into polycarbonate membranes. Next, the biofilms were treated with 0.99 
mg/filter tobramycin of different particle sizes (< 11.7 µm and < 8.06 µm), This was followed 
by incubation for 24 h at 37°C. Then the viable count was measured as described in the 
Materials and Methods chapter (Section 2.6.2). The results (Figure. 4.15, A to C) revealed that 
in all tested clinical isolates, there was a trend for smaller micron-sized tobramycin particles 
being more effective than larger micron-sized particles against P. aeruginosa biofilms, albeit 
the difference was statistically not significant (p= 0.36, 0.83, and 0.45 in Figure 4.15 A-C, 
respectively). Only for the lab strain PAO1 (Figure 4.15, D, p=.97), this trend was not observed.  




Figure 4.15. The influence of differently sized tobramycin particle on the eradication of P. 
aeruginosa biofilms. (A-C) show clinical isolates, (D) indicates a lab strain PAO1.  Bacterial cells 
were grown in ASM as colony biofilms for 48 h at 37°C and then were treated with different tobramycin particle 
sizes (< 11.7 µm and < 8.06 µm) for 24 h. The data shown represent the standard error of the mean from three 
biological repeats and each biological repeat consisted of at least two technical repeats. Statistical significance 
was analysed using unpaired 2-tailed t test. Full details of the statistical analysis are shown in appendix 1. 
 
4.2.5.2 The influence of tobramycin particles < 11.7 µm and < 2.82 µm against P. 
aeruginosa biofilms 
 
In the section above, the influence of a small difference in particle size range was evaluated 
against P. aeruginosa. Here, the influence of a wide difference in particle size range was 
investigated. This was technically more challenging to achieve involving a lot of trial and error, 
as it was difficult to get an equal mass of particles with a significant different particle size. 
However, it was hoped that the difference observed would be more pronounced with a larger 
difference in particle sizes and with smaller doses than that were used in section 4.2.5.1. In this 
respect, P. aeruginosa biofilms were grown as mentioned earlier with the addition of the 
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controls, that were used as a baseline, but was not included in the statistical evaluations. The 
biofilms were challenged with a dose of 0.5 mg/filter tobramycin of different tobramycin 
particle size (< 11.7 µm and < 2.82 µm). In the same way, filters without tobramycin were 
placed on each control. Afterward, the biofilms were incubated for 24 h and the viable count 
was determined. The results revealed (Figure 4.16, A- D) that the trend of better activity with 
smaller particles, which was observed in section 4.2.5.1 disappeared and no distinct difference 
was noticed between small and large tobramycin particles. As mentioned earlier, the difference 
is with the previous experiments is, however, that in this case the total mass of tobramycin used 
was about half as compared to the experiments in section 4.2.5.1.  
Figure 4.16. The influence of differently sized tobramycin particles on the eradication of P. 
aeruginosa biofilms. (A-C) show clinical isolates, (D) indicates a lab strain PAO1.  Bacterial cells 
were grown in ASM as colony biofilms for 48 h at 37°C and then were treated with different tobramycin particle 
sizes (< 11.7 µm and < 2.82 µm) for 24 h. The data shown represent the standard error of the mean from three 
biological repeats and each biological repeat consisted of at least two technical repeats. Statistical significance 
was analysed using unpaired 2-tailed t test. Full details of the statistical analysis are shown in appendix 1. 
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The rate of dissolution for drug particles is a kinetic and time-dependent process (Watts and 
Williams, 2011). Therefore, these results directed us to investigate the effect of particle size at 
various incubation times. In the CF lung, it has been reported that almost 2-3 h following 
tobramycin inhalation treatment, about 90% of tobramycin concentration is cleared out lung 
(Schulz and Schmoldt, 2003; Garo et al., 2007) and others have reported that the elimination 
of tobramycin is variable ranging from 1.5 h to 13 h (Geller et al., 2002). Therefore, we selected 
to test the activity of tobramycin particles at different physiological relevant incubation times. 
The results suggested that at t = 3 h, smaller tobramycin particles < 2.82 µm resulted in better 
efficacy by 20% reduction in viable count with a statistically significant difference as compared 
to larger particles < 11.7 µm in the two clinical isolates (Figure 4.17, A and B). In comparison, 
for the other strains (Figure 4.19, C and D) the trend toward smaller sized particles being more 
effective than the larger counterparts was still present but it was statistically not significant. 
Figure 4.17. The influence of differently size tobramycin particle on the eradication of P. 
aeruginosa biofilms. (A-C) show clinical isolate, (D) indicates a lab strain PAO1.  Bacterial cells were 
grown in ASM as colony biofilms for 48 h at 37°C and then were treated with different tobramycin particle sizes 
(< 11.7 µm and < 2.82 µm) for 3 h. The data shown represent the standard error of the mean from three biological 
repeats and each biological repeat consisted of at least two technical repeats. Statistics were analysed using 
unpaired 2-tailed t test. Statistically significant differences between large and small particles are indicated (*, 
p<0.05). Full details of the statistical analysis are shown in appendix 1. 
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As can be deduced from the results above, the effect of particle size seemed to be time and 
strain dependent. Therefore, these encouraging results were considered for further 
investigations, in which we had a closer look at the effect of particle size at different incubation 
times. We selected LMG 27649 clinical isolate for further investigation and as can be seen in 
Figure 4.18, the data showed that at a shorter incubation time of 1.5 h (Figure 4.18), smaller 
particles < 2.82 µm resulted in a ⁓35% reduction in viable count as compared to the larger 
particles < 11.7 µm. This was the larger difference between differently sized particles as 
compared to other longer incubation times of 3, 5, 8, and 24 h (Figure 4.18). For instance, the 
reduction in viable count for smaller particles as compared to larger particles was ⁓20%, 10%, 
20%, at 3, 5, 8 h respectively, with almost no difference at 24 h. Although a statistically 
significant difference was not achieved at all tested incubation times, however, the trend was 
reproducible with every repeat.  
 
 
Figure 4.18. The influence of differently sized tobramycin particle on the eradication of LMG 
27649 clinical isolate P. aeruginosa biofilms.  Bacterial cells were grown in ASM as colony biofilms for 48 
h at 37°C and then were treated with different tobramycin particle sizes (< 11.7 µm and < 2.82 µm) at several 
incubation time points (1.5, 3, 5, 8, 24) h. The data shown represent the standard error of the mean from three 
biological repeats and each biological repeat consisted of at least two technical repeats. The data were normalized 
relative to controls. Statistical significance was analysed using two-way ANOVA followed by multiple 
comparison Tukey test. Full details of the statistical analysis are shown in appendix 1. 
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4.3 Discussion  
 
In this chapter, we studied tobramycin dry powder inhaler and investigated the influence of 
differently sized tobramycin particles against P. aeruginosa biofilms. This work was preceded 
by multiple preliminary experiments. Firstly, a quantification assay for tobramycin was 
established and validated. Secondly, the model to fractionate tobramycin into different sizes 
was developed and optimized. Finally, the influence of these differently sized tobramycin 
particles was assessed against CF clinical isolates of P. aeruginosa biofilms. 
 
Particle size analysis of tobramycin dry powder was performed using two techniques, which 
were the SEM analysis and the NGI. To begin with SEM analysis, we were able to visualise 
tobramycin particles and to calculate the geometric diameters of particles. However, this assay 
is associated with limitations, which are not easy to control or minimize. For instance, the 
adjacent particles could be measured as one particle. Moreover, errors result from manual 
measurements, for example, the bias in the selection of  particles and measuring of a very small 
proportion of all the particles in a sample (Shekunov et al., 2007). The other particle sizing 
techniques in our study was the NGI, which is the most up to date pharmaceutical impactor for 
aerosol particle size analysis. NGI overcomes the limitations of other impactors such as the 
Anderson Cascade Impactor (ACI) (Taki et al., 2011).  For instance the ACI measurements are 
limited to a specific flow rate of 28 L/min and less applicable at higher flow rates (Yoshida et 
al., 2017) that were important in our work to get a variety of particle size ranges. Therefore, 
we used the NGI, however, it still has some restrictions. For instance, the re-entrainment of 
particles where particles bounce off the stage and re-enter the air stream and subsequently 
impact on the following stage (Wang et al., 2017). This limitation was minimized by coating 
the surface of impactor stages as described in Materials and Methods chapter (Section 2.8.5). 
 
An important drawback for our purposes is that the NGI separates powder into different size 
fractions with different masses for each fraction. To compare between differently sized 
particles, it was essential to equalize the masses between each fraction. Using a trial and error 
process, differently sized but an equal mass of tobramycin particles was collected from the 
NGI.  Consistency between experiments was important here, but initial results were not very 
                                                                                                                   Chapter 4: Results Section II  
 
123 
reproducible. This was due to the hygroscopic nature of tobramycin, which can negatively 
affect its aerosolization. To improve that, all the conditions that could affect tobramycin 
aerosolization such as humidity, temperature, and capsule types were standardized and adjusted 
as described in Materials and Methods chapter (Section 2.8.4).  
 
The evaluation of different tobramycin particles was made depending on the NGI stages that 
were selected. These include stage 2 and stage 4. Stage 2 was chosen because it captures all 
the particles with a diameter of less than 11.7 µm at 30 L/min and lower than 8.06 µm at 60 
L/min. Such a range is known to penetrate and deposit in the lung. Stage 4 was included in the 
comparison because it collects all the fine particles with a diameter of < 3.99 µm at 30 L/min 
and < 2.82 µm at 60 L/min. The particles within this range are considered optimal particles the 
can distribute and penetrate further peripherally to the smaller airways and deposit in the zone 
where the infection is found (Geller et al., 2011; Buttini et al., 2016). Comparisons were made 
between particles that were collected from stage 2 and stage 4. This was due to the difficulty 
in comparing stage 2 with the later stages as there was a large difference in masses. Because 
of such difference, it was challenging to collect similar amounts of tobramycin from these 
stages as compared to the mass that was collected from stage 2.  
 
The influence of differently sized tobramycin particles was determined against P. aeruginosa 
biofilms. For P. aeruginosa, to be inhibited with tobramycin particles, these must firstly 
dissolve in order to exert their pharmacological activity and the dissolution process depends on 
particle size and time (Wang et al., 2016). Accordingly, the influence of tobramycin particles 
was investigated by testing differently sized particles combined with various incubation times 
from 1.5 h to 24 h.  For instance, it was observed that at short incubation time, there was a trend 
for small particles of < 2.82 µm were being more effective by a 20% as compared to large 
particles < 11.7 µm, with a significant difference being found at t = 3 h in LMG 27649 and 
LMG 27643 clinical isolates. However, at longer incubation time of t = 24 h, the activity of 
small and large tobramycin particles in inhibition biofilms did not show any pronounced 
difference. One plausible explanation for the observed results could be related to the properties 
of tobramycin particles. For instance, small size particles are known to have a faster dissolution 
rate than the larger size counterparts because of a relatively larger surface area of the small 
particles. Indeed, the dissolution is a kinetic and time-associated process (Watts and Williams, 
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2011), accordingly, this could explain the difference in inhibitory activity between the tested 
particles at shorter versus longer incubation times. The effects were not seen in all P. 
aeruginosa strains, which might be because the tested strains are phenotypically and 
genetically different. That, in turn, could result in the formation of heterogeneous biofilms (e.g. 
compositions and thickness) (Wimpenny et al., 2000), which consequently could lead to 
different responses.  For example, the studied clinical isolates but not PAO1 are known to be 
alginate producers. Another difference that was observed with the clinical isolate LMG 27649 
(but not other strains), this strain was unable to grow unless casamino acids were added to the 
MOPS growth medium (data not shown), which suggests that the LMG 27649 is auxotrophic. 
The other strains were able to grow without casamino acids and this indicates that they are 
prototrophic strains. Whether this would influence the effects of tobramycin particles is not 
known, but it does clearly show that the strains differ from each other. Overall the observed 
influences of small tobramycin particles are most likely related to the faster dissolution rate of 
these particles as compared to the larger counterparts, in which the dissolution rate appeared to 
be a rate-limiting step at only short incubation time. Interestingly and similar to our work, the 
influence of differently sized particles of other drugs were evaluated, in which the results from 
these studies indicated better efficacy for smaller sized particles as compared to the larger 
counterparts (Shah et al., 1997; Jinno et al., 2006; Leach et al., 2009; Liu et al., 2015). One of 
these drugs is cilostazol, which is an oral vasodilator. Smaller cilostazol particles of 2.4 µm 
had shown better dissolution rate and efficacy than the larger particles of 13 µm (Jinno et al., 
2006). Another drug is inhaled solution of dornase alfa, which is a mucolytic agent used in CF 
patients to decrease the viscosity of sputum. This drug was more effective, when it was 
administered as small particles of 3.42 µm as compared to particles 6.87 µm (Shah et al., 1997). 
In the same way, inhaled beclomethasone corticosteroid solution was more effective in particle 
size of 1.1 µm as compared to 4 µm (Vanden Burgt et al., 2000; Van Schayck and Donnell, 
2004; Leach et al., 2009).  
 
In our work, it was important to develop an assay to quantify tobramycin from the NGI. We 
initially used a conventional bioassay, which is a microbiological technique in which 
tobramycin was dissolved and deposited on a 6 mm paper disc, followed by a disc diffusion 
assay using a sensitive strain. However, it was difficult to achieve a reproducible relationship 
with an appropriate correlation coefficient even by applying a different type of regressions such 
as linear, polynomial, and exponential regression (data not shown). Moreover, this assay has 
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several restrictions. For example, it is sensitive to parameters such as the thickness of the agar 
plates, the concentration of inoculums, and the conditions of incubations (Dafale et al., 2016). 
Thereby, it was not feasible to continue with this assay. The HPLC-MS assay was developed 
and optimised for the determination of tobramycin. Due to the hydrophilic and polar properties 
of tobramycin, several columns and mobile phases were evaluated during HPLC-MS 
methodology development. The final chromatographic conditions were outlined in the 
Materials and Methods chapter (Section 2.8.3). We were able to establish a quantification 
assay, but this was required optimization. For instance, for tobramycin standard curve, multiple 
trials were made to improve the correlation coefficient of the curves. These were including 
trying several concentration ranges, in which we experienced difficulties with including small 
concentrations within the standard curve. Also, we tried to prepare these concentrations by 
serial dilutions to decrease errors. However, these steps were not able to improve the poor 
correlation coefficient. Therefore, the internal standard was included, which significantly 
improved the results. Finally, our HPLC-MS assay was successfully applied to quantify 
tobramycin content that was extracted from the NGI. 
 
We should acknowledge that our study has a number of limitations. Firstly, the slight 
differences of <10% in the tobramycin masses that were collected for small and large sized 
particles from different stages/flow rates, however, such difference was statistically not 
significant (p> 0.05). In addition, in our work we know the maximum particle size that we 
collected on the filters, but we could not control the minimum particle size. So, although the 
average particle sizes were different, they could have been more different from each other if 
we had been able to control the minimum particle size as well. Our hypothesis was only tested 
for one dry powder inhaler antibiotic, tobramycin, and it will be of interest to test this with 
other antibiotics particularly those with less solubility than tobramycin, in which the dissolution 
rate could be a rate-limiting step and a more pronounced effect for small particles might be 
found. Furthermore, our system had used the in vitro colony biofilm model (Merritt et al., 2005) 
that possibly simulates lung in vivo conditions, in which such model allows biofilm to be grown 
at an air-interface and enables dry powder antibiotic to be deposited on those biofilm. However, 
in the future more advanced models should be used that better mimic the in vivo lung 
pathological conditions such as the ex vivo model (Harrison and Diggle, 2016) or the in vivo 
models (Kukavica-Ibrulj and Levesque, 2008). Finally, more molecular or genetic studies are 
required to better understand the difference in behavior between bacterial strains. This could 
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be due to levels of alginate production, but we have not demonstrated that directly and other 
factors may be involved. 
 
4.4 Conclusion  
 
Inhaled antibiotics are the fundamental treatment of care for CF patients with P. aeruginosa 
lung infections. Tobramycin dry powder inhaler is one of the most widely used inhaled 
antibiotics in the treatment of CF lung infections. In this chapter, the influence of tobramycin 
dry powder inhaler in terms of particle size was investigated against P. aeruginosa biofilm. 
Small micron-sized tobramycin particles (< 2.82 µm) showed better efficacy by a 20% 
reduction in the viable count as compared to larger particles (< 11.7 µm) at shorter incubation 
times (3 h) against P. aeruginosa biofilms of LMG 27649 and LMG 27643. This short 
incubation time is clinically important, in which tobramycin is cleared from the lung at a short 
time ~ 2-3 h. These initial findings highlight that particle size can affect tobramycin dry powder 
inhaler antibiofilm activity, however, more in vitro and in vivo research are still required. 
Finally, these findings could be more significant with less soluble antibiotics than tobramycin.    
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Nowadays, antimicrobial resistance is becoming a significant health hazard at the global level 
(Silver, 2016; Wright, 2016; Momin et al., 2018; Miró-Canturri et al., 2019). The British 
government and the Wellcome Trust have predicted that there will be many deaths by 2050 
following the rapid dissemination of multi-drug resistant pathogens (Nikaido and Pagès, 2012; 
Miró-Canturri et al., 2019). For instance, a report from northern Europe has stated that almost 
60% of P. aeruginosa isolates from cystic fibrosis patients were found to be multi-drug 
resistant (Tunney et al., 2018). Such resistance was found most commonly against penicillin, 
cephalosporins, and aminoglycosides (Tunney et al., 2018; Oliva et al., 2019). Aminoglycoside 
antibiotics such as tobramycin have been effectively used in the treatment of this pathogen 
(Hentzer et al., 2002; Ratjen et al., 2009; She et al., 2018; Oliva et al., 2019). However, the 
emergence of P. aeruginosa resistance towards tobramycin has been increasingly documented 
(Field et al., 2005; Herrmann et al., 2010; Roberts et al., 2015; Wright, 2016; Fong et al., 2018). 
This recalcitrance is attributed to several types of resistance mechanisms (Detailed explanation 
discussed in Chapter 1, Section 1.4), which are intrinsic, phenotypic, and acquired (Taylor et 
al., 2014; Wright, 2016).  
 
P. aeruginosa is known to have several intrinsic resistance mechanisms such as low 
permeability across the outer membrane. This restricted permeability for instance could act as 
a major barrier that reduces the penetration of several antibiotic agents (Taylor et al., 2014). 
Such limited permeability is a significant resistance mechanism in P. aeruginosa toward 
aminoglycoside antibiotics (Whiteley et al., 2001). Another intrinsic mechanism is the 
abundance of efflux pump systems (Breidenstein et al., 2011). For example, twelve resistance 
nodulation division (RND) efflux pumps are described in P. aeruginosa (Diggle and Whiteley, 
2019). Among them, it has been found that overexpression of multidrug efflux pump termed 
MexXY-OprM, results in P. aeruginosa resistance to aminoglycoside such as tobramycin 
(Hoiby et al., 2010a). Moreover, the resistance of P. aeruginosa to aminoglycosides results 
from aminoglycoside modifying-enzymes such as acetyltransferases and phosphoryl 
transferases (Beceiro et al., 2013).  
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In addition to the intrinsic mechanisms, another type is called phenotypic tolerance, which also 
has an important role in P. aeruginosa tolerance to antibiotic therapies (Fernández et al., 2011). 
The phenotypic tolerance is mainly stimulated by triggering factors and particular conditions 
such as antibiotics at sub-minimum inhibitory concentrations (Sub-MICs), nutrient and oxygen 
depletion, and importantly the biofilm mode of growth (Taylor et al., 2014). The phenotypic 
tolerance due to biofilm behaviour is clinically important (Hill et al., 2005; Wright, 2016) and 
it is attributed to several factors. These include the presence of dormant cells inside a biofilm 
(Zenga et al., 2012; Maiden et al., 2018). Such populations are known to be very tolerant to 
antibiotics, especially anti-microbial agents that mostly act on rapidly dividing cells (Fong et 
al., 2018). Another factor that also contributes to biofilm tolerance is the extracellular 
polymeric substance (EPS) matrix that surrounds cells in a biofilm (Haagensen et al., 2007; 
Rybtke et al., 2011; Liu et al., 2017). Such a matrix may act as a barrier that decreases the 
penetration of antibiotics such as aminoglycosides and polymyxins (Fong et al., 2018). This 
reduced penetration most probably results from the electrostatic interactions between the EPS 
and drug molecules  (Al-Azemi et al., 2011; Liu et al., 2017; Maiden et al., 2018). As it is clear 
from the discussion above, P. aeruginosa is intrinsically and phenotypically tolerant to 
antibiotics. Therefore, with the restricted pharmacological options that are available for treating 
this pathogen, there is an urgent need to find alternative approaches that can improve the 
activity of the already available antibiotics (Doern, 2014; Wright, 2016; Umerska et al., 2018). 
Such an approach could involve using tobramycin in combination therapy (Balke et al., 2006; 
Imperi et al., 2013; Otto et al., 2019).   
 
Combination antibiotic therapy is one of the promising strategies that currently being tested in 
the treatment of multi-drug resistant pathogens (Fischbach and Walsh, 2009; Domalaon et al., 
2018). This strategy can be used to promote antimicrobial activity, to minimize the emergence 
of resistance, and to mitigate toxicity owing to the lower doses being used for the combined 
drugs (Sader et al., 2003; Wright, 2016). Normally, combination therapy takes place by 
combining two or more antibiotics from different classes, but recently considerable attention 
has been made towards using combination therapy of antibiotics with drugs referred to as "non-
antibiotics" (Wright, 2016; Laudy et al., 2017; Liu et al., 2017; Otto et al., 2019). These drugs 
are already approved for different indications from treating bacterial infections, but they are 
found to have antibacterial and anti-virulence properties (Imperi et al., 2013; Nehme et al., 
2018; Miró-Canturri et al., 2019).  Using these non-antibiotic drugs that are clinically in use 
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can be beneficial, as their pharmacokinetics and safety profiles are well-documented, so their 
development would be much faster and quicker than developing new antibiotics (Rampioni et 
al., 2017b; Maiden et al., 2018; Miró-Canturri et al., 2019). Therefore, testing such drugs as 
adjuvants with the available antibiotics can be scientifically and economically advantageous 
(Kaatz et al., 2003).  
 
Numerous numbers of FDA-approved non-antibiotic drugs have been described in the literature 
for their additional anti-bacterial and anti-virulence properties (Bohnert et al., 2011; Ayaz et 
al., 2015). Examples of those drugs are anti-depressants (Mandal et al., 2010; Bohnert et al., 
2011; Ayaz et al., 2015), anti-helminthics (Imperi et al., 2013; Rajamuthiah et al., 2015; 
Domalaon et al., 2019), anti-hypertensives (Middleton et al., 2005; Treerat et al., 2008), anti-
psychotics (Hendricks et al., 2003; Coutinho et al., 2008; Nehme et al., 2018), chelating agents 
(Finnegan and Percival, 2015; Liu et al., 2017; Umerska et al., 2018), and other naturally 
derived compounds such as quercetin and furanones (Kristiansen and Amaral, 1997; Ayaz et 
al., 2015; Singh and Bhatia, 2018; Otto et al., 2019). From these non-antibiotic drugs and based 
on the evidence (see below), we selected one antibiotic and several non-antibiotic drugs from 
different classes to be tested in combination with tobramycin. The chosen drugs with their 
chemical structures are displayed in Figure 5.1, and the scientific evidence about their anti-
bacterial potentials will be discussed in the following paragraphs. 
 
Colistin (COL) is an old antibiotic that, due to issues with multidrug resistance, has been 
revived in the current clinical management of P. aeruginosa infections (Cummins et al., 2009). 
COL has a good in vitro and in vivo activity against Gram-negative pathogens such as P. 
aeruginosa (Lee et al., 2016). In this study,  colistin was selected specifically, because it has 
been used frequently with tobramycin for the management of P. aeruginosa lung infections in 
CF patients, and several studies have reported a synergistic interaction of colistin with 
tobramycin (Hill et al., 2005; Herrmann et al., 2010). However, such studies evaluated this 
using standard growth media and against the PAO1 lab strain, therefore, it is essential to 
investigate this combination using more clinically relevant media and against a large number 
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In addition to colistin, we selected non-antibiotic drugs. The first one was amitriptyline (AMT).  
AMT is a tricyclic antidepressant that is used to treat patients with depression and neuropathic 
pain (Seale et al., 2014). The antibacterial activity of amitriptyline has been investigated against 
several Gram-negative bacteria including P. aeruginosa (Kaatz et al., 2003; Mandal et al., 
2010; Ayaz et al., 2015). There is conflicting data about the possible antibacterial mechanism 
of amitriptyline. For instance, one study suggested that this could be due to its ability to inhibit 
efflux pumps (Kristiansen et al., 2010), but another paper indicated that AMT is a substrate for 
efflux pumps (Laudy et al., 2017). Besides amitriptyline, sertraline is another anti-depressant 
termed a selective serotonin reuptake inhibitor, which has been also found to exert antibacterial 
actions, due to its role in the inhibition of efflux pumps (Munoz-Bellido et al., 2000; Bohnert 
et al., 2011). 
 
Anti-virulence activity has also been reported with niclosamide (NIC), which is an anti-
helminthic drug for the treatment of human tapeworm infections (Chen et al., 2018). Recently, 
a study found that NIC has antibacterial activity against P. aeruginosa PA14 (Imperi et al., 
2013). Such activity was attributed to its ability to inhibit the quorum sensing system (Imperi 
et al., 2013; Rajamuthiah et al., 2015; Singh and Bhatia, 2018; Miró-Canturri et al., 2019). 
Furthermore, the anti-virulence activity of niclosamide was also observed against Gram-
positive bacteria (Rajamuthiah et al., 2015; Domalaon et al., 2019).  
 
As in the case with AMT and NIC, the anti-bacterial activity of amiloride (AML) has been also 
studied. AML is a sodium channel blocker for the treatment of hypertensive patients (Treerat 
et al., 2008). AML has been found to display antibacterial activity and to synergise tobramycin 
against Burkholderia cepecia in a pilot clinical trial study (Middleton et al., 2005).  This 
antibacterial activity was attributed to its effect on sodium and potassium ions in bacterial cells 
(Giunta et al., 1985). It was found that these cations can antagonize the action of 
aminoglycosides by blocking their uptake through the outer membrane in Gram-negative 









                                                                                                                                                                     
                      
                                               
              
 
Figure 5.1. Chemical structures antibiotics and non-antibiotic drugs. colistin, amitriptyline, 
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Quercetin (QUE) in turn is a flavonoid, which is naturally found in fruits and vegetables, and 
has also been found to have anti-virulence properties (Pawlikowska-Pawlęga et al., 2007; 
Siriwong et al., 2016; Roy et al., 2018). This antibacterial activity has been found against P. 
aeruginosa, in which this activity was related to either its role to inhibit the quorum sensing 
system or to its ability to disrupt the inner bacterial cytoplasmic membrane (Hirai et al., 2010; 
Gopu et al., 2015; Siriwong et al., 2016).     
 
Like the above-mentioned drugs, the anti-psychotic phenothiazine chlorpromazine (CPH) has 
been studied in vitro for its antibacterial action (Dastidar et al., 2013). For instance, CPH 
showed antibacterial activity against Gram-negative bacteria such as Salmonella spp., 
Klebsiella pneumonia, and P. aeruginosa (Dastidar et al., 2013). This antibacterial activity was 
proposed to be due to its action on the bacterial cytoplasmic membrane (Dastidar et al., 2013).  
 
Besides these drugs, another FDA-approved drug with a different mechanism of action and 
therapeutic indication has also been evaluated for antibacterial activity. This drug, 
diethylenetriaminepentaacetic acid (DTP), is a metal chelating agent for the treatment of 
patients with heavy metal ion poisoning such as with lead and mercury (Umerska et al., 2018). 
Currently, it has been found that DTP has anti-biofilm potency because of its ability to 
sequester the outer membrane-associated cations such as calcium and magnesium  (Liu et al., 
2017; Umerska et al., 2018). Additionally, a derivative of DTP is EDTA that has also been 
used as an anti-biofilm agent in treating wound infections alone and in combinations with anti-
microbial agents (Finnegan and Percival, 2015).   
 
Other drugs or compounds with anti-virulence properties against bacterial pathogens are 
natural compounds such as furanones (FUR), which are released from seaweed (Hentzer et al., 
2002; Maeda et al., 2012; Rampioni et al., 2017b). FUR antibacterial properties have been 
reported against Gram-negative bacteria including E. coli and P. aeruginosa. Such activity was 
attributed to the disruption of quorum sensing systems and to the inhibition of biofilm 
formation in these bacteria (Hentzer et al., 2002; Kuehl et al., 2009). However, furanones were 
found to stimulate biofilm formation in some Gram-positive bacteria (Kuehl et al., 2009).  
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The current studies on tobramycin address its activity mostly in combination with other 
antibiotics, while its combination with non-antibiotic drugs is poorly studied. Therefore, this 
chapter aimed at the investigations of the potential in vitro combination of tobramycin and 
several FDA-approved non-antibiotic drugs belonging to different classes against P. 
aeruginosa. Such in vitro combinations were tested using a clinically relevant artificial sputum 
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5.2 Results  
5.2.1 In vitro interactions between tobramycin and antibiotic/non-
antibiotic drugs against planktonic PAO1 
As outlined in the introduction section, tobramycin tolerance is growing, and several non-
antibiotic drugs have been reported to have antimicrobial activity against Gram-negative 
bacteria. So, we aimed to assess the antibacterial activity of these drugs alone, and also in 
combination with tobramycin against P. aeruginosa. Therefore, we used the checkerboard 
assay (See Materials and Methods Chapter) to examine the potential interactions between 
tobramycin and antibiotic/non-antibiotic drugs against P. aeruginosa PAO1 using the standard 
Mueller Hinton Broth (MHB) medium. The results are summarized in Table 5.1.  
Table 5.1. In vitro interactions between tobramycin and antibiotic/non-antibiotic drugs against P. 















COL TOB/COL 0.5/0.5 1/0.5 3 Indifferent 
AMT TOB/AMT 0.5/512 2/2 4 Antagonist 
NIC TOB/NIC 0.5/512 2/2 4 Antagonist 
AML TOB/AML 0.5/512 1/2 2 Indifferent 
QUE TOB/QUE 1/512 2/2 2 Indifferent 
CHL TOB/ CHL 1/512 2/2 2 Indifferent 
DTP TOB/DTP 1/512 2/2 2 Indifferent 
HDF TOB/HDF 0.5/256 1/4 2 Indifferent 
TOB, tobramycin; COL, colistin; AMT, amitriptyline; NIC, niclosamide; AML, amiloride; QUE, quercetin; CHL, 
chlorpromazine; DTP, diethylenetriaminepentaacetic acid; HDF, 4-hydroxy-2,5-dimethyl-3(2H)-furanone. a the 
MIC: Minimum Inhibitory Concentrations (µg/ml) alone or combined, b the FIC: Fractional Inhibitory 
Concentration index. c tobramycin in all combinations, d the other drugs in the combination as sequenced in the 
table 
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The checkerboard data revealed that none of the tested antibiotics/non-antibiotic drugs 
displayed a synergistic interaction with tobramycin. For instance, the majority of drugs showed 
indifferent interaction as the measured FICs index was ≥ 2. The other drugs, AMT and NIC 
resulted in antagonistic interactions with FICs that were ≥ 4. As a monotherapy, it was observed 
that tobramycin or colistin demonstrated a good activity with MIC values of 0.5 µg/ml, while 
none of the other tested drugs displayed anti-bacterial activity against PAO1 with MICs ≥ 256 
µg/ml.  
 
Currently, tobramycin combination studies are mostly evaluated using the standard growth 
media e.g. MHB, which are not adequately representative of the in vivo conditions. Therefore, 
our aim was to test such tobramycin interactions using a more clinically relevant ASM medium, 
which could better reflect the influence of such combinations in a condition as similar as 
possible to the in vivo environment. In this regard, these tobramycin combinations were also 
re-evaluated using the ASM medium. The results are depicted in Table 5.2.  
 
Table 5.2.  In vitro interactions between tobramycin and antibiotic/non-antibiotic drugs against P. 

















COL TOB/COL 0.5/4 1/4 3 Indifferent 
AMT TOB/AMT 0.5/512 4/512 9 Antagonism 
NIC TOB/NIC 0.5/512 2/2 4 Antagonism 
AML TOB/AML 0.5/ 256 1/2 2 Indifferent 
QUE TOB/QUE 0.5/256 2/2 4 Antagonism 
CHL TOB/ CHL 0.5/1024 2/2 4 Antagonism 
DTP TOB/DTP 0.5/1024 32/2 64 Antagonism 
HDF TOB/HDF 0.5/1024 4/16 8 Antagonism 
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The observed data suggested that using ASM medium resulted in some interactions, which 
were not observed using standard MHB. For instance, QUE, CHL, DTP, and HDF showed 
antagonistic interactions, with FIC reaching to 64 when DTP was used. Moreover, much higher 
MIC values up to 1024 µg/ml were documented as compared to 512 µg/ml in MHB. Such 
results indicate that testing the drug interactions using MHB could not simulate the in vivo 
conditions, and it is important to use more clinically relevant media to evaluate drug 
combination therapies. Accordingly, for the following studies, the ASM medium was used to 
test the influence of these tobramycin combinations against P. aeruginosa biofilms. 
 
5.2.2 In vitro interactions between tobramycin and antibiotic/non-
antibiotic drugs against PAO1 biofilm 
 
In the previous section, tobramycin interactions were evaluated against planktonic PAO1. In 
the current section, our aim was to evaluate such interactions against PAO1 biofilms. This is 
because of the different lifestyles between planktonic and biofilm phenotypes (Das et al., 2016; 
Ghorbani et al., 2017), and also due to different infections that are caused by these phenotypes. 
For instance, acute infections are mostly caused by planktonic forms, while chronic infections 
are mainly associated with biofilms. Therefore, we further determined the influence of 
tobramycin interactions with antibiotic/non-antibiotic drugs against biofilms of P. aeruginosa 
PAO1.  
 
To that purpose, the 96-well plate biofilm assay was used, in which PAO1 biofilms were grown 
in ASM medium and were challenged with either tobramycin/drugs alone or in combination 
for 24 h. The concentrations for antibiotic/non-antibiotic drugs were chosen because these have 
been shown to elicit antimicrobial activity against P. aeruginosa in the literature. The results 
(Figure 5.2 A-C) showed that COL, AMT, and NIC significantly (p< 0.05) potentiated activity 
of tobramycin with more than 50% reduction in biofilm biomass as compared to the controls 
and tobramycin alone against PAO1 biofilms. 
 
 





Figure 5.2 The effect of TOB, COL, AMT, NIC, AML, QUE, CHL, DTP, and HDF alone and in 
combination against P. aeruginosa PAO1 biofilms in ASM medium. Control (drug free); TOB 50 = 50 
µg/ml tobramycin; Col 4 = 4 µg/ml colistin; AMT 100 = 100 µg/ml amitriptyline; NIC 50 = 50 µg/ml niclosamide; 
AML 100 = 100 µg/ml amiloride; QUE 80 = 80 µg/ml quercetin; CHL 125 = 125 µg/ml chlorpromazine 
hydrochloride; DTP 100 = 100 µg/ml diethylenetriaminepentaacetic acid; HDF 100 = 100 µg/ml 4-hydroxy-2,5-
dimethyl-3(2H)-furanone. Error bars represent the standard error of the mean from three independent experiments 
with at least six technical replicate wells. Statistical significance was analysed using one-way analysis of variance 
(ANOVA) followed by Tukey multiple comparison test. The same letters indicate non-significant difference. Full 
details of the statistical analysis are shown in appendix 1. 
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Conversely, the other drugs showed no difference when combined with tobramycin (Figure 5.2 
D-H). Notably, neither tobramycin nor any of these drugs alone displayed anti-biofilm activity. 
The only exception was observed in the biofilms that were challenged with DTP (Figure 5.2 
G), in which significant (p< 0.05) reduction in biofilm biomass was observed. This could be 
because DTP acts as a chelating agent, which can chelate metal cations such as calcium, 
magnesium, and importantly iron (Lambert et al., 2004; Wright, 2016). Interestingly, when 
DTP was combined with tobramycin, it resulted in apparent antagonism (p= 0.07), which could 
confirm the antagonism that we observed against planktonic PAO1 in section 5.2.1.  
 
5.2.3 In vitro interactions between tobramycin and antibiotic/non-
antibiotic drugs against biofilms of clinical P. aeruginosa isolates 
 
In the previously described section, tobramycin combinations were evaluated against biofilms 
of the lab strain PAO1. In this section, this was further expanded against clinical CF isolates 
P. aeruginosa of LMG 27643 and LMG 27648 biofilms. The results (Figure 5.3 A-H and I-P) 
for LMG 27643 and LMG 27648, respectively, suggested different responses between clinical 
CF isolates and PAO1(Section 5.2.2). For instance, in the previous section with PAO1 three of 
the tested drugs (COL, AMT, NIC) were able to synergize tobramycin against PAO1 biofilms. 
In contrast, for both clinical CF isolates we only found one synergistic interaction for a 
combination of tobramycin with AMT (p< 0.05) (Figure 5.3 B) against LMG 27643 biofilms, 
in which AMT-TOB combination caused 80% reduction in biofilm biomass as compared 
tobramycin alone (Figure 5.3 B). The other drugs either alone or in combination with 
tobramycin did not have anti-biofilm activity against either biofilm of LMG 27643 (Figure 5.3 
A and C-H) or LMG 27648 (Figure 5.3 I-P). Such data indicate that every P. aeruginosa strain 
responds differently to the same drug combinations.  
 











Figure 5.3 The effect of TOB, COL, AMT, NIC, AML, QUE, CHL, DTP, and HDF alone and in 
combination against biofilms of clinical P. aeruginosa isolate in ASM. LMG 27643 (A-H) and 
LMG 27648 (I-P). Control (drug free); TOB 50 = 50 µg/ml tobramycin; Col 4 = 4 µg/ml colistin; AMT 100 = 
100 µg/ml amitriptyline; NIC 80 = 80 µg/ml niclosamide; AML 100 = 100 µg/ml amiloride; QUE 80 = 80 µg/ml 
quercetin; CHL 125 = 125 µg/ml chlorpromazine hydrochloride; DTP 100 =100 µg/ml 
diethylenetriaminepentaacetic acid; HDF 100 = 100 µg/ml 4-hydroxy-2,5-dimethyl-3(2H)-furanone. Error bars 
represent the standard error of the mean from three independent experiments with at least six technical replicate 
wells. Statistical significance was analysed using one-way analysis of variance (ANOVA). The same letters 
indicate non-significant difference. Full details of the statistical analysis are shown in appendix 1. 
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5.3 Discussion  
 
In this chapter, we tested various tobramycin combinations with antibiotic/non-antibiotic drugs 
and other natural compounds using ASM medium against P. aeruginosa. These combinations 
were performed using the checkerboard assay, in which the antibacterial activity of each drug 
alone and in combination with tobramycin was assessed.  
 
The detection of potential synergistic or antagonistic interactions between drug combinations 
is determined using several in vitro assays (Orhan et al., 2005). These include techniques of 
Epsilometer (E-test), time-kill curve, and checkerboard (Bonapace et al., 2000). Each of these 
methods measures synergy using different endpoint parameters (White et al., 1996; Balouiri et 
al., 2016; Brennan-Krohn and Kirby, 2019). For instance, the time-kill assay determines the 
rate of killing over several time points, while the E-test and the checkerboard assays measure 
the inhibitory activity at a fixed time point (Doern, 2014). For all these methods, there is no 
consensus on which assay is the most clinically relevant. However, the most established and 
widely used assay is the checkerboard assay (Cappelletty and Rybak, 1996; Doern, 2014). The 
checkerboard assay was therefore employed to test tobramycin combinations.  
 
Using antibiotic agents in combination with non-antibiotic drugs is now becoming an 
interesting strategy to treat bacterial infections (Laudy et al., 2017; Otto et al., 2019). Therefore, 
in this work we evaluated tobramycin combinations with antibiotic/non-antibiotic drugs and 
natural compounds against P. aeruginosa. Our tobramycin combinations data indicated mixed 
results, in which these results were different according to the growth media, the bacterial 
lifestyles, and the strains that were used.  
 
Firstly, using different growth media in the checkerboard assay indicated varying results. For 
example, testing tobramycin interactions using the standard MHB medium resulted mostly in 
indifferent interactions, while only amitriptyline and niclosamide showed antagonistic 
interaction. On the other hand, using a clinically relevant ASM medium more antagonistic 
interactions were observed with only two drugs, colistin and amiloride showed indifference. 
Such multiple antagonistic interactions that were noticed with ASM medium, suggest that the 
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cells responded differently to tobramycin combination under CF-like sputum conditions. This 
could be attributed for instance to the components of the ASM medium. These include for 
instance DNA and mucin glycoproteins, which might have a role in the adsorption of both 
tobramycin and also non-antibiotic drugs. For example, it is known that some of these non-
antibiotic drugs are highly protein binding such as amitriptyline, niclosamide, and 
chlorpromazine (Brinkschulte et al., 1982; Silva et al., 2004; Domalaon et al., 2019). These 
data indicate that using a more clinically relevant ASM medium is essential in testing the 
influence of drug combinations. Importantly and after further in vitro and in vivo studies, such 
antagonistic interactions suggested that careful attention should be considered when these 
drugs are used in combination with tobramycin particularly in acute P. aeruginosa infections. 
Comparing our results with other studies might be difficult because most of tobramycin 
combination studies in literature are with antibiotic drugs, however, limited studies about 
tobramycin combination with non-antibiotic drugs are available. Indeed, if there are studies for 
tobramycin with non-antibiotic drugs, they were evaluated using different non-antibiotic drugs, 
growth media, and strains.  
 
Secondly, testing tobramycin combinations against different bacterial lifestyles and strains 
showed variations in the observed results. For example, as discussed above, mostly antagonistic 
interactions were observed against planktonic PAO1 such as amitriptyline, niclosamide, 
quercetin, chlorpromazine, diethylenetriaminepentaacetic acid, and furanone. In contrast, for 
the biofilm phenotypes, some tobramycin combinations such as colistin, amitriptyline, and 
niclosamide showed synergistic interactions against PAO1 biofilms with 80% reduction in 
biofilm biomass. However, this was not observed with clinical isolate biofilms, with one 
exception being with LMG 26743, where the only synergistic interaction was observed with 
amitriptyline. One plausible explanation for such a difference could be attributed to the 
profoundly different gene expressions and behaviours between planktonic and biofilm 
counterparts (Haagensen et al., 2007; Das et al., 2016). Such behaviour was also observed by 
other investigators (Hill et al., 2005; Ghorbani et al., 2017), where they found different 
responses between planktonic/biofilm P. aeruginosa when the latter were challenged with the 
same combination of antibiotics. In the same way, other researchers observed different 
bacterial response to the combination therapies of tobramycin with non-antibiotic agents such 
as bicarbonate and triclosan (Kaushik et al., 2016; Maiden et al., 2018). For instance, Kaushik 
et al (2016) found a synergistic interaction for tobramycin-bicarbonate against planktonic cells 
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but not biofilms. Other investigators Maiden et al (2018) found that tobramycin-triclosan 
combination was synergistic against biofilm, while no difference was observed against 
planktonic cells. The findings from our study and other cited papers highlight the importance 
of considering the bacterial mode of growth when the drug combinations are evaluated. 
Additionally, our data indicate that the influence of tobramycin combinations vary according 
to bacterial isolates. Therefore, this suggests the importance of evaluating drug combinations 
with diverse strain collections.  
 
The synergistic interactions that were discussed above with colistin, amitriptyline, and 
niclosamide could be explained by a different mechanism of action. However, the exact 
mechanism behind such synergy for these drugs is not known and, in this work, we have not 
carried out further studies to investigate this. These synergies could result from specific 
mechanisms for each drug. For example, the observed synergy between colistin and tobramycin 
could be explained by different molecular targets that were attacked by these drugs. Colistin 
mainly acts on the bacterial outer membrane (Stein et al., 2015), where this might enhance 
penetration of tobramycin into its cellular target site. Another explanation could be related to 
the different bacterial cell populations inside biofilms (Williamson et al., 2012), where there is 
a population at the top of the biofilm with high metabolic activity and another population at the 
bottom of the biofilm with low metabolic rate (Herrmann et al., 2010; Rybtke et al., 2011). 
These populations have different susceptibility towards antibiotics (Williamson et al., 2012). 
For instance, tobramycin inhibits the actively diving bacterial cells at the surface, while colistin 
is highly active against the cells with the low metabolic rate at the bottom of biofilms (Rybtke 
et al., 2011). Our data were in agreement with other studies (Hill et al., 2005; Herrmann et al., 
2010). For instance, Hill et al (2005) found that combination of tobramycin and colistin was 
the best as compared to other tobramycin combinations with meropenem or ciprofloxacin 
antibiotics against biofilms P. aeruginosa CF isolates. Similarly, Herrmann et al (2010) showed 
superior efficacy of tobramycin-colistin combinations against biofilms of PAO1. Thus, this 
combination seemed to be more effective than the monotherapy of each drug against biofilms.  
 
For the other combination synergies with amitriptyline and niclosamide, none of these drugs 
have been tested before in combination with tobramycin against P. aeruginosa biofilms. 
Firstly, the synergy that was obtained with amitriptyline could be explained by the ability of 
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amitriptyline to inhibit efflux pumps (Kristiansen et al., 2010), which in turn could enhance the 
accumulation of tobramycin inside the cell. Another synergy that was observed with 
niclosamide, could be explained by one of the possible mechanisms. For instance, tobramycin 
tolerance in P. aeruginosa is affected by the quorum sensing system (Roberts et al., 2015) and 
it is known that this system largely controls biofilm formation in P. aeruginosa (She et al., 
2018). Therefore, combining these data with the current evidence about the role of niclosamide 
in inhibiting quorum sensing system in P. aeruginosa (Domalaon et al., 2019) might explain 
the enhanced activity of tobramycin with niclosamide.  
 
Finally, for any of the tested non-antibiotic drugs and natural compounds as a monotherapy we 
did not see any antibacterial or anti-biofilm activity, which could be expected as some of these 
non-antibiotic drugs are presumed to act as inhibitors for efflux pumps or quorum sensing in 
bacterial cells. Our results for chlorpromazine, amitriptyline, and niclosamide were in line with 
studies that showed very poor activity of these drugs against Gram-negative P. aeruginosa  
(Hendricks et al., 2003; Nehme et al., 2018; Domalaon et al., 2019; Otto et al., 2019). For 
another compound, quercetin, there is conflicting evidence, with some studies (Hirai et al., 
2010) showing no effect (similar to the results obtained here), and others showing a reduction 
in biofilm formation (Gopu et al., 2015). Such discrepancy can be explained by the different 
P. aeruginosa strain (PUFSTb04) and growth medium (Luria-Bertani) were used in that study. 
For amiloride, we did not find any activity either alone or in combination with tobramycin. 
This was in conflict with a paper that shown synergy with tobramycin (Treerat et al., 2008), 
however, as mentioned earlier the comparison is difficult as different strains, growth media, 
and method design were used.  
 
Furanone has been shown to exert quorum sensing inhibitory activity, but in our study, we have 
not found an activity for furanone against P. aeruginosa. Some studies (Kuehl et al., 2009; 
Maeda et al., 2012) have shown similar results to that observed here, while another paper 
(Hentzer et al., 2003) suggested that furanone has antibiofilm activity and could enhance 
tobramycin susceptibility. Such discrepancy with our work could be explained firstly by using 
different furanone derivatives, as it has been demonstrated that minor modifications of the 
functional groups in the structure of furanone, can significantly affect its activity against the 
tested bacteria (Kuehl et al., 2009). Secondly, the biofilm model, strain, medium, and technique 
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of treatment were all different. Collectively, it is clear that there is a lack of standardization in 
biofilm testing which can make interpretation of data quite complicated when comparing data 
from different laboratories (Boudarel et al., 2018). 
 
Our work with DTP was in accordance with studies that found using chelating agents such as 
EDTA at only very high concentrations (up to 16384 µg/ml) were able to inhibit the growth of 
P. aeruginosa (Lambert et al., 2004; Umerska et al., 2018). They found that using such high 
concentrations of EDTA can displace calcium, magnesium from the outer membrane, whereas 
at low concentrations no cell lysis was observed (Lambert et al., 2004). However, these high 
concentrations are not physiologically achievable. For DTP action in combination with 
tobramycin against PAO1 biofilms, we apparently found an antagonism. This might be related 
to tobramycin’s cationic properties, which could result in interaction with DTP. Another 
possible explanation could be related to tobramycin bacterial cell killing mechanism. It has 
been found that part of aminoglycoside antibacterial activity is associated with stimulating the 
production of hydroxyl radicals through a Fenton reaction (Kohanski et al., 2007). This means 
using DTP, which is known to chelate iron could reduce the ability of tobramycin to kill cells 
by inhibition of the Fenton reaction.  
 
5.4 Conclusion  
 
P. aeruginosa biofilm tolerance to antibiotics is a serious health problem, which the medical 
community is now facing. This current situation also combines with decreasing production and 
development of new antibiotics. Therefore, finding alternative strategies to efficiently use the 
available antibiotics is highly desired. Accordingly, in this chapter, we evaluated tobramycin 
in combination with several non-antibiotic drugs and natural compounds using a clinically 
relevant ASM medium against planktonic and biofilm P. aeruginosa. We found only the 
combination of tobramycin with colistin, amitriptyline, and niclosamide resulted in enhanced 
tobramycin activity against P. aeruginosa PAO1 biofilms, where such synergy resulted in 80% 
reduction in biofilm biomass as compared to tobramycin alone. The safety profiles of these 
drugs are known and established. Therefore, further cytotoxicity studies are not required. 
However, further investigations are needed to clearly understand the antibiofilm mechanisms 
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of action for these drugs, the influences of different doses, and their role in the treatment of P. 
aeruginosa biofilm infections. Moreover, the ability of this in vitro synergy to predict in vivo 
correlation is unknown, therefore, further clinical studies are warranted especially as the 
effectiveness of drug combinations is strain dependent. Finally, these drugs could be 
appropriate candidates to be used as adjuvant therapy with tobramycin to improve its activity 
against chronic P. aeruginosa biofilm infections. However, caution should be taken using some 
of these non-antibiotics combinations against acute P. aeruginosa infections, as our results 
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6.1 General overview  
 
 P. aeruginosa infections in CF patients are considered amongst the most challenging 
infections for treatment. One of the extreme difficulties in the treatment of these infections is 
attributed to the ability of P. aeruginosa to grow in sessile structured communities called 
biofilms, which have a major role in antibiotic tolerance to many antibacterial classes. Among 
these are aminoglycosides and particularly tobramycin, which is the most widely used 
antibiotic in the treatment of P. aeruginosa infections.  
  
The general aim of the work presented in this thesis was to investigate the role of tobramycin 
and possible potential ways to improve its activity in the eradication of P. aeruginosa biofilms. 
Specifically, this work had three overarching aims. Firstly, to determine the activity of 
tobramycin using a clinically relevant artificial sputum medium (ASM) against P. aeruginosa 
clinical CF isolates. Secondly, to investigate the activity of tobramycin dry powder inhaler 
(TOBI Podhaler®) in terms of particle size. Thirdly, to evaluate tobramycin activity in 
combination therapy with non-antibiotic drugs. These experiments designed to address the 
aims that have been described in this thesis in chapters 3-5, and the following paragraphs will 
briefly summarise them.  
 
6.2 The activity of tobramycin in eradication P. aeruginosa biofilms  
 
To address aim one (chapter 3), the activity of tobramycin was evaluated against a number of 
clinical CF isolates and PAO1 lab strain. This was performed using two different in vitro 
biofilm models, which were the 96-well plate and the colony biofilm models. The latter could 
be a much better simulation than the microtiter plate assay for biofilms grow in the lung, as it 
provides an air-interface surface. Two different growth media minimal MOPS and artificial 
sputum medium (ASM) were used. The former is a standard minimal medium, whereas the 
latter is a clinically more relevant medium, as it has CF-sputum like properties. For instance, it 
contains DNA, mucin, and salts. Our key findings from using these media suggested different 
values for MICs of tobramycin. For example, we observed that the MIC values of tobramycin 
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for the tested strains were four-fold higher when ASM was used as compared with MOPS, 
which might be explained by the interactions between ASM components and tobramycin. 
Therefore, such data indicate that it is important to consider using the more clinically relevant 
ASM medium for determining antibiotic susceptibility. Other key findings from this work 
suggested that tobramycin was able to reduce biofilm biomass and viable count by 40-60% in 
most of the tested strains, but that complete eradication of P. aeruginosa biofilms was difficult 
to achieve. This is mainly attributed to the advantages that growing in a biofilm-like structure 
offers to bacterial cells. We have not investigated this specifically for tobramycin in our biofilm 
models, but it is likely to be a combination of several reasons. For instance, biofilms can act as 
a barrier that decreases the penetration of tobramycin because of the electrostatic binding 
between tobramycin and biofilm matrix components. Additionally, bacterial cells inside the 
biofilm grow at a low metabolic rate, which could also reduce the activity of tobramycin. 
Moreover, the microaerobic environment inside a biofilm could also affect the anti-biofilm 
activity of tobramycin. Therefore, these data have a critical clinical implication and strongly 
suggest that further research and studies are warranted to improve the activity of tobramycin 
against P. aeruginosa biofilms.   
 
6.3 The activity of tobramycin dry powder inhaler in terms of 
particle size 
 
Following the findings described in section 6.2, the work was continued by evaluating the 
activity of tobramycin dry powder (TOBI Podhaler®). This work addressed the second aim 
(chapter 4), where we determined the efficacy of tobramycin dry powder inhaler against P. 
aeruginosa with a specific aim to analyse the effect of particle size. In the first step, we 
optimized a model to fractionate tobramycin dry powder into different particle size categories, 
which was performed using the Next Generation Impactor (NGI). In the second step, we 
developed and optimised an HPLC-MS assay, allowing us to quantify the mass of differently 
sized tobramycin particles from the NGI. These were preliminary steps before testing the 
activity of different tobramycin particle sizes against P. aeruginosa biofilms. In the next step, 
we used ASM as a growth medium and also optimized an in vitro biofilm model that allows 
growing biofilms at an air-interface. This was performed by using the colony biofilm assay. 
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The main aim of using these models was to develop an in vitro model that might be a better 
reflection for the conditions in the CF lung by growing biofilms at an air-interface, and also 
allow us to apply tobramycin as a dry powder directly to the biofilms.  
 
The key findings suggested that the particle size of tobramycin does influence the antibiofilm 
activity in a time-dependent fashion. Smaller tobramycin particles (< 2.82 µm) were more 
effective by about ⁓20% reduction in viable count as compared to the larger particles (< 11.7 
µm) in the eradication of P. aeruginosa biofilms of LMG 27649 and LMG 27643 after a short 
incubation time (3 hours). This time of incubation is potentially important, as this is similar to 
the time taken for the clearance of tobramycin from the lung. Because of the effect that was 
observed at 3 hours, further experiments were conducted with LMG 27649 clinical isolate at 
different incubation time points which showed a reproducible trend of better efficacy of smaller 
particles when the incubation time was less than 24 hours, although statistical significance was 
not achieved. With respect to our in vitro results, it is not yet clear whether our data have a 
clinical significance, and further experiments both in vitro and in vivo are required to confirm 
this.  
 
6.4 The activity of tobramycin in combination therapy  
 
Following determination of the influence of tobramycin in terms of particle size, we further 
studied the potential improvement of tobramycin activity by evaluating the combinations of 
tobramycin with another antibiotic (colistin) or non-antibiotic drugs (amitriptyline, 
niclosamide, amiloride, quercetin, chlorpromazine, diethylenetriaminepentaacetic acid, and 
furanone). This work addressed the third aim (Chapter 5), where we determined the influence 
of these non-antibiotic drugs in combination with tobramycin against planktonic and biofilms 
of P. aeruginosa. The evaluation of tobramycin combined with non-antibiotic drugs was 
carried out using the checkerboard technique, which was analysed using the Fractional 
Inhibitory Concentrations (FICs). Mueller-Hinton Broth (MHB) and ASM growth media were 
used to evaluate these combinations. The data obtained from this work suggested vital 
information about tobramycin combinations using ASM as compared with MHB against 
planktonic cells. For instance, using ASM resulted mostly in antagonistic interactions with 
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tobramycin, whereas with MHB most of the combinations showed indifference. Therefore, 
such findings contained in this chapter are important as they highlight, similar to chapter 3, the 
importance of using a more clinically relevant medium in testing antibiotic activity. Despite 
we used in our study a more physiologically relevant medium, which is a better reflection to in 
vivo lung conditions than standard growth media. The in vivo implications of our findings 
remain to be investigated. Accordingly, our in vitro results cannot be expanded to clinical 
practice until further in vivo data are obtained.   
 
Besides studying the activity of tobramycin combined with other drugs against planktonic cells, 
we also investigated the influence of these combinations against biofilms. Our data showed 
mixed results with some combinations showing no difference, while others showed synergistic 
interactions with tobramycin. It is noteworthy that there is a large variation in the results of 
such combinations in the literature, which may relate to the lack of standardization in biofilm 
research. In our study, we observed no difference when tobramycin was combined with 
amiloride, quercetin, chlorpromazine, diethylenetriaminepentaacetic acid, and furanones. For 
other drugs, we found synergistic combinations with colistin, niclosamide, and amitriptyline. 
These combinations resulted in about 80% reduction in biofilm biomass as compared to 
tobramycin alone. Such synergistic interactions were mostly observed against PAO1 but were 
not always obvious with all clinical isolates except LMG27643, in which amitriptyline 
synergized tobramycin. These data indicate that it is essential to test drug combinations against 
a wide range of clinical isolates. Finally, for these tobramycin combinations to be considered 
for therapeutic potential, further experiments both in vitro and in vivo are warranted. 
 
Finally, as a general conclusion from this thesis, it is obvious that P. aeruginosa biofilm 
eradication is challenging and difficult. Therefore, considerable efforts and research are needed 
to preserve or further improve antibiotic activity to be able to eliminate these biofilms. Such 
improvement should be expanded and not only be focused on antibiotics themselves, as it is 
not the sole determinant. Other factors such as a pharmaceutical formulation, delivery to the 
target organ, and a combined antibiotic formulation can all play major roles and contribute to 
enhance the efficacy of the available antibiotics. Meanwhile, early aggressive antibiotic therapy 
can have a major role in the prevention establishment of chronic infections.  
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6.5 Future work 
 
1- In future studies, it could be of interest to test the influence of using differently sized 
tobramycin particles against other species such as Burkhoderia cepacia and Staphylococcus 
aureus that are also part of polymicrobial lung infections in CF patients. Furthermore, it 
would be desirable to test the effect of particle size in more advanced models such as ex-
vivo and in vivo lung models. 
 
 
2- Here a successful model for testing the dry powder inhaler antibiotic has been developed. 
Our study needs to be expanded to test other antibiotics administered via a dry powder 
inhaler. This might be of particular importance for those antibiotics with a lower aqueous 
solubility than tobramycin. Examples of these drugs are ciprofloxacin and colistin. For 
instance, the octanol-water partition coefficient (log P oct) of ciprofloxacin is 2.3, and for 
colistin is - 2.4 as compared to -7.3 for tobramycin. Particles of these drugs are therefore 
likely to dissolve more slowly than those of tobramycin, so there could be a more 
significant effect of the particle size on the rate of dissolution and thus biofilm activity. The 
potential results from testing these drugs could improve the activity of dry powder inhaler 
antibiotics by formulating dry powder inhaler with higher percentages of the most effective 
particle size range.  
 
 
3- In future studies of tobramycin combined with other drugs, it would be interesting to test 
these synergistic tobramycin combinations against a large library of clinical isolates and 
strains to confirm their efficacy. Additionally, this work can be further expanded by 
evaluating a broader range of non-antibiotic drugs for their antibacterial activity and role 
as adjuvant therapy with tobramycin. This could offer further knowledge that could help to 
determine the possible synergistic as well as antagonistic interactions of tobramycin with 
non-antibiotic drugs. When the synergistic activity of drugs with tobramycin or other 
antibiotics is confirmed, these then need to be formulated and tested for their behaviour as 
a dry powder. This would initially involve studies using the NGI as outlined in chapter 4, 
as well as studies testing these formulations in in vitro and in vivo models.      
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Research output from this thesis 
 
The 6th European Congress on Biofilms. Euro-biofilms 3-6 September 2019, Glasgow, 
Scotland-UK. Investigating the influence of dry powder inhaler antibiotics against P. 
aeruginosa biofilms (Poster presentation). 
 
The 8th Congress of European Microbiologist FEMS 7-11 July 2019, Glasgow, Scotland-UK. 
Investigating the influence of dry powder inhaler antibiotics against P. aeruginosa biofilms 
(Poster presentation). 
 
Outreach Public Engagement Activity (oral talk) at Soapbox Science, 13 July 2019, Bristol- 
UK. http://soapboxscience.org/soapbox-science-2019-bristol/. 
 
Center Therapeutic Innovation Showcase CTI Showcase 25 June 2019 University of Bath-
UK, Investigating the influence of dry powder inhaler antibiotics against P. aeruginosa 
biofilms (Poster presentation). 
 
Annual Microbiology Society conference 8-11 April 2019 ICC Belfast-UK. Investigating the 
influence of dry powder inhaler antibiotics against P. aeruginosa biofilms (Poster 
presentation). 
 
Meeting Abstract in Microbiology Journal investigating the effect of tobramycin dry powder 
inhaler on the eradication of Pseudomonas aeruginosa biofilms. First Published: 08 April 
2019 https://doi.org/10.1099/acmi.ac2019.po0039. 
 
BSAC Spring Conference 21 – 22 March 2019, Birmingham-UK, Investigating the influence 
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Appendix 1: full details of the statistical analysis  
Table A1: overall details of the statistical analysis 
Figures Statistical tests Overall statistical analysis 
3.1 A ANOVA F= 9.55, df= 23, p= 0.0001 
3.1 B ANOVA F= 1.23, df= 29, p= 0.32 
3.1 C ANOVA F= 47.97, df= 29, p= < 0.0001 
3.1 D ANOVA F= 13.95, df= 17, p= 0.0001 
3.1 E ANOVA F= 144.1, df= 17, p <0.0001 
3.2 A t-test t= 9.87, df= 10, p<0.0001 
3.2 B t-test t= 7.95, df= 10, p<0.0001 
3.2 C t-test t=9.7, df= 10, p<0.0001 
3.2 D t-test t=7.42, df= 10, p<0.0001 
3.2 E t-test t=5.18, df=10, p<0.0001 
3.3 A ANOVA F= 2.08, df= 12, p= 0.17 
3.3 B ANOVA F= 1.7, df= 23, p= 0.17 
3.3 C ANOVA F= 0.33, df= 23, p= 0.92 
3.3 D ANOVA F= 3.01, df=25, p= 0.28 
3.4 A ANOVA F= 0.46, df= 14, p= 0.75 
3.4 B ANOVA F= 0.85, df= 23, p= 0.36 
3.4 C ANOVA F= 0.24, df= 23, p= 0.96 
3.4 D ANOVA F= 0.12, df= 26, p= 0.99 
3.6 A ANOVA F= 0.3, df= 8, p= 0.75 
3.6 B ANOVA F= 1.76, df= 8, p= 0.24 
3.6 C ANOVA F= 2.6, df= 8, p= 0.153 
3.6 D ANOVA F= 2.5, df= 8, p= 0.158 
3.7 A ANOVA F= 0.71, df= 5, p= 0.629 
3.7 B ANOVA F= 1.98, df= 5, p= 0.117 
3.7 C ANOVA F= 2.93, df= 5, p= 0.034 
3.7 D ANOVA F= 1.83, df= 5, p= 0.146 
3.8 A t-test t= 5.64, df= 8, p= 0.0005 
3.8 B t-test t= 4.79, df= 10, p= 0.0007 
3.8 C t-test t= 3.69, df= 8, p= 0.006 
3.8 D t-test t= 5.17, df= 10, p= 0.0004 
3.9 A t-test t= 2.35, df= 8, p= 0.046 
3.9 B t-test t= 2.08, df= 10, p= 0.064 
3.9 C t-test t= 3.12, df= 10, p= 0.011 
3.9 D t-test t= 4.45, df= 10, p= 0.001 
4.11 t-test t= 0.31, df= 8, p= 0.76 
4.13 A t-test t= 0.22, df= 4, p= 0.834 
4.13 B t-test t= 0.24, df= 4, p= 0.82 
4.13 C t-test t= 0.95, df= 4, p= 0.39 
4.13 D t-test t= 0.13, df= 6, p= 0.89 
4.13 E t-test t= 0.39, df= 4, p= 0.72 
4.13 F t-test t= 0.61, df= 4, p= 0.58 
4.13 G t-test t= 0.87, df= 6, p= 0.42 
4.13 H t-test t= 1.23, df= 4, p= 0.29 
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4.14 t-test t= 1.76, df= 4, p= 0.15 
4.15 A t-test t= 1.02, df= 4, p= 0.36 
4.15 B t-test t= 0.24, df= 4, p= 0.83 
4.15 C t-test t= 0.85, df= 4, p= 0.45 
4.15 D t-test t= 0.038, df= 4, p= 0.97 
4.16 A t-test t= 0.19, df= 4, p= 0.85 
4.16 B t-test t= 0.32, df= 4, p= 0.76 
4.16 C t-test t= 0.16, df= 4, p= 0.88 
4.16 D t-test t= 0.55, df= 4, p= 0.61 
4.17 A t-test t= 2.77, df= 4, p= 0.04 
4.17 B t-test t= 2.96, df= 6, p= 0.02 
4.17 C t-test t= 1.5, df= 4, p= 0.26 
4.17 D t-test t= 0.52, df= 4, p= 0.63 
4.18 ANOVA F= 0.43, df= 2, p= 0.66 
5.2 A ANOVA F= 8.91, df= 11, p= 0.006 
5.2 B ANOVA F= 11.56, df= 11, p= 0.03 
5.2 C ANOVA F= 19.58, df= 11, p= 0.0005 
5.2 D ANOVA F= 3.97, df= 11, p= 0.156 
5.2 E ANOVA F= 1.02, df= 11, p= 0.43 
5.2 F ANOVA F= 1.58, df= 11, p= 0.27 
5.2 G ANOVA F= 14.5, df= 7, p= 0.012 
5.2 H ANOVA F= 2.45, df= 11, p= 0.52 
5.3 A ANOVA F= 1.3, df= 11, p= 0.32 
5.3 B ANOVA F= 10.5, df= 7, p= 0.02 
5.3 C ANOVA F= 1.4, df= 11, p= 0.31 
5.3 D ANOVA F= 2.56, df= 11, p= 0.125 
5.3 E ANOVA F= 0.46, df= 11, p= 0.71 
5.3 F ANOVA F= 0.59, df= 11, p= 0.637 
5.3 G ANOVA F= 10.5, df= 7, p=0.02 
5.3 H ANOVA F= 5.28, df= 11, p= 0.026 
5.3 I ANOVA F= 0.192, df= 11, p= 0.89 
5.3 J ANOVA F= 4.87, df= 11, p= 0.03 
5.3 K ANOVA F= 9.4, df= 11, p= 0.005 
5.3 O ANOVA F= 5.61, df= 11, p= 0.02 
5.3 L ANOVA F= 9.5, df= 11, p= 0.005 
5.3 M ANOVA F= 4.89, df= 11, p= 0.032 
5.3 N ANOVA F= 3.61, df= 11, p= 0.06 
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Appendix 2: Anova analysis with considering tobramycin 
concentrations as continuous variables  
 
 
Table A2: overall Anova analysis  
 
Figure 3.1 A F= 28.15, df= 188, p= <0.0001 
Figure 3.1 B F= 9.76, df= 188, p= 0.002 
Figure 3.1 C F= 17.83, df= 174, p= <0.0001 
Figure 3.1 D F= 15.31, df= 105, p= 0.0002 





















Table A3: overall ANOVA analysis 
 
Figure 3.3 A F= 1.4, df= 88, p= 0.23 
Figure 3.3 B F= 11, df= 142, p=0.001 
Figure 3.3 C F= 1.4, df= 143, p= 0.24 




















Table A4: overall ANOVA analysis 
 
Figure 3.4 A F= 2.62, df= 89, p= 0.11 
Figure 3.4 B F= 0.02, df= 142, p= 0.88 
Figure 3.4 C F= 0.26, df= 141, p= 0.61 
Figure 3.4 D F= 0.26, df= 153, p= 0.61 
 
